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INTRODUCTION 
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BLADDER CANCER OCCURRENCE 
Among the 15 million inhabitants of the Netherlands, approximately 2700 new 
cases of bladder cancer are diagnosed each year in men and 700 in women." 
After lung cancer and prostate cancer, it is the third most frequently occurring 
tumour in men. Approximately 800 and 300 Dutch men and women die from 
the disease each year, respectively.3 
In most Western communities, bladder cancer incidence and mortality rates 
are still increasing, although these increasing trends seem to have leveled off 
in males over the past few years.17 The latter observation may be explained by 
the fact that an increasing proportion of male Western populations are life-long 
non-smokers. It is possible that the introduction of various new classification 
and registration procedures for low-stage bladder cancer since the 1970s have 
biased the interpretation of these trends in incidence.1215 Since the 
implementation of the WHO grading system in 1973,'3 the controversial 
opinions concerning the most appropriate nomenclature for low-grade papillary 
lesions of the urinary bladder have swung firmly in favour of considering the 
great majority of these lesions to be malignant.5 
SUPERFICIAL BLADDER CANCER 
The majority (approximately 65 per cent) of newly diagnosed bladder cancers 
are low-stage, or 'superficial', transitional cell carcinomas (TCC).4 Superficial 
is defined as tumour extension limited to the mucosa (flat pTis and papillary 
shaped pTa tumours) or the lamina propria (pTl) of the bladder wall.18 Even 
though, strictly speaking, pTl tumours show invasion beyond the basal layer 
of the urothelium, in urology practice only the muscle-invasive pT2-pT4 tumo 
urs are actually called 'invasive'. This difference between the official TNM 
definition of invasiveness and the definition used in urological practice, is caus 
ed by the clear differences in prognosis and management policy for superficial 
and invasive bladder cancer. Whereas invasive bladder cancer is routinely 
treated with cystectomy, radiotherapy or a combination of these two modalities 
with or without upfront chemotherapy, superficial tumours are managed more 
conservatively by transurethral resection (TUR), which may be followed by 
intravesical instillations with chemotherapeutical or immunotherapeutical 
agents.14 
PROGNOSIS 
Patients diagnosed with superficial bladder cancer have a relatively good 
prognosis quoad vitam and are therefore treated conservatively. Nevertheless, 
there is a strong tendency for new tumours to form after initial surgery. 
Approximately 60 per cent of all the patients suffer at least one recurrence 
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within five years of the initial diagnosis.4,8 Many patients experience multiple 
recurrences, necessitating repeated resections or fulguration. Additional 
measures are required, however, if recurrent tumours show muscle invasion 
and/or appear to be poorly differentiated. In 10 to 30 per cent of all the 
patients with primary superficial TCC, sooner or later such progressive 
tumour behaviour is observed.' Because of disease progression, it is estimated 
that 10-15 per cent of all the patients who initially present with a superficial 
tumour die from bladder cancer within five years of the first TUR.2,7 At least 
in theory, the administration of more aggressive treatment could prevent 
bladder cancer death in some of these 'high risk' patients. It is very important 
therefore to identify patients with a poor prognosis at the earliest possible 
stage. 
PROGNOSTIC FACTORS 
The major prognostic factors for recurrent tumour formation and disease 
progression in superficial TCC are tumour stage, degree of differentiation, 
size and multicentricity. Once a patient has suffered a recurrence, he or she is 
prone to having more recurrences.1,4,8 Despite the presence of these 
prognosticators, it is the urologist's experience that superficial bladder cancer 
is a heterogeneous disease with a rather unpredictable clinical course. 
Therefore, current research is aimed at identifying more powerful 
prognosticators, especially for disease progression. For example, much work 
has focused on identifying chromosomal and DNA content differences between 
urothelial tumours which are associated with later muscle invasiveness, and 
those with fairly benign behaviour.19 In urological practice, however, patient 
management is still based on the aforementioned clinical (size, multicentricity) 
and histological (stage, grade) characteristics.20 The only additional prognostic 
test which is being used by an increasing number of urologists is the histologic 
al examination of random urothelium biopsy specimens. 
RANDOM UROTHELIUM BIOPSIES 
During TUR, random urothelium biopsies can be taken from the 
cystoscopically normal-looking urothelium, and examined for the presence of 
dysplasia or carcinoma in situ. The presence of these dysplastic lesions is belie 
ved to reflect a premalignant state of the entire urothelial surface, from which 
multiple tumour formation is very likely. Recently, some evidence has been 
presented that this urothelial 'field defect' is not the result of the independent 
transformation of many urothelial cells, but that the progeny of a single 
transformed cell spread through the bladder, giving rise to topologically 
distinct but genetically related tumours.16 
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It is more than 30 years ago that the first report appeared on the potential 
prognostic value of concomitant microscopical lesions in macroscopically 
normal urothelium.6 Since then, a number of studies have confirmed this prog 
nostic significance. However, these studies were very small and probably 
highly selective, whereas most of them did not assess the prognostic significan 
ce for the endpoint tumour progression. Furthermore, none of these studies 
evaluated prognostic significance, apart from the effect of the other available 
prognosticators. If the prognostic ability of intraurothelial dysplasia is caused 
by its association with, for instance, a low degree of differentiation of the 
primary tumour, then random biopsies may appear to be quite useless for patie 
nt management. 
RATIONALE OF RANDOM BIOPSIES 
In primary superficial bladder cancer, no definite consensus has been reached 
on treatment policy so far. The principal aim of taking random urothelium 
biopsies is to improve the urologist's ability to distinguish between patients 
who should be treated with adjuvant intravesical instillations and those who 
should not. Therefore, even if concomitant dysplastic lesions in random biopsy 
specimens prove to have prognostic ability, this does not necessarily justify 
taking biopsies from all newly diagnosed patients. Among other factors, it is 
also important to consider the number of patients who have dysplastic 
abnormalities in normal-looking mucosa, as well as the proportion of this grou 
ρ of patients who would have been treated with adjuvant instillations anyway. 
Thus, once the prognostic ability of random biopsies has been verified, a decis 
ion-analytical approach should be used to evaluate the rationale of the 
implementation of this test in everyday urological practice. 
PREDICTION IN INDIVIDUALS 
After the determination of a set of prognostic factors which are going to be 
used in clinical practice, it is important to evaluate the value of the complete 
set for patient management. In many situations, the value of prognosticators is 
claimed with statistical significance only. Statistical significance, however, 
does not in any way quantify the extent to which a test can differentiate 
between patients with a good prognosis and patients with a poor prognosis. 
Hazard ratios resulting from the proportional hazards model (which is 
becoming increasingly popular for prognostic assessment) do have such 
quantitative meaning. In the diagnostic process, the post-test probability of 
disease can be calculated from the pre-test probability and the test's likelihood 
ratio. Similarly, in prognostic assessment, the post-test risk of disease outcome 
can be calculated from the pre-test risk and the prognostic test's hazard ratio. 
This post-test risk can also be calculated using a combination of prognostic 
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tests. In this case, the combination of hazard ratios is called a prognostic 
index. 
With this prognostic index, one can differentiate high-risk subgroups of 
patients from low-risk ones, at least to some degree. The ability to segregate 
these subgroups would enable us to frame appropriate, and perhaps very 
different, therapeutic management regimes for each subset. If the prognostic 
index is valid, then on average, the predictions of disease outcome for these 
subgroups will be correct. This validity, however, does not imply that the 
prediction will be accurate for an individual patient. The accuracy may be 
very poor despite the presence of highly statistically significant 
prognosticators. On an individual level, it is this precision or predictive power 
(in combination with treatment efficacy) that determines the extent of overtreat 
ment or undertreatment. Recently, a number of possible measures have been 
described for the predictive power of a set of prognostic factors.10 Until now, 
the predictive power of the available prognostic factors in superficial bladder 
cancer (with or without random biopsies) has never been assessed. 
AIMS OF THIS THESIS 
On the basis of the brief outline on superficial bladder cancer given above, the 
aims of this thesis were: 
- To study trends in bladder cancer occurrence and mortality in the 
Netherlands. 
- To study the prognostic significance of concomitant intraurothelial dysplastic 
lesions (detected by means of random urothelium biopsies) for recurrent 
tumour formation and disease progression in primary superficial bladder 
cancer. 
- To quantify the predictive power of the available set of prognostic factors in 
primary superficial bladder cancer. 
- To evaluate the rationale of the implementation of random urothelium 
biopsies in the management of patients with primary superficial bladder cane 
er. 
In an attempt to answer most of these clinical epidemiological research 
questions, data were used from a bladder cancer documentation project. These 
data were compiled by a large number of urologists, pathologists and 
radiotherapists from hospitals in the south-eastern part of the Netherlands. 
This documentation project (Chairman: Dr R.P. Heijbroek) was supported 
financially by the Comprehensive Cancer Centres IKO (Nijmegen), IKZ 
(Eindhoven) and IKA-ST (Enschede). 
The datamanagement and the administrative coordination of the project was 
carried out by the Comprehensive Cancer Centre IKO. 
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SUMMARY 
In 1955, 234 men and 116 women died from bladder cancer in the 
Netherlands. In 1988 the numbers were 794 and 317 respectively· After 
adjusting for the ageing of the Dutch population since 1955, female 
mortality rates per 10s person-years appear to be very stable: 2.9 from 
1955 to 1959 and 3.0 from 1985 to 1988. By contrast, an increasing trend 
exists in males. From 1955 to 1959 and from 1985 to 1988, bladder cancer 
mortality rates per 10s person-years were 7.5 and 12.4 respectively. For 
men in particular, increasing mortality (and incidence) rates are seen all 
over the world. In many cases this increasing trend is thought to originate 
from a higher risk of dying from bladder cancer in successive birth 
cohorts rather than from a higher risk in successive calendar periods. This 
so-called cohort effect is explained by changes in smoking behaviour in the 
male population. 
Statistical modelling of bladder cancer mortality data from 1955 to 1988 
in the Netherlands shows that the increasing temporal trend in men can 
also be described as a cohort effect. The risk of dying from bladder 
cancer increases from the 1875 birth cohort to the 1910 birth cohort, but 
decreases thereafter. It is concluded that this decreasing risk for generado 
ns born after 1910 will probably result in a decreasing trend in mortality 
in the near future, when more and more of these "youngsters" reach the 
age of 70+. 
INTRODUCTION 
An increase in the incidence and mortality rates of bladder cancer is seen in 
nearly all Western communities.M In Alberta, Canada, male age-standardised 
incidence rates per 105 person-years increased from 10.8 in 1964 to 20.3 in 
1984.2 National cancer survey data from the USA showed a 51% increase in 
age-standardised rates among white men from 14.1 to 21.3 cases per 105 
person-years in 1937 to 1939 and 1969 to 1971 respectively. In the same 
period the rates in Connecticut rose from 10.6 to 23.4.1β In Denmark, the age-
standardised incidence rates for men increased from 10.8 in 1953 to 1957 to 
24.7 in 1978 to 1982.1019 Trends in bladder cancer incidence among women 
are less consistent. Although a number of registries showed increasing rates, 
in the US national cancer survey data for example, decreasing rates were 
found for women. 
This presentation of rates from different calendar periods is more or less the 
standard method of describing temporal trends in the occurrence of cancer. It 
is possible, however, that period of birth, in stead of period of mortality, 
gives a better description of the observed rates. The relevance of 
differentiating these 2 types of temporal trend is that they may lead to very 
different hypothesised underlying causal factors.8 
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Using data from the Connecticut cancer registry Roush et air2 demonstrated 
that the increase in (invasive) bladder cancer rates could be accounted for by a 
simple so-called age-cohort pattern in both sexes. This means that starting with 
some specific birth cohort the incidence is increasing for successive birth coho 
rts (with a similar age profile) rather than for successive calendar periods. In 
the Connecticut analyses males show a consistent rise beginning at least with 
those born in 1870 and a peak in those born around 1930, whereas for females 
a sharp rise begins around 1900 with the increase persisting into at least the 
1940 cohort. According to the authors these findings are consistent with trends 
by birth cohort for cigarette smoking, which strengthens the hypothesised 
association between cigarette smoking and bladder cancer. 
In this report temporal trends in the occurrence of bladder cancer in the 
Netherlands are summarised. Since a national cancer registry from which incid 
enee data can be obtained has started only recently. Mortality statistics from 
the Dutch Central Bureau of Statistics from 1955-1988 are used for analyses. 
Statistical modelling is used to examine whether temporal variations in rates 
are attributable to a cohort effect and/or to a calendar period effect. The 
results from this modelling are also used to obtain some indication of a change 
in temporal trend in the near future. 
METHODS 
In the Netherlands, the Central Bureau of Statistics (CBS) has registered 
underlying causes of death since 1900. The number of men and women with 
bladder cancer as cause of death, as well as age and sex specific numbers of 
the Dutch population, were abstracted from the annual publications of the CBS 
for the years 1955 to 1988.5 In this time period 4 revisions of the International 
Classification of Diseases were used. For the sixth and seventh revisions, 
ICD-code 181.0 and for the eighth and ninth revisions ICD-code 188 were 
used as definitions for bladder cancer. Only a small difference exists between 
the ninth revision and the former 3, using these codes: in the ninth revision 
the urachus is coded under "bladder cancer", whereas in the former editions 
the urachus is coded under "other urinary organs". 
For statistical analysis the numbers of bladder cancer deaths were organised 
according to 5-year age groups and 5-year calendar periods of registration. 
Rates per 103 person-years based on these numbers are illustrated in Tables 2. 
1 and 2.2. Ages under 35 were ignored because of the rarity of mortality from 
the disease under this age. The highest age-group (85+) was also ignored beca 
use no specific period of birth can be defined for this birth cohort. Birth 
cohorts were defined by combining age and calendar periods (see step lines in 
Tables 2.1 and 2.2). 
To compare bladder cancer mortality rates in different calendar periods, 
adjustment for the change in age distribution of the Dutch population is 
necessary. Thus mortality rates in 7 successive calendar periods from 1955 to 
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1959 to 1985 to 1988 were age-standardised to the European standard 
population. This means that for each calendar period we calculated what the 
mortality rate in this standard population with a constant age distribution woul 
d have been if it had experienced the same age-specific mortality as the Dutch 
population. 
TABLE 2.1 Age-specific bladder cancer mortality rates per 100,000 
man-years in the Netherlands, 1955-1988* 
Calendar year of mortality 
Age 
35-39 
40-44 
45-49 
50-54 
55-59 
60-64 
65-69 
70-74 
75-79 
80-84 
1955-
1959 
0 1 
08 
24 
45 
10 3 
15 6 
22 7 
42 6 
66 8 
73 6 
1960-
1964 
03 
06 
1 9 
67 
10 7 
20 2 
31 9 
47 2 
67 9 
107 4 
1965-
1969 
04 
09 
23 
5 1 
12 0 
23 7 
36 8 
59 0 
80 2 
110 0 
1970-
1974 
02 
09 
2 1 
57 
11 8 
24 6 
42 1 
66 5 
93 9 
128 7 
1975-
1979 
0 1 
06 
27 
5 7 
11 2 
22 4 
42 8 
71 7 
95 5 
139 8 
1980-
1984 
02 
04 
1 8 
40 
11 6 
23 5 
442 
68 6 
113 2 
155 2 
1985 
1988 
04 
06 
1 8 
48 
99 
23 3 
39 6 
68 4 
1175 
176 9 
The step line indicates the 1910 birth cohort 
To estimate the separate effects of age, calendar period and birth cohort on 
trend in mortality, a simultaneous analysis of these factors was performed by 
use of a statistical model. A somewhat simple model is the multiplicative one, 
where the mortality for a specific age-period-cohort combination is, apart from 
random fluctuation, described as a product of these 3 factors." 
Yape = aa*pTc 
where Y^ is mortality rate for age group a, born in period c, as experienced 
during calendar period p; a
a
 is a factor describing the effect on mortality of 
age group α; π
ρ
 is a factor describing the effect on mortality of calendar 
period p; т
с
 is a factor describing the effect on mortality of birth cohort с 
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Such a model is also called a log-linear model, because by taking the 
logarithm (In) on both sides of the equality sign one obtains a linear model: 
In (Y^J = In a
a
 + In тг
р
 + In r
c 
The age factor, period factor and cohort factor are fitted so that their products 
in all age period groups in Tables 2.1 and 2.2 are as close to the observed 
rates as possible. The statistical procedure used here for estimating the factors 
is the maximum likelihood method. The software package GLIM was used for 
computations. 
To test the goodness-of-fit of the models with the observed mortality rates 
as well as to test the models against each other the Chi-square approximation 
to the -2 In (likelihood-ratio) was used. For an explanation of log-linear 
models for analysis of temporal variation in cancer, 2 reports of Clayton and 
Schiffers are recommended.6"7 
TABLE 2.2 Age-specific bladder cancer mortality rates per 100,000 
woman-years in the Netherlands, 1955-1988* 
Age 
35-39 
40-44 
45-49 
50-54 
55-59 
60-64 
65-69 
70-74 
75-79 
80-84 
1955-
1959 
0.1 
0.6 
0.4 
1.6 
3.0 
5.3 
9.0 
15.9 
25.4 
39.8 
1960-
1964 
0.1 
0.3 
0.8 
1.4 
2.4 
5.6 
8.6 
13.9 
32.5 
39.5 
Calendar 
1965-
1969 
0.3 
0.2 
0.9 
1.3 
2.7 
4.9 
9.2 
14.8 
26.7 
41.2 
year of mortality 
1970-
1974 
0.1 
0.4 
0.8 
1.7 
2.9 
3.9 
6.8 
15.3 
24.4 
46.1 
1975-
1979 
0.2 
0.5 
0.6 
0.7 
2.5 
4.3 
6.7 
14.1 
24.3 
37.9 
1980-
1984 
0.2 
0.6 
0.7 
1.8 
2.1 
4.6 
7.3 
13.1 
24.9 
37.2 
1985-
1988 
0.3 
0.2 
0.3 
1.7 
3.2 
4.6 
7.8 
13.9 
26.2 
48.2 
The step line indicates the 1910 birth cohort 
RESULTS 
From 1955 to 1959 the age-standardised bladder cancer mortality rates per 105 
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person-years were 7.5 in men and 2.9 in women. From 1985 to 1988 therse 
rates were 12.4 and 3.0 respectively (Figure 2.1). 
FIGURE 2.1 Trend in bladder cancer mortality in the Netherlands between 
1955 and 1988 (age-standardised to the European standard 
population) 
Deaths per 100,000 
-
_ 
Men ^ • 
Women 
I I I I I 
1955-59 1960-64 1965-69 1970-74 1975-79 1980-84 1985-88 
The increasing temporal trend in men seems to originate from a higher risk of 
dying from bladder cancer in the four oldest age groups (Figure 2.2). In men 
over 65 years of age the rates doubled in this 34-year time period. In women 
such an increase was not seen in the older age groups (Figure 2.3). Mortality 
rates were stable over time in all age groups, reflecting a situation of no 
temporal trend. 
Since male mortality rates did not rise in all age groups, this suggests that a 
calendar period effect is not responsible for the increasing trend. Statistical 
modelling of the rates in men yields the results summarised in Table 2.3. 
Model 1 is the model which assumes that there is no temporal trend in male 
bladder cancer mortality. Since an increasing trend exists in male bladder 
cancer mortality, this model gives a very poor description of the data. This is 
reflected in the relatively large deviance from the model compared with the 
number of degrees of freedom (df). If a model gives a good description of the 
observed rates the deviance from the model is about the same as the number 
of df and far from significant. In that situation the Ρ value is close to 0.50. 
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FIGURE 2.2 Age-specific bladder cancer mortality in Dutch men according to 
registration period 
200 
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100 
mortality per 100,000 man-years 
5 0 -
1955-1959 
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19Θ0-19Θ4 
1965-1969 
1965-1988 
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FIGURE 2.3 Age-specific bladder cancer mortality in Dutch women according 
to registration period 
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Since the Ρ value in the age-only model is very small the model does not hold, 
which means that there is some temporal variation. 
TABLE 2.3 GLIM statistics for bladder cancer mortality in the Netherlands 
Model 
(1) 
(2) 
(3) 
(4) 
(5) 
Age® 
Age + Drift' 
Age + Period 
Age + Cohort 
Age + Period + cohort 
Model (4) vs. Model (5) 
Deviance 
555.2 
234.6 
182.9 
53.3 
37.8 
15 5 
df 
60 
59 
54 
45 
40 
5 
Ρ 
< 0.001 
< 0.001 
< 0.001 
0.19 
0.57 
0.01 
® The AGE model describes the situation in which rates are predicted by age factors 
only and represents the null hypothesis of no temporal variation 
' The AGE + DRIFT model is a model with temporal trend in which no distinction can 
be made between period effects (model 3) and cohort effects (model 4) 
The simplest model to describe temporal variation is the so-called age-drift 
model.6 If this age-drift model gives a good description of the data, then a 
temporal trend exists for which no distinction can be made between period 
effects and cohort effects (model 2). However, the age-drift model does not 
hold either, since there is large deviance from the model. The next two 
models to consider are the age-period model (model 3) and the age-cohort 
model (model 4). Obviously the variation in bladder cancer mortality rates is 
much better explained by cohort effects than by calendar period effects. 
Unlike the age-period model, the age-cohort model provides an adequate 
description of the data (there is no significant deviance from the model: Ρ = 
0.19). 
The parameter estimates r
c
 from the age-cohort model are interpretable as 
relative risks between 2 birth cohorts. Defining the 1910 cohort as a reference 
group, the relative risks of bladder cancer mortality in Dutch men are 
illustrated in Figure 2.4. It can be seen that mortality increased until this 1910 
cohort. Figure 2.4 also shows that the relative risk of dying from bladder 
cancer decreases for successive younger birth cohorts after the 1910 cohort. 
For example, compared with men born in 1910, the risk of dying from 
bladder cancer for men (of the same age) born in 1940 is only 67%. The 
standard graphical presentation of temporal trends (Figure 2.1) fails to identify 
this decreasing risk experienced by recent cohorts. Next to a cohort effect, a 
calendar period effect cannot be ruled out since there exists no significant 
deviance from the age-period-cohort model (model 5) as well (P = 0.57). 
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FIGURE 2.4 Relative risk of male bladder cancer mortality in the Netherlands 
according to year of birth and registration period 
1.2 
1 
0.8 
0.6 
0.4 
0.2 
Relative risk 
_ l I I I l _ 
1870 1880 1890 1900 1910 1920 1930 1940 1950 1960 1970 1980 1990 
Calendar year 
Cohort effects ' Period effects 
Compared with the age-cohort model this full age-period-cohort model gives a 
significantly better fit to the observed rates (P = 0.01). It is hard to assess, 
however, how great this calendar period effect is, because there is a major 
difficulty in the use of the age-period-cohort model. Knowing any 2 of age at 
death, year of birth and year of death fixes the third. Thus the 3 variables are 
not independant. A consequence of this relationship is that the solution from 
the model is not unique, although each solution produces the same fitted 
rates.20 To overcome this problem one of all solutions from the age-period-
cohort model was chosen in which the cohort effect is the same as in model 4: 
the age-cohort model. Through this, the period effect is identified. Taking the 
first calendar period (1955-1959) as reference, the relative risks of dying from 
bladder cancer in more recent calendar periods appear to be close to 1 
(Figure 2.4). Although the inclusion of a period effect describes the observed 
rates significantly better than the age-cohort model, the period effect is not 
relevant quantitatively. 
DISCUSSION 
When the incidence rates of a particular cancer are changing with time, the 
first question to be asked is whether the change represents a real change in 
disease occurrence or simply a change in diagnostic / registration practice or 
acuity. In the case of trends in mortality rates also, a change in prognosis is 
Chapter 2 - Mortality 24 
possible. Examples of changes in diagnostic / registration practice might be 
changes in (1) the definition of the malignancy, (2) histological confirmation, 
(3) autopsy rate and (4) diagnostic accuracy.23 Differences or changes in 
applied therapeutics are another possible explanation of trends in mortality. 
As stated before, there were no important changes in the definition of 
bladder cancer in the 4 revisions of the ICD used by the Dutch Central Bureau 
of Statistics. Furthermore, changes in histological confirmation and autopsy 
rate will presumably not be very important for bladder cancer. A change in 
histological confirmation is more relevant in the case of cancers that can be 
classified under 2 or more different rubrics, such as lymphomas of the 
gastrointestinal tract, or when specific histological subtypes of a tumour are 
studied. A change in histological confirmation is also important when cancer 
sites are studied to which other cancers frequently metastasise, e.g. lung and 
liver cancer. A change in autopsy rate is more relevant if tumours are studied 
that may remain latent, such as prostate cancer. 
Changes in diagnostic and registration accuracy probably have less impact 
on bladder cancer mortality than on bladder cancer incidence. One of the most 
important registration problems in bladder cancer incidence is the classification 
of papillomas. Because of the absence of criteria which allow a clear 
distinction between papillomas with benign behaviour and those that will 
eventually manifest malignancy, for the last two decades non-invasive 
papillomas were notified to cancer registries more frequently. This change in 
policy may bias bladder cancer incidence rates but will have less effect on 
bladder cancer mortality. 
In recent decades, survival rates of patients suffering from bladder cancer 
have shown a tendency to increase. In Alberta, Canada, the 5-year survival 
rate for men increased from 52% in 1964 to 65% in 1988.2 However, if this 
increase is due to an increase in the proportion of superficial bladder cancers 
(pTa and pTl), the apparent improvement in treatment results may have little 
effect on mortality statistics.24 It is not known whether this is the case in the 
Netherlands. 
If one is satisfied that a change in incidence or mortality is not an artefact 
but real, it is interesting to identify the environmental or other changes that 
might be responsible. In identifying the factors responsible for the change in 
rates it is helpful to differentiate calendar period and birth cohort patterns in 
the data by means of statistical modelling.8 A calendar period model suggests 
an immediate (or a fixed delayed) effect upon incidence (or mortality) which is 
constant across all age groups. A birth cohort model suggests an effect which 
affects rates in a specified generation equally throughout life. 
Whereas no temporal trend was observed in female bladder cancer mortality 
in the Netherlands, for male bladder cancer mortality the increasing trend was 
found to be due mainly to a cohort effect. This difference between male and 
female trends in mortality is seen all over the world.1·14·16'24'25 The fact that 
there is no temporal trend in mortality in women also lends support to the idea 
that the temporal trend in men is not caused by an artefact. 
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The cohort effect in men shows an increasing trend for successive birth 
cohorts until those born after 1910. The same was reported for England and 
Wales male mortality by Armstrong and Doll.1 In Italian male mortality the 
increasing trend lasts at least until the 1935 cohort.6 
Almost all authors correlate the cohort effect with the rise in cigarette 
consumption, the best known risk factor in bladder cancer. Differences in 
trends in males and females could also be attributed to smoking.1·9·1116"17,21'24'23 
Other risk factors may also have an effect on bladder cancer occurrence. The 
most important of these potential risk factors is exposure to carcinogenic dye-
stuffs, e.g. j(?-naphtylamine and benzidine, in certain occupations. However, 
although the relative risk of this factor is perhaps reasonably large (4.6 
according to La Vecchia et α/.),15 the effect on trends in occurrence will 
probably be small because the proportion of the population that is exposed to 
these dyes is small.17 
If cigarette consumption is indeed the aetiologic factor responsible for the 
increasing bladder cancer mortality and incidence rates, then presumably 
trends will decline in the near future, since more and more people will be life­
long non-smokers. For example, in the Netherlands there has been a sharp fall 
in the proportion of smokers among men from 90% in 1958 to 44% in 1984. 
Such a decline is not yet visible in the more or less standard method of 
illustration of temporal trends (Figure 2.1). When this effect can be expected 
is hard to tell. Among other factors, this depends especially on the proportion 
of the disease attributable to smoking and the length of the latent period of 
bladder cancer. Considering the relative risks for successive male birth cohorts 
(Figure 2.4), perhaps the decline will be seen within the next decade when 
more cohorts with a decreasing relative risk will reach ages over 70. In this 
respect, it is also illustrative that the incidence of lung cancer and laryngeal 
cancer is already declining in Scotland,3 since the length of the latent period 
for these smoking-related cancers is presumed to be shorter than that for 
bladder cancer.1 3 , 1 7·2 4 Perhaps the relatively long latency for bladder cancer is 
also the reason why, contrary to lung cancer mortality in females, which has 
been rising steeply since 1980,26 an increasing trend for bladder cancer 
mortality is not (yet) seen in Dutch women. 
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SUMMARY 
Trends in cancer occurrence and survival may reflect changing risks and 
prognosis, respectively, but may also be caused by changes in detection, 
classification and registration. Changed classification of low-stage 
papillary carcinomas may have a material effect on observed trends in the 
occurrence of bladder cancer. We studied the effect of the implementation 
of the WHO 'grading system' and the third edition of the TNM staging 
system on bladder cancer incidence in the south-eastern part of the 
Netherlands. 
Data on superficial and invasive bladder cancer incidence between 1975 
and 1989 were derived from the population-based Eindhoven cancer 
registry. Data on survival of patients with stages І-Г bladder cancer were 
derived from the municipal population registers. 
Bladder cancer incidence per 100,000 person-years (age-adjusted to the 
European standard population) rose from 25.9 to 40.7 in males and from 
3.1 to 8.5 in females. This increasing trend was caused almost entirely by 
non-invasive pTa papillary carcinoma. In 1975, not one pTa tumour was 
recorded by the cancer registry, whereas in 1989 the incidence rates were 
15.7 and 3.6 in males and females, respectively. A considerable shift was 
observed towards lower disease stages, which was less evident within the 
group of invasive tumours. The relative 5-year survival of patients with 
stages І-Г invasive bladder cancer was 59% in 1975 to 1977 and 70% in 
1984 to 1986. After stratification by stage, however, no striking 
improvement was observed in the prognosis. 
We conclude that the increasing trend of bladder cancer occurrence in the 
Netherlands since 1975 has largely been caused by changed classification 
systems and reporting procedures for ρ Ta tumours (formerly classified as 
'papillomas')· However, there may have been a small increase in the risk 
of invasive bladder cancer in females. 
INTRODUCTION 
One of the major problems in cancer registration is the reporting and 
classification of low-grade noninvasive papillary shaped bladder tumours.1 
This problem relates particularly to the distinction between papillary shaped 
tumours with benign behaviour and those that will eventually manifest 
(progressive) malignancy if left untreated. As such non-invasive carcinomas 
can form a substantial proportion of all bladder tumours and treatment may 
prevent them from progressing to invasive disease then the incidence of 
malignant bladder cancer probably relates to differences in urological care.2 
Furthermore, changes in the reporting and classification of these low-stage 
papillary tumours have resulted in biased trends in time of both bladder cancer 
incidence and survival.3 For the past 10 to 20 years, the pendulum of opinion 
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has swung firmly in favour of considering the great majority of these lesions 
malignant, albeit of low grade, and most pathologists presently diagnose 
almost all of these lesions that appear cytologically innocuous as noninvasive 
papillary urothelial carcinoma or transitional cell carcinoma grade 1.4 
In this study we explored trends in incidence of bladder cancer from 1975 
to 1989 in the south-eastern part of the Netherlands. Special emphasis is laid 
on changes in stage distribution and survival. 
METHODS 
Data source 
Data on bladder cancer incidence and survival were derived from the 
population-based cancer registry in the area of Eindhoven.5 The registry 
covers the south-eastern part of the province of North-Brabant and the 
northern part of the province of Limburg. It is considered to be complete in a 
core area with a population of approximately 850,000 since the early 1970s. 
Newly diagnosed cancer patients are notified to the registry through three 
pathology laboratories in the cities of Venlo, Helmond and Eindhoven and the 
Radiotherapy Department in the city of Eindhoven. Furthermore, the registry 
receives hospital discharge diagnoses from all the community hospitals in the 
area. After notification, professional registrars collect data from the clinical 
records. 
We included all new patients with bladder cancer (International 
Classification of Diseases for Oncology: code 188)6 diagnosed between 
January 1 1975 and January 1 1990. Diagnoses which were originally 
classified according to ICD revisions 8 and 9, were converted into ICD-0 
codes. There is no routine reporting of benign and/or unspecified papilloma of 
the bladder (ICD-0 behaviour codes 0 and 1, respectively) in the cancer 
registry, so these tumours were not included. All the tumours were staged 
according to the TNM classification of malignant tumours.7 See Table 3.1. 
The second edition of the TNM staging system was used until 1980, the third 
since that year. All new tumour occurrences in bladder cancer patients, 
whether or not in a higher tumour stage category, were considered to be 
recurrences. 
Analyses 
Incidence rates per 100,000 person-years in males and females were calculated 
for 1975 to 1989 inclusive. To adjust for the pronounced ageing of the 
population during this period, the incidence rates were age-adjusted to the 
European standard population.' 
Trends in incidence rates were presented as 3-year moving averages (2-year 
averages were used for the first and last year of the study interval). The 
incidence rates were calculated separately for superficial and invasive tumours. 
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TABLE 3.1 TNM stage grouping of urinary bladder cancer (UICC, 1987) 
Stage Primary tumour Regional lymph Distant metastases 
Tis 
Ta 
Tl 
T2 
ТЗа 
ТЗЬ 
Т4 
Any Τ 
Any Τ 
nodes 
NO 
NO 
NO 
NO 
NO 
NO 
NO 
N1, N2, N3 
Any N 
MO 
MO 
MO 
MO 
MO 
MO 
MO 
MO 
Ml 
Superficial tumours comprise three stages of disease7: pTis, a flat 
non-papillary high-grade carcinoma of the mucosa; pTa, a papillary carcinoma 
confined to the mucosa; and pTl, a tumour which invades the lamina propria 
but does not involve the superficial muscle layer of the bladder wall (stage 0-1 
in the stage grouping; see Table 3.1).® The stage distribution as well as the 
mean age at diagnosis of bladder cancer was compared in five triennial 
calendar periods (1975-77; 1978-80; 1981-83; 1984-86; 1987-89). 
Except for patients with stage 0 disease (Table 3.1), data on vital status until 
July 1 1991 were collected from the municipal population registers. Less than 
1 % of all the patients were lost to follow-up. We calculated the actuarial 
relative survival rate as a measure of patient survival adjusted for the effect of 
mortality attributable to competing risks of death.9 Relative survival was 
defined as the ratio between the observed survival rate and the survival rate 
which can be expected in a group of the general population similar to the 
group of patients at the time of diagnosis, with respect to age, sex and 
calendar time. We calculated the 5-year relative survival for patients diagnosed 
in the total study period, as well as for the successive calendar periods 
1975-77, 1978-80, 1981-83 and 1984-86. The standard errors of the relative 
survival estimates were obtained using Greenwood's formula.10 Owing to the 
relatively small number of female patients, the relative survival in successive 
triennial periods was calculated for both sexes combined. For the calculations, 
we used a computer programme developed by the Finnish Cancer Registry." 
Stage I (pTl N0 MO) bladder cancer is defined as superficial in urology even though it 
is an invasive tumour according to the TNM classification 
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RESULTS 
Between 1975 and 1989, 1909 newly diagnosed patients with bladder cancer 
were registered, 1537 (80.5%) males and 372 (19.5%) females. Of all the 
tumours, 97.5% had been histologically verified (of which 0.2% at autopsy); 
1.6% had been verified with urine cytology only, and in 0.9% no 
microscopical verification had taken place. 95.4% of the tumours were 
classified as transitional cell carcinoma (pure or mixed with another 
morphology), 2.2% as squamous cell carcinoma, 1.2% as adenocarcinoma and 
1.2% had another or unknown morphology (including the cases without 
microscopical verification). These latter 1.2% (N=23) were excluded from 
further analyses. 
FIGURE 3.1 Bladder cancer incidence per 100,000 person-years in males and 
females in the south-eastern part of the Netherlands between 
1975 and 1989. Rates are presented as 3-year moving averages 
after age adjustment to the European standard population 
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Age-adjusted urinary bladder cancer incidence in men rose from 25.9 per 
100,000 person-years in 1975 to 40.7 per 100,000 person-years in 1989. In 
women, these rates were 3.1 and 8.5, respectively. See Figure 3.1. This 
increase in bladder cancer incidence can be attributed almost entirely to an 
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increase in the number of superficial tumours reported (Figure 3.2). For men, 
the incidence of superficial (stages 0 and I) bladder cancer doubled in the first 
half of the 1980s. Except for a temporary decrease in the same period, the 
incidence of invasive bladder cancer (stages II-IV) increased only marginally 
from 10.6 per 100,000 person-years in 1975 to 12.8 per 100,000 person-years 
in 1989. An increase in the incidence of superficial bladder cancer was also 
seen in women (Figure 3.3). However, in women there seems to have been a 
small increasing trend in invasive bladder cancer as well (from 2 to 3 cases 
per 100,000 person-years). 
FIGURE 3.2 Superficial and invasive bladder cancer incidence per 100,000 
person-years in males in the south-eastern part of the 
Netherlands between 1975 and 1989. Rates are presented as 
3-year moving averages after age adjustment to the European 
standard population 
Incidence per 100,000 person-years 
1975 1977 1979 19Θ1 19Θ3 19Θ5 1987 19Θ9 
Calendar year 
Stage distribution 
The increase in superficial bladder cancer (pTis, pTa and pTl) was caused 
almost entirely by an increase in noninvasive papillary pTa tumours. In 1975, 
not one pTa tumour was entered into the cancer registry. In 1989, the 
age-adjusted incidence of pTa tumours in males and females was 15.7 and 3.6, 
respectively. Flat intraurothelial pTis tumours and papillary or solid pTl 
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FIGURE 3.3 Superficial and invasive bladder cancer incidence per 100,000 
person-years in females in the south-eastern part of the 
Netherlands between 1975 and 1989. Rates are presented as 
3-year moving averages after age adjustment to the European 
standard population 
Incidence per 100,000 person-years 
1975 1977 1979 19Θ1 1983 19Θ5 1987 1989 
Calendar year 
tumours with invasion into the lamina propria of the bladder wall, hardly 
increased: the incidence of pTis and pTl tumours was 10.4 in 1975 for males; 
the incidence in 1989 was 11.3. For females these rates were 0.8 and 1.8, 
respectively. 
There has been a clear shift towards superficial tumours in the stage 
distribution of all bladder cancer (Figure 3.4). A shift towards lower disease 
stages was less evident when stage 0 tumours (pTis and pTa) were excluded 
(Figure 3.5), although it appeared that after 1980, relatively fewer tumours 
were diagnosed in stages III and IV. 
The mean age at diagnosis remained almost constant during the study interval, 
despite considerable ageing of the population. In 1975-77 the mean age of 
newly diagnosed male bladder cancer patients was 67.4 years (SD = 11.2) 
and 6.2% of all the patients were diagnosed under the age of 50 years. In 
1987-89, the mean age in males was 67.9 years (SD = 11.0), 6.3% of all the 
patients were younger than 50 years. The mean ages in women in the first and 
last triennial periods were 70.9 and 69.2 years, respectively. The proportion 
of female patients who were younger than 50 years at the time of diagnosis in 
the first and last triennial periods was 6.1% and 8.3%, respectively. 
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FIGURE 3.4 Stage distribution of (male plus female) bladder cancer in the 
south-eastern part of the Netherlands in five successive triennial 
calendar periods 
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FIGURE 3.5 Stage distribution of (male plus female) invasive bladder cancer 
in the south-eastern part of the Netherlands in five successive 
triennial calendar periods 
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Relative survival 
The observed cumulative five-year survival in male and female patients with 
stages I-IV bladder cancer in the total study period was 48%. The relative 
five-year survival was calculated to be 64% (95% CI: 60%-68%). On 
average, the male patients were diagnosed with lower staged disease than the 
female patients: 28% of the male patients with invasive disease had stage III 
or IV disease at diagnosis compared to 43% of the female patients. This 
favourable disease stage distribution resulted in a higher five-year relative 
survival for male patients: 69% (95% CI: 65%-73%) vs. 47% (95% CI: 
38%-56%) in female patients. The relative survival of the patients diagnosed 
in the four successive triennial periods (for both sexes combined) is illustrated 
in Table 3.2. In the calendar period 1975-77, the relative survival was 59% 
(95% CI: 49%-69%). For the patients diagnosed between 1984 and 1986, the 
relative survival was 70% (95% CI: 63%-77%). The increase in relative 
survival was less evident after stratification by stage group. In the patients 
with stage I bladder cancer, the survival was 83% in 1975 to 1977 and 90% in 
1984 to 1986. In patients with stages II-IV bladder cancer, the survival was 
34% in the first and 41% in the latter triennial period. The confidence 
intervals show considerable overlap because of relatively small numbers. 
TABLE 3.2 5-year relative survival (S^ of patients with invasive bladder 
cancer (95% CI) 
Calender 
period 
Stage I Stage II-IV Stage I-IV 
N S, 95% CI N 95% CI N S5 95% CI 
1975-1977 92 83% (70-96) 
1978-1980 88 93% (81-99) 
1981-1983 151 83% (73-93) 
1984-1986 201 90% (82-98) 
93 34% (22-16) 
134 45% (34-56) 
103 35% (23-17) 
155 41% (31-51) 
185 59% (49-69) 
222 65% (56-74) 
254 64% (56-72) 
356 70% (63-77) 
DISCUSSION 
Between 1975 and 1989, bladder cancer incidence in the south-eastern part of 
the Netherlands almost doubled in males and more than doubled in females. In 
both sexes, this increasing trend appeared to be caused almost entirely by an 
increase in the number of diagnoses of noninvasive papillocarcinoma (pTa) 
entered into the cancer registry, which resulted in a shift towards a more 
favourable disease stage distribution (Figure 3.4). Within the group of invasive 
bladder cancer (stages I-IV) the shift was not so evident (Figure 3.5). 
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These findings raise serious doubts as to whether or not the increasing trend 
in bladder cancer occurrence reflects a real increasing risk. It is more likely 
that there has been a change in classification and/or registration practice. Until 
the WHO grading system was implemented in 197312 all low-grade 
non-invasive papillary shaped tumours were called 'papillomas'. After 1973, 
pathologists and urologists started to define tumours with 'the least degree of 
cellular anaplasia compatible with a diagnosis of malignancy' as grade 1 
papillocarcinomas.13 It took a number of years, however, before these tumours 
were reported to and/or entered into the cancer registry. Until the third edition 
of the UICC TNM classification became available (in 1978), which the 
Eindhoven registry started to use in 1980, there was no separate code for 
noninvasive papillocarcinoma. Classifying these tumours as pTis would have 
been wrong because flat carcinoma in situ of the bladder is known to be a 
relatively aggressive lesion which is often widespread over the urothelium and 
(by definition) poorly differentiated. It was only after the implementation of 
the 3rd edition of the staging system that all papillary noninvasive tumours 
with some degree of morphological atypia were classified as papillocarcinomas 
(pTa). 
In theory, the increased incidence of pTa tumours could have also resulted 
from earlier diagnosis due to improved acuity and heightened public 
awareness. However, a substantial reduction in diagnostic delay is unlikely in 
the Netherlands where all the inhabitants have easy access to medical care and 
there are no long urologica! waiting lists (not even in 1975 when the number 
of urologists in the Eindhoven region was only 7 compared to 14 in 1989). 
The initial symptom in more than 80% of the male and more than 70% of the 
female patients with bladder cancer is macroscopical, painless haematuria.14"15 
This symptom will probably be enough reason to seek medical care. It is 
possible that there may occasionally be some delay in the diagnosis of bladder 
cancer, caused by the patient himself or by the general practitioner. Such a 
delay could exist, for example, in patients with cystitis as the presenting 
symptom instead of haematuria and in female patients in whom haematuria 
may be attributed to infection.14 Although this may be an explanation for the 
differences in disease stage distribution and survival between males and 
females, there is little reason to assume that this diagnostic delay has changed 
over the years. In recent years, more low-stage bladder tumours may have 
been diagnosed as a coincidental finding during transurethral resection of the 
prostate or with a routine medical examination (microscopical haematuria). 
However, this cannot explain the pronounced increase in pTa bladder cancer 
in the first half of the 1980s. The same holds true for new techniques, such as 
flow cytometry using monoclonal antibodies. A careful history, physical 
examination, cytology and cystoscopy are still the accepted diagnostic 
methods.16 New diagnostic approaches will probably be implemented in the 
follow-up of cancer (prognostic tests) rather than at initial diagnosis. 
As mentioned above, an alternative explanation for the increased incidence 
of pTa bladder cancer, is a real increase in the risk of developing this disease. 
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The major risk factor for bladder cancer in males and females is smoking.17 It 
has been suggested that smoking as an aetiological factor is largely confined to 
noninvasive bladder cancer.18 However, in a recent study in Denmark, the 
influence of smoking on bladder cancer risk appeared to be similar for low 
and high stage tumours as well as for low and high grade tumours at 
diagnosis.19 The prevalence of smoking among male adults in the Netherlands 
decreased from 90% in the 1950s to about 40% in the 1980s, whereas women 
exhibited an increase from 20% to 40%. These changes in smoking behaviour 
have led to a decrease in lung cancer incidence and mortality since 1980 in 
men, and an increase in women since 1975.20 Although we have not yet 
observed any similar trends for bladder cancer mortality in the Eindhoven 
region (Figure 3.6), it has already been shown that the risk of dying from 
bladder cancer in the Netherlands decreases in successive male birth cohorts.21 
FIGURE 3.6 Bladder cancer mortality per 100,000 person-years in males and 
females in the south-eastern part of the Netherlands between 
1975 and 1989. Rates are presented as 3-year moving averages 
after age adjustment to the European standard population 
(Source: Central Bureau of Statistics, the Netherlands) 
Mortality per 100,000 person-years 
1975 1977 1979 1981 1983 1985 1987 1989 
Calendar year 
Therefore, one would expect a decreasing trend in male bladder cancer 
incidence, if any, rather than an increasing one (Figure 3.1). In women, a 
slight increase in bladder cancer was expected but one would not expect it to 
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be confined to superficial tumours almost entirely (Figure 3.3). Thus, apart 
from a small increased risk of invasive bladder cancer in females, it is highly 
likely that the increase in urinary bladder cancer incidence is the result of 
changing classification following the implementation of the WHO grading 
system and the third edition of the TNM staging system. 
The actuarial relative 5-year survival in male and female patients with 
invasive bladder cancer was 70% in 1984 to 1986 compared to 59% in 1975 
to 1977. One has to bear in mind, however, that the relative survival only 
compares the observed survival to the expected survival in a given population. 
It does not adjust for differences in the distribution of tumour and host 
characteristics in patient populations diagnosed in successive calendar periods. 
Therefore, we also calculated the relative survival after stratification by stage 
(Table 3.2). It appeared that the trend towards a higher survival in more 
recent years had almost disappeared, although small numbers complicated the 
interpretation of the results. 
The absence of any real trend in stage-specific survival rates since 1975 is 
not very surprising. Over the past 15 years, there have been no major changes 
in the treatment of stages II-IV invasive bladder cancer. As in the late 
seventies, the treatment of invasive bladder cancer comprises either 
radiotherapy alone, radical cystectomy alone, or occasionally a combination of 
these modalities. The radiotherapy techniques (with simulation and linear 
accelerators) and cystectomy techniques (with the development of continent 
forms of urinary diversion and nerve-sparing approaches) have been improved 
but have not led to a significantly better prognosis.22 Recently, some 
promising results from neoadjuvant chemotherapy regimens (such as M-VAC) 
have been reported,23 but the ultimate benefit of these regimens remains yet to 
be proven.24 
In contrast with stages II-IV bladder cancer, progress has been achieved in 
the management of stages 0-1 bladder cancer. The past two decades of clinical 
experimentation have provided convincing evidence that adjuvant intravesical 
chemotherapy, after transurethral tumour resection, lowers the recurrence 
rate.25 Furthermore, the intravesical administration of Bacillus 
Calmette-Guérin (BCG) causes a significant reduction in the rate of relapse 
and prolongs the relapse-free interval.26 However, the ability of cytotoxic 
drugs and BCG to prevent progression to muscle invasion, metastatic bladder 
cancer and death from bladder cancer, is still a matter of debate.27 Thus, 
although innovations in treatment management may have improved the quality 
of life of patients with invasive bladder cancer, as well as the recurrence-free 
interval of superficial bladder cancer, they may have less merit with regard to 
the ultimate disease outcome. 
We conclude that over the past 15 years, there has been no clear shift 
towards a more favourable disease stage distribution or a far better prognosis 
in patients with primary invasive bladder cancer. There has been a small 
increase in the occurrence of invasive bladder cancer in females. The increase 
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in the occurrence of superficial bladder cancer which has caused a relative 
shift towards lower disease stages, can be explained by changes in 
classification and is therefore artificial 
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SUMMARY 
Even though the majority of patients with bladder malignancies initially 
present with low stage disease, the clinical epidemiology of these so-called 
superficial bladder tumours is not well known. In this paper, disease 
characteristics at initial presentation and during follow-up are described in 
1745 primary cases documented prospectively in the Netherlands. The risk 
of recurrent disease after primary treatment is very high: in 60% of cases, 
at least one recurrence is diagnosed within 5 years (95% CI: 58%-62%). In 
patients with a small solitary pTa grade 1 tumour, the 3-year recurrence 
risk is 37%. In patients with multiple large high grade pTl tumours, this 
risk is as high as 77%, despite a significant beneficial effect of adjuvant 
intravesical chemotherapy. The actuarial risk of disease progression is 
10.2% after 3 years (95% CI: 8.6%-U.8%). This risk of progression 
depends on the patient's age at diagnosis, tumour stage, grade and 
multiplicity. The use of intravesical instillations with chemotherapy or 
BCG vaccine after TUR does not prevent progressive disease, although 
this finding is difficult to interpret from a non-randomised study. The 
five-year relative survival in patients with superficial TCC of the bladder 
is 86% (95% CI: 84%-88%). 
INTRODUCTION 
Bladder cancer is a heterogeneous disease with an unpredictable clinical 
course. In urology practice, bladder cancer cases are differentiated on the 
basis of the extent of bladder wall invasion. The largest group is the group of 
superficial transitional cell carcinomas (TCC). Patients with superficial TCC 
have a fairly good prognosis with a 5-year relative survival of 80% to 90%.4 
Therefore, the greatest concern in these patients is not to reduce mortality but 
to lower and postpone the number of recurrences (which are very common in 
superficial TCC) and thereby to prevent progression to invasive disease.13 To 
accomplish this, initial treatment by transurethral resection (TUR) is often 
followed by intravesical instillations with chemotherapy or immunotherapy. 
Until now, all knowledge of disease characteristics of superficial bladder 
cancer (such as stage distribution, the risk of recurrences and disease 
progression and survival) has been based on fairly small case series which 
were often selective in one or more respects. In this paper, quantitative data of 
clinical epidemiological features of superficial bladder cancer are presented 
from a large case series in the Netherlands. 
PATIENTS AND METHODS 
In the southeastern part of the Netherlands, there has been a close cooperation 
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between urologists, pathologists and radiotherapists from 23 district hospitals, 
1 university hospital and 6 radiotherapy centres since 1981 (the Dutch South-
East Cooperative Urological Group). In 1983, this resulted in a consensus 
report on the diagnosis and treatment of patients with bladder cancer. 
Furthermore, it was agreed that the participating urologists would document 
every newly diagnosed bladder cancer patient. This documentation project 
started in 1983. Intake registration continued until January 1990. Follow-up 
registration continued until July 1991. 
The following items of each patient with a primary bladder tumour were 
registered: date of birth, sex, date of histological confirmation, main 
complaint, tumour morphology, grade of differentiation (according to the 
WHO grading system)20, localisation, TNM classification,29 tumour 
multiplicity and intravenous urogram result. Furthermore, all participating 
urologists were asked to take (and document) at least four random quadrant 
biopsies in macroscopically normal-looking urothelium (left and right lateral 
wall, trigone and dome) at the time of resection of the tumour(s). The therapy 
to be applied was transurethral resection of the tumour (TUR) in all patients. 
Urologists were advised to consider adjuvant intravesical instillations with 
chemotherapy or BCG vaccine in the case of multiple tumours. In pTl grade 3 
patients more aggressive therapy, such as radical surgery or external or 
interstitial radiotherapy, would have to be considered. To detect recurrences, 
cystoscopy and urine cytology were used every three months in the first year 
after treatment. From the second year onwards, this check-up was performed 
every six months. Follow-up data concerning disease and life status were 
collected for each patient once every year. 
Between 1983 and 1990, 2805 cases were documented. In 1991, all the data 
in the documentation project were reviewed using the medical files. After this 
check, the records of 100 cases were excluded. Of these, 30 had an inverted 
papilloma (which was considered to be benign), 58 had recurrent instead of 
primary disease at first registration, 5 did not have TCC in the bladder but in 
the upper urinary tract. In the records of 7 cases, there were major 
inconsistencies, which could not be corrected with information from the 
medical files. Of the remaining 2705 cases, 1745 (64.5%) had superficial 
TCC. "Superficial" is defined as tumour extension limited to the mucosa (pTa) 
or the lamina propria (pTl) of the bladder wall with or without carcinoma in 
situ in random biopsies. In urology practice, primary carcinoma in situ (pTis) 
is considered to be very different from pTa and pTl tumours because of its 
relatively aggressive clinical behaviour. For that reason, patients with primary 
pTis (N=52 in our series) were not evaluated in this study. 
Survival free of recurrence, survival free of progression and survival itself 
were measured from the date of histological diagnosis to the date of first 
recurrence, first evidence of disease progression and the date of death, 
respectively. Survival curves were based on the life table method, statistical 
significance being determined by the log rank test. The independence of host 
and tumour characteristics in determining survival free of recurrence and 
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progression was evaluated multivariately using the Cox proportional hazards 
model.5 
Although the case series in this documentation project is large, registration 
was not population based, which implies that incidence rates cannot be 
calculated from the project. However, nine Comprehensive Cancer Centres in 
the Netherlands keep population based regional cancer registries. One of these 
registries (IKL), covering a population of approximately 850,000 in the 
southern part of the Netherlands, has complete data on the incidence of 
superficial bladder cancer since 1986.26 Information from this registry from 
the period 1986-1989 was used to calculate age and sex-specific incidence 
rates. The population based cancer registry was also used to check whether 
patient intake in the documentation project was selective in any way. There 
appeared to be hardly any difference in age, sex, stage and grade distribution 
between the cancer registry and our case series, indicating no under or over 
representation in our series. 
RESULTS 
Incidence 
In the southern part of the Netherlands, the total bladder cancer incidence rate 
per 105 person-years (age-standardised to the European standard population) is 
36.3 for males and 6.7 for females. Superficial bladder cancer incidence rates 
for males and females are 23.7 and 3.9, respectively. This accounts for 65% 
of the total bladder cancer incidence in males and 58% in females. The 
proportion of all bladder cancers diagnosed as superficial disease is higher in 
the younger age categories than in the older ones (Figure 4.1). In males, the 
lifetime risk of developing bladder cancer (before the age of 75 years) is 
2.8%. The risk of superficial bladder cancer is 1.9%. In females, these risks 
are 0.5% and 0.4%, respectively. 
Initial presentation 
In the documentation project, 1745 patients with superficial (pTa or pTl) TCC 
were registered. Characteristics of this group of patients at inital presentation 
are listed in Table 4.1: 32% of all the patients had a pTl tumour; 16% of the 
tumours were classified with differentiation grade 3 and 29% had multiple 
tumours. Random biopsies of macroscopically normal-looking urothelium were 
taken in 1044 patients. In 22% of these patients, dysplasia or carcinoma in situ 
was diagnosed in at least one biopsy specimen. 
The median age at the time of diagnosis was 67 years. There was a clear 
shift towards a higher disease stage with increasing age (Figure 4.2). In 
patients under the age of 40 years, pTa grade 1 or 2 disease accounted for 
more than 85% compared to only 52% in patients over 80 years of age. The 
proportion of patients diagnosed with multiple tumours was also different for 
these age groups: 13% versus 37%. 
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From the total group of patients, 64% were treated with transurethral 
resection only; additional intravesical instillations were administered in 32% of 
the cases and more extensive therapy was given in 4% of the cases 
(radiotherapy and/or cystectomy). The latter 4% were excluded from the 
analyses of the risks of recurrence and progression. 
FIGURE 4.1 Age-specific incidence rates of total bladder cancer and 
superficial bladder cancer in males and females in the province 
of Limburg (NL), 1986-1989 
Incidence per 100,000 person-years 
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First recurrence 
The life-table (or actuarial) risk of recurrent disease after primary treatment in 
superficial bladder cancer was very high. Within 5 years, nearly 60% of all 
the cases had at least one recurrence (Figure 4.3). A proportion of this group 
of patients with a recurrence were prone to having more recurrences. The risk 
of recurrent disease in the first year of follow-up was 33% (95% CI: 31%-
35%). In the second year of follow-up, this risk was as high as 47% among 
the patients who had already had recurrent disease, compared to only 18% of 
the patients without recurrence in the first year of follow-up. 
The risk of recurrent disease in superficial bladder cancer was dependent on 
a number of prognostic indicators. In the univariate analyses, tumour stage 
(pTl vs. pTa), degree of differentiation (grade 3 vs. 2 vs. 1), multiplicity 
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TABLE 4 1 Clinical characteristics at disease presentation and the therapy 
applied in 1745 patients with primary superfical TCC 
Sex 
Men 
Women 
Age 
< 39 
40-49 
50-59 
60-69 
70-79 
80+ 
Main complaint (N=1227) 
Haematuna 
Irritative bladder symptoms 
Not urologica! 
Stage 
pTa 
pTl 
Grade' 
1 
2 
3 
Multiplicity 
Solitary 
Multiple 
Unknown 
Areas involved 
Neck only 
Trigone only 
Posterior wall only 
Right lateral wall only 
Left lateral wall only 
Dome only 
Anterior wall only 
2 Areas 
3 Areas 
^ 4 Areas 
Quadrant biopsies (N= 1044) 
No abnormalities 
Dysplasia in 1 or more areas 
Carcinoma in situ 
Therapy 
TUR only 
TUR + instillations 
TUR + (Partial) cystectomy or interstitial radiotherapy 
N 
1415 
330 
46 
103 
295 
550 
546 
205 
991 
156 
80 
1187 
558 
669 
793 
283 
1223 
510 
12 
27 
55 
123 
384 
390 
38 
25 
373 
166 
164 
816 
142 
86 
1116 
558 
71 
% 
81 1 
189 
2 6 
5 9 
16 9 
31 5 
31 3 
11 7 
80 8 
12 7 
6 5 
68 0 
32 0 
38 4 
45 4 
16 2 
70 1 
29 2 
0 7 
1 5 
3 2 
7 0 
22 0 
22 3 
2 2 
1 4 
21 4 
9 5 
9 4 
78 2 
13 6 
8 2 
640 
32 0 
4 1 
' In cases with different grades in one tumour, the highest grade was documented 
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FIGURE 4.2 Distribution (%) of stage and grade by age category in patients 
with superficial TCC of the bladder 
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FIGURE 4.3 Actuarial risk (%) of recurrent disease in patients with 
superficial TCC of the bladder (with 95% confidence interval) 
100 
Actuarial nek of recurrence (%) 
3 4 5 
Follow-up (years) 
No. of patients is 1,722 (cystectomy patients excluded) 
Chapter 4 - Clinical epidemiology 50 
(multiple vs. solitary) and extent of the tumour (involvement of more than 1 
bladder area vs. 1 area) had statistically significant effects on the risk of 
recurrence (all log-rank tests yielded Ρ values < 0.001). In our study, the risk 
of recurrence was not significantly different in maJe and female patients (P = 
0.56) and in patients younger and older than 70 years of age (P = 0.93). 
Even though intravesical chemotherapy or BCG was applied more 
frequently in patients with a poor prognostic profile, adjuvant therapy proved 
to be effective for preventing recurrences. In the patients who were treated 
with TUR alone, the 3-year risk of recurrence was 55%, whereas this risk was 
49% (P = 0.005) in the cases treated with intravesical instillations. 
We subsequently re-evaluated all the factors in a multivariate proportional 
hazards regression model. In this model, we also adjusted for the potential 
distorting effect of adjuvant intravesical chemotherapy. The results remained 
practically the same compared to those from the univariate analyses. Tumour 
stage, grade, extent and multiplicity had statistically significant independent 
prognostic value regarding the risk of first recurrence. See Table 4.2. 
TABLE 4.2 Results of the multivariate proportional hazards regression model 
on the risk of first recurrence 
Factor Relative 95% Confidence 
Risk Interval 
Sex 
Male vs. female 
Age 
^ 70 vs. < 70 
Tumour stage 
pTl vs. pTa 
Tumour grade 
2 or 3 vs. 1 
Tumour extent 
> 2 areas vs. 1 
Multiplicity 
Multiple vs. solitary 
Therapy 
Instillations vs. TUR alone 
1 01 
0 92 
1 38 
1.22 
1.34 
1.42 
0.67 
0 84-
0 80-
1 ΙΟ­
Ι.04-
1.Κ­
Ι.21 -
0.57-
• 1.21 
• 1.06 
1.65 
• 1.43 
• 1.57 
• 1.67 
0.80 
Patients with the most favourable prognostic profile may therefore be defined 
as those with a solitary pTa grade 1 tumour located in just one area. In our 
study cohort, 390 patients had such a favourable score on all four factors. The 
3-year risk in this group of patients (20% of whom were treated with 
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intravesical instillations) was 37 %. In the prognostically least favourable group 
of 55 patients with multiple pTl grade 3 tumours located in more than one 
area, the 3-year risk was as high as 77%, even though 69% of these patients 
were treated adjuvantly. 
Progression 
In the documentation project, disease progression was defined as a shift to a 
higher stage category (or the development of metastases). The three-year 
actuarial risk of progressive disease was 10.2% (95% CI: 8.6-11.8%). After 
five years, this risk had hardly increased: 13.3%. As is the case with the risk 
of recurrence, tumour stage, grade, extent and multiplicity appeared to have 
prognostic significance for the risk of progression. Furthermore, the three-year 
risk in patients older than 70 years was 12.7%, whereas this risk was only 
7.4% in patients younger than 70 years of age (P = 0.001). Contrary to the 
effect on recurrence, intravesical instillations did not lower the risk of 
progression. Because the group of patients who received adjuvant therapy had 
a poorer prognostic profile, the risk of progression in this group was even 
higher than in the patients treated with TUR alone (12% versus 8%). 
Except for tumour extent, all the factors with prognostic value in the 
univariate analyses retained their statistically significant quality in the 
multivariate regression model. 
Survival 
The actuarial risk of dying within 5 years after diagnosis was 25% (95% CI: 
23-27%). See Figure 4.4. This risk has to be compared to the expected risk of 
dying from all causes given the age and sex distribution of this group of 
patients. Using data from the Registration of Causes of Death from the Dutch 
Central Bureau of Statistics, we calculated the expected risk to be 13%. 
Therefore, the relative 5-year survival of patients with superficial bladder 
cancer was (100-25) / (100-13) = 86%. Thus, the excess risk of dying within 
5 years was approximately 14%. 
DISCUSSION 
The reported distributions of disease characteristics at initial diagnosis in our 
patients with primary superficial TCC, may not be representative for the 
situation in other countries. Especially the distribution of tumour grade and 
cold biopsy results may differ because there are not yet any objective criteria 
available to enable all pathologists to classify urothelium specimens in a 
reproducible manner.16,23,25 Although the stage distribution is believed to be a 
better measure for comparison, different interpretations of the pT category by 
different pathologists are also possible.1'14,17'22 Another factor which very often 
influences the distribution of disease characteristics is the inclusion of patients 
with recurrent instead of primary disease. 
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FIGURE 4.4 Actuarial survival (%) in patients with superficial TCC of the 
bladder (with 95% confidence interval) compared to the Dutch 
population (adjusted for differences in age and sex distribution) 
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B
~ Superficial TCC ~^~ Dutch population 
Over the past 15 years, it is likely that an increasing number of 
"papillomas" have been classified as papillocarcinomas (until 1978, the UICC 
listed only the category pTl for superficial bladder cancer).29 For this reason, 
comparison with other case series is only worthwhile if these series were 
documented fairly recently. In a recent study by Abel, 107 (62.6%) out of the 
171 cases with bladder cancer had superficial disease at presentation.2 Of 
these, 71% were classified as pTa. From the total group, 60.7% (compared to 
70.1% in our study) had solitary tumours. Grades 1, 2 and 3 accounted for 
6.5%, 85.0% and 8.4% of all the tumours, respectively. This distribution, 
which is very different from the finding in our study, illustrates the need for 
better reproducible methods for the assessment of certain indicators used for 
prognosis. In a recent Danish study, 61 % of 500 bladder cancer cases had 
superficial disease, of whom 69% had stage pTa.31 These numbers are very 
similar to those in our study. In the Danish case series, 7.9% of the pTa/pTl 
patients had carcinoma in situ in the cold-cup biopsy specimens taken at the 
first presentation of disease. Another 15.4% showed atypia grade 2. In a study 
by Flamm and Dona, CIS was found in the quadrant biopsy specimens in 6% 
of 216 patients. Dysplasia was found in 18%.8 In our study, the corresponding 
percentages were 8.2 and 13.6, respectively. In a recent study by Solsona,28 
48 out of the 306 patients with superficial bladder tumours had associated 
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carcinoma in situ, but this high number was caused by the inclusion of random 
area as well as suspicious area biopsies. 
Nearly 60% of all the patients in our study had at least one recurrence within 
5 years; most of them within 2 years (two-year recurrence risk: 45%). In fact, 
the recurrence risk in superficial bladder cancer is so high that (as apposed to 
other cancer sites) a second occurrence of TCC in the bladder is always 
interpreted as a recurrence, although this is theoretically incorrect.3 The 
recurrence risk is dependent on a number of prognostic factors.319 In our case 
series, we studied the effect of six prognostic factors and found that tumour 
stage, grade, extent and multiplicity were statistically significant prognostic 
indicators. Using these indicators, it may be possible to discern groups of 
patients with very different risks of recurrence. This, however, does not mean 
that it will be possible to predict the risk for individual patients fairly 
accurately. After all, for an individual patient there are only two possible 
outcomes: either he suffers a recurrence or he does not. Until we are able to 
differentiate all superficial bladder cancer patients into one group with a 100% 
recurrence risk and one group with a 0% recurrence risk, predictions for 
individuals will always be inaccurate.18 The finding in our project that even 
the best prognostic group still had a three-year recurrence risk of 37%, rather 
than 0%, shows that the inaccurate measurement of prognostic indicators 
together with biological variability inevitably leads to inaccurate predictions. 
Although we have a number of highly significant prognostic indicators for the 
risk of recurrence, apparently we do not have enough of these indicators yet. 
Superficial bladder cancer patients have a relatively high survival rate. In our 
study, the five-year survival was 75%, compared to 87% for the Dutch 
population adjusted for age, sex and calendar period. This finding is very 
similar to the 88% five-year survival rate for early stage bladder cancer 
(adjusted for normal life-expectancy) in the USA.4 In a recent study in the 
United Kingdom, the five-year survival in 150 pTa and 85 pTl patients was 
80 and 69%, respectively.10 Flamm and Havelec9 found a tumour-related 
mortality rate of 12.5% in 345 patients with primary superficial TCC treated 
with TUR and intravesical instillations. 
Despite the fact that the excess mortality in superficial bladder cancer is small, 
it may be asked why there is any excess mortality at all. Theoretically, it is 
possible that some of the superficial bladder cancers were already higher stage 
cancers at initial diagnosis. It is not exceptional for the pathologist to receive a 
resection specimen that does not contain any muscle tissue. Thus, some T2 
tumours (with a poorer prognosis) may have been staged as pTl tumours. In 
the surveillance programme of the U.S.A. National Bladder Cancer 
Collaborative Group, for example, there was no muscle tissue present in the 
specimens of 40 out of the 95 tumours classified as pTl.6 By contrast, in a 
recent study by Abel et al.,1 muscle tissue was present in 95% of the pTa/pTl 
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biopsy specimens. Unfortunately, comparable information was not available in 
our project. 
Another possible explanation for excess mortality is undertreatment. 
Especially multiple high grade tumours which extend into the lamina propria 
are often seen to progress to higher stage disease.6"·2 4 But until now, this 
knowledge has not led to a consensus policy of treating all "high risk" 
tumours with (at least) intravesical instillations. According to our data, a 
surprisingly high number (26%) of patients with multiple pTl grade 3 tumours 
were treated with TUR only. Nevertheless, it is dubious whether intravesical 
instillations prevent progression. Intravesical chemotherapy will usually 
decrease the rate and number of recurrences, but according to many authors it 
does not necessarily alter the ultimate outcome of the disease.9·12'21'27,30 
TABLE 4.3 Influence of the use of intravesical instillations for the treatment 
of the primary tumour on the five-year actuarial risk of 
progressive disease" 
N = 1674 
Sex 
Male 
Female 
Age 
< 70 
> 70 
Stage 
ρ Ta 
pTl 
Grade 
1 
2 
3 
Multiplicity 
Solitary 
Multiple 
TURc 
11.1 
11.0 
9.1 
13.6 
8.3 
19.3 
4.1 
15.9 
25.3 
8.8 
18.6 
5-
эпіу 
(N = 
(N = 
(N = 
(N = 
(N = 
(N = 
(N = 
(N = 
(N = 
(N = 
(N = 
year risk of progressive 
902) 
214) 
 634) 
482) 
 840) 
276) 
531) 
495) 
 90) 
 856) 
254) 
Intravesical 
instillations 
14.7 
19 6 
14.5 
17.0 
10.1 
24.7 
7.7 
12.0 
32.2 
10.4 
24.1 
(N = 
(N = 
(N = 
(N = 
(N = 
(N = 
(N = 
(N = 
(N = 
(N = 
(N = 
disease (%) 
499) 
 109) 
 314) 
244) 
339) 
 219) 
 137) 
277) 
 144) 
325) 
229) 
Log-rank 
Ρ value 
0.05 
0.06 
0.01 
0.29 
0.66 
0.07 
0.29 
0.24 
0.29 
0.27 
0.32 
' Progressive disease is defined as any shift to a higher stage category or the 
development of metastases 
Our data support the observation of these authors. As Table 4.3 illustrates, 
intravesical instillations seem to increase rather than decrease the five-year 
risk of progressive disease. However, this finding was caused by the fact that 
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more patients with a relatively poor prognosis received adjuvant therapy. In a 
proportional hazards model with sex, age, tumour stage, grade, multiplicity 
and therapy, the relative risk of TUR-only versus intravesical instillations was 
1.0 (95% CI: 0.7-1.3) Nevertheless, even though analysed multivariately, this 
finding has to be interpreted with caution because our study was not initiated 
to study therapy effects and therefore was not randomised. Furthermore, most 
of the patients in our study who were treated adjuvantly, received intravesical 
instillations with Adriamycin or Mitomycin-C Intravesical immunotherapy 
with Bacillus Calmette-Guérin RIVM, a strain produced by the Dutch National 
Institute of Public Health and Environmental Hygiene, was applied less 
frequently Two recent studies give some indication that BCG may be more 
effective in preventing progression than the chemotherapeutical agents.7 '5 
Also, at the present time an EORTC phase II study is going on in which a 
sequential combination of intravesical chemotherapy with Mitomycin-C and 
intravesical immunotherapy with BCG is evaluated in recurrent superficial 
TCC of the bladder. Possibly, in the near future such a combination regimen 
may appear to be effective in delaying or preventing disease progression 
In summary, we can conclude that even superficial TCC, as a distinct 
subgroup of bladder cancer, is a heterogeneous disease with an unpredictable 
clinical course. Even though some important indicators for future recurrences 
and progressive disease can be identified (such as tumour stage, grade and 
multiplicity), it remains a challenge to find more and stronger prognosticators 
which can more accurately predict the disease outcome in individual patients. 
Only then will it be possible to treat patients with a poor prognosis more 
aggressively and to avoid overtreatment of patients with a fairly good 
prognosis. 
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INTRODUCTION 
Cancer statistics in the USA show that in 1990, cancer of the urinary bladder 
accounted for 1.9% of all cancer-related deaths (9,700 deaths/year); 4.7% of 
newly diagnosed cancers were located in the bladder (49,000/year).1 Bladder 
cancer is a disease of the elderly, with a male predominance (4:1). The 
majority of bladder tumours present as superficial transitional cell carcinomas 
(TCC, pTa-1, grades 1-3). Approximately 60% of endoscopically resected 
superficial bladder tumours recur, usually within 1 year;2 10-20% of 
superficial TCC show progression to invasive and/or metastatic cancer.3 
Although all superficial TCCs are considered to be low-stage disease, they 
still comprise a heterogeneous group of tumours. A minority of patients have a 
relatively benign type of tumour which does not recur after transurethral 
resection (TURT). In these patients adjuvant treatment seems to be 
unnecessary. The largest group consists of patients who develop recurrent 
superficial bladder cancer without progression. A small group of patients, 
however, already have relatively malignant superficial tumours at presentation 
and develop muscle invasion despite adjuvant intravesical treatment. Cutler 
and associates hypothesised that 25% of all superficial bladder tumours are 
'aggressive' tumours from the start.4 It is important to distinguish these 
patients as early as possible. Many prognostic factors which might aid in this 
selection have been described over the past decades, but none of them is able 
to predict recurrence or progression with any real accuracy. In this paper the 
current knowledge about prognostic factors in superficial TCC of the bladder 
is reviewed. 
CLINICAL FACTORS 
Bladder cancer in the first decades of life carries a relatively good prognosis. 
This can be explained by the fact that bladder cancer at a young age is usually 
diagnosed as low-stage disease.5 Within the older age groups, however, age 
may affect survival to some extent, but the evidence is not very strong.6"8 
Probably, the prognostic significance of age is entirely determined by its 
correlation with tumour stage and grade.' Sex has never been found to be an 
important prognostic factor in superficial bladder cancer. 
The recurrence rate of superficial bladder tumours established before adjuvant 
treatment is initiated, has a significant impact on future recurrence and 
progression.4,10"12 Cutler and associates studied 404 patients with newly 
diagnosed bladder cancer and 446 patients with recurrent bladder cancer.4 
They found that the average time interval between the first and second 
recurrence (13 months, 93 patients), or between the second and third 
recurrence (12 months, 48 patients) was markedly shorter than that from the 
initial diagnosis to first recurrence (31 months, 233 patients). Dalesio et al. 
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found that the recurrence rate (the number of follow-up cystoscopy studies at 
which a recurrence was noted divided by the total number of months of 
follow-up) in 190 patients with primary tumours was 5.2 compared to 10.1 
(p<0.001) in 118 patients with recurrent tumours.10 They also found that 
patients with less than one recurrence per year when they entered the study 
had a similar prognosis to that of patients with a primary tumour. Loening et 
al. studied eight prognostic factors in 178 patients and found that in patients 
with a history of bladder cancer only the pretreatment recurrence rate had any 
influence on the later recurrence rate.11 In a retrospective study by Lutzeyer 
and colleagues on 315 patients, recurrences were noted in 45% of the patients 
within 3 years and were followed by a second recurrence in 84%.'2 Tumour 
progression was observed in 20-25% of primary pTa-pTl tumours, whereas 
56% of recurrent pTl tumours progressed. 
Tumour multiplicity is generally accepted as an important risk factor for a 
higher recurrence rate 4 1 0 1 2 1 7 and progression.12·14 Dalesio studied 308 patients 
with pTl bladder cancer who were treated with TURT and intravesical 
instillations. In a multivariate analysis, the number of tumours was the most 
important prognostic factor: 161 patients with 1 tumour had a recurrence rate 
of 4.8, 71 patients with 2-3 tumours had a recurrence rate of 7.8 and 68 
patients with more than 3 tumours had a recurrence rate of 12.3.10 The British 
Medical Research Council found similar results in a multivariate analysis of 
305 patients with superficial bladder cancer: the 2-year risk of recurrence for 
91 patients with a single tumour was 31%, for 214 patients with multiple 
tumours this was 58% (p<0.001).13 
The size of the tumour also seems to have prognostic
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although the 'critical' size of a tumour differs from study to study. Tumour 
localisation was found to be of importance in some studies. In the study by 
Loening, patients with a tumour in the trigone tended to have a shorter 
disease-free interval than those without trigonal involvement, but this was not 
statistically significant." Stephenson et al. found significant differences among 
subsites of the bladder.18 Tumours in the bladder neck (n=101) had a 
significantly poorer prognosis (5-year survival of 39 %, compared to 50-56 % 
for other subsites, ρ < 0.01). Localisation in the dome (n=70) was associated 
with higher grade lesions (p<0.001). However, although Stephenson's study 
incorporated a large number of patients (914), the absence of any correction 
for other prognostic factors makes these results difficult to interpret. 
Response to intravesical instillations also gives important information.1519 
Recurrent tumour 3 months after intravesical instillations was the most 
important prognostic factor in a multivariate analysis conducted by Parmar et 
al.: in 258 patients with a negative urethrocystoscopy (UCS) at 3 months, the 
2-year recurrence rate was 34%, while in 47 patients with positive findings at 
UCS this was 70% (p<0.001).15 Herr found similar results in a group of 221 
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patients with superficial bladder cancer treated with TURT and Bacillus 
Calmette-Guérin (BCG).19 If a pTl lesion was found, three months after BCG 
therapy, the risk of progression was 82% (14/17 patients), with a median 
interval of only 8.4 months, compared to 25% (44/178 patients) after a 
median period of more than 5 years in patients with no tumour or a pTa 
tumour after 3 months. 
In conclusion, recurrence rate established before adjuvant treatment, recurrent 
tumour after adjuvant treatment and tumour multiplicity are important 
prognostic factors. Tumour size and localisation may also have some 
prognostic value. 
mSTOPATHOLOGICAL FACTORS 
High grade tumours appear to have a higher risk of recurrence4,10·11 and 
progression4,6'712·13'20"23 and carry a higher risk of bladder cancer-related death.8 
Flamm and Havelec retrospectively studied the 5-year tumour-related mortality 
in a multivariate analysis. They found that poor differentiation was an 
important prognostic factor: 26/286 deaths occurred in grade 1 and 2 lesions, 
versus 14/59 in grade 3 (p=0.04).22 However, the interpretation of tumour 
grade may differ between pathologists. Pannar et al. found that tumour grade 
was a prognostic factor when assessed by a reference pathologist, but that it 
was of no prognostic value when assessed by local pathologists (Table 5.1).15 
Ooms et al. compared the grading results of 57 bladder tumours by 7 
pathologists and found an inconsistency of about 50% among pathologists 
(interobserver variability) and for individual pathologists across time (intra-
observer variability).24 
Tumour stage also has prognostic significance,«•б-мычлдэ.и ^,
ut again, the 
limitations of the histological classification should be taken into account 
(Table 5.1). Cutler et al. found that 25% of the patients with pTl tumours 
(and 40% with pTl grade 3 tumours) developed muscle invasion within two 
years as compared to 3% of the patients with pTa tumours.4 In a multivariate 
regression analysis, Loening and associates found that tumour stage had a 
statistically significant relation with the recurrence rate in patients with no 
bladder cancer history (hazard ratio = 1.6)." Malmstrom et al. studied the 
clinical course in 195 patients. Tumour stage appeared to be the most 
significant predictor of cancer-related death in a multivariate analysis.8 Other 
studies also found that tumour stage was the most significant determinant for 
survival7,25 and cancer-related death.21 
The presence of histological abnormalities adjacent to the tumour seems to be 
a positive predictor for subsequent tumour progression.26 Random bladder 
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biopsies can give information about concomitant macroscopically invisible 
abnormalities of the urothelium, which might also influence the prognosis. 
However, urologists should be aware of the imprecision and lack of 
reproducibility with regard to the interpretation of such biopsies.27 There is a 
correlation between the appearance of the mucosa at cystoscopy and the 
histology of the biopsy. Wallace et al. studied 585 mucosal biopsies in 154 
patients.28 All the carcinomas, whether carcinoma in situ (CIS), papillary or 
invasive carcinoma, were grouped together. In 399 biopsies of normal-looking 
mucosa, histological abnormalities were found in 33%, including carcinoma in 
4.5%. In 98 biopsies of red but flat mucosa, abnormalities were found in 
52%, including carcinoma in 14%. In 88 biopsies of granular or mossy 
mucosa, these figures were 81.5% and 42%, respectively. Random biopsies 
are taken from normal-looking mucosa. An abnormal biopsy result (dysplasia 
and/or CIS) suggests a higher risk of recurrence414·20·29 and progression.4 1 3 
These studies, however, involved small numbers of patients (58-216) and had 
limited follow-up periods (1.6-3 years). Furthermore, the relation between the 
biopsy result and the risk of recurrence was not adjusted for other prognostic 
factors, even though the result of random biopsies is known to be strongly 
correlated with tumour stage and tumour grade.29"30 
TABLE 5.1 Difference in the prognostic value of tumor grade and stage as 
assessed by reference or local pathologist14 
Reference pathologist 
Grade 1 
Grade 2 
Grade 3 
pTa 
pTl 
Local pathologist 
Grade 1 
Grade 2 
Grade 3 
pTa 
pTl 
Patients 2-year recurrence 
rate, % 
188 36 
91 38 
26 70 
254 37 
51 48 
182 37 
110 43 
13 30 
151 32 
154 46 
ρ value 
(log rank) 
0.009 
0.11 
0.4 
0.02 
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Urine cytology is a useful routine and noninvasive test for the early detection 
of bladder cancer and for monitoring a patient after treatment, although its 
accuracy depends on the tumour grade and the experience of the 
cytopathologist.3133 The use of monoclonal antibodies in urine cytology might 
increase its accuracy.32 The prognostic value of cytology is questionable, 
although Heney et al. found a 3-year disease-free survival of more than 50% 
in 113 patients with negative cytology compared to a disease-free survival of 
less than 25% in 39 patients with positive cytology (p<0.01). 1 3 
In conclusion, tumour stage and especially tumour grade are major 
histopathological prognostic determinants, even though there is considerable 
variability in the classification of these factors. The value of random mucosal 
biopsies remains controversial. Urine cytology is useful for diagnosis, but 
probably has no prognostic value. 
BLOOD GROUP ANTIGENS 
In the late seventies, a relation was reported between a loss of cell surface 
ABH blood group antigens (BGA) and urothelial malignancy. Loss of BGA 
expression indicated tumour cell dedifferentiation and hence carried a poor 
prognosis.34 In 1979, Emmott et al. published data on the BGA status of 76 
bladder tumours.35 They found that 70% of grade 1 lesions were BGA 
positive, compared to none of the 26 grade 3 tumours. None of the 48 
invasive tumours were positive, compared to 12 of the 16 stage A tumours. Of 
the 9 superficial tumours which progressed, only 1 was BGA positive. Other 
studies found similar results: the absence of BGA was associated with a 
markedly higher risk of progression in muscle invasion.36"38 
These initially promising results, however, were followed by less positive and 
even contradictory reports. Fujita and associates found that 43% of grade 3 
tumours, 43% of invasive tumours and 60% of metastatic tumours retained the 
isoantigen, and concluded that it was an invalid predictive indicator.3' It was 
only possible to detect all grade 2 or 3 tumours and all invasive tumours if the 
patients had blood group A or B, and there was H but no A and В activity (a 
total blockade of the conversion of H substance into A and В substances). 
Pauwels et al. analyzed 78 TCCs of the bladder.40 In 51% of the 59 superficial 
tumours, BGAs were present, whereas all 19 infiltrating and high grade 
tumours were negative (p=0.001). However, in superficial tumours no 
correlation was found between antigen expression and tumour recurrence or 
progression: the mode of BGA expression had no additional prognostic value 
to tumour grade. 
Nakatsu et al. investigated immunoperoxidase detection of BGA and 
carcinoembryonic antigen (CEA) on preserved paraffin blocks of histo-
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pathologically verified pTl and pT2 TCC.41 Absence of BGA was not 
correlated with histological grade and stage, but the presence of CEA was. 
BGA could not predict poor survival, whereas CEA detection could. In a 
prospective study with a 3-year follow-up, Abel et al. studied the prognostic 
value of BGA expression.42 They precluded the use of BGA as a guide to 
prognosis when used alone or in combination with the pathological stage. 
ABH antigenicity of mucosal biopsies has also been studied.17,23 In a small 
series, Das and colleagues found that ABH antigenicity was a significant 
predictor of recurrent disease: in 21 patients with antigen-positive mucosal 
biopsies, the recurrence rate was 0.3 per year compared to 2.0 in 13 negative 
patients (p<0.001).'7 Its predictive value was better than that of number, size, 
grade and ABH antigenicity of the primary tumour. Huland et al. found 
similar results.23 Loss of BGA was found in 7 tumours and 5 biopsies in 8 
patients who developed progression, compared to 5 tumours and 5 biopsies in 
14 patients with non-progressive tumours. 
The possibility that ABH isoantigen change is an early event in bladder 
carcinoma, together with the assumption that bladder carcinoma is a 
heterogeneous disease might be an explanation for these controversial findings. 
The limited value of the ABH blood group antigen expression and its failure in 
blood group О individuals, encouraged the evaluation of other blood group 
related antigens. For example, in a group of 93 tumours, a relation was found 
between an abnormal pattern of the Lewis A antigen and tumour stage and 
grade (p<0.01).43 Lewis X antigen can be used on exfoliated bladder cells and 
enhances the detection of urothelial tumour cells, particularly from low stage 
and low grade tumours.44 
In conclusion, it is not yet clear whether or not the expression of blood-group-
related antigens has any additional prognostic value to the prognostic 
characteristics already available. 
CYTOGENETIC FACTORS 
It has been hypothesised that disease progression is associated with genomic 
instability. Therefore, measurement of the DNA content (ploidy analysis) may 
be of use to determine progression. DNA ploidy seems to be an important 
marker in predicting tumour behaviour. Highly aneuploid tumors of the 
bladder have a strong propensity to progress to invasive and metastatic 
growth. A small proportion of grade 2 and 3 tumors have a predominantly 
tetraploid DNA distribution and this pattern appears to express an intermediate 
grade of clinical malignancy, with a high recurrence rate and a moderate 
invasive tendency.43 The diagnostic accuracy of the DNA ploidy and its value 
for predicting recurrence can be increased especially when determined by flow 
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cytometry.45,4é Recently, chromosome abnormalities have been examined with 
in situ hybridisation, a new and rapid technique, which assesses DNA ploidy 
even more specifically than flow cytometry.47 
Lamb was one of the first to report on a large series of bladder tumours in 
which a correlation was found between histopathology and chromosome 
counts.48 When cellular differentiation was lost, this was associated with a 
change in the average number of chromosomes in the tumour. He also found a 
wider range of chromosome numbers among the individual tumour cells and 
an increase in structural chromosome abnormalities. Later on, more studies 
confirmed the importance of DNA ploidy. Masters et al. found that tumour 
aneuploidy had similar prognostic significance to high tumour grade and a 
high proportion of tumour cell nuclei in the proliferative S phase.49 
Progression occurred in 35% of the patients with one of these 3 features 
within 3 years. All of these features were found in 8 tumours, 6 of which 
became invasive. In a retrospective study on 195 évaluable patients, 
Malmstrom et al. found that ABH status and DNA ploidy had no significant 
value in a Cox multivariate analysis.8 However, a combination of both factors 
was an independent predictor of early tumour progression in addition to 
tumour stage. Pauwels and associates also found a consistant correlation 
between chromosome numbers, tumour grade and stage and the clinical 
course. Chromosome abnormalities, however, were of no additional prognostic 
value to grading.40 
DNA ploidy has also been investigated in superficial bladder cancer. DeVere-
White et al. found that tumour aneuploidy in pTa grades 1-2 bladder tumours 
was closely related to disease recurrence and progression: 6/21 patients with a 
diploid-tetraploid <20% hyperdiploid histogram developed recurrent tumours, 
compared to 9/9 patients with a nontetraploid-aneuploid, a tetraploid-
aneuploid, or a diploid-tetraploid > 20% hyperdiploid histogram. Also, the 
ploidy pattern changed during recurrent disease in 20/28 cases.50 This gave 
additional prognostic information to stage and grade classification. 
In an earlier study using flow cytometry, Norming et al. found the same 
DNA ploidy in random mucosal biopsies and exophytic tumours, which 
supported the concept that despite normal morphology, intraurothelial lesions 
might develop into frank tumours.51 Histopathology and DNA flow cytometry 
of random mucosal biopsies were also compared in 290 patients with untreated 
bladder carcinoma.52 There was a clear relation between histopathology and 
DNA ploidy. Biopsies with CIS, atypia or no atypia showed aneuploidy in 
76%, 41% and 10%, respectively. The DNA profiles of the aneuploid cell 
populations, however, were similar, irrespective of the corresponding 
histopathology. These findings suggest that apart from ploidy, other factors, 
such as the DNA profile, may appear at an early stage of tumour 
development. 
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The volume corrected mitotic index (M/V index) also carries prognostic 
value.21 In a series of 83 bladder cancer patients with a mean follow-up of 13 
years, the M/V index correlated with disease recurrence, survival and 
metastatic potential. In a multivariate analysis with tumour stage and grade, 
the M/V index had statistically significant prognostic value. 
Marker chromosomes are abnormal morphological forms, which are thought 
to occur in diseases which predispose to cancer. Some reports describe that 
recurrences
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 and progression56 in moderately and well-differentiated 
superficial bladder tumours only occur in marker chromosome positive 
tumours. An absence of marker chromosomes, however, had no prognostic 
value. Falor and Ward studied a small series of patients and stated that the 
triad of tetraploidy, marker chromosomes and submucosal invasive carcinoma 
appeared to carry such a lethal prognosis that it justified early radical 
cystectomy: out of 6 patients with this combination, 3 required cystectomy 9-
25 months after diagnosis and 3 patients (1 after cystectomy) died from 
metastatic disease within 28 months.53 Sandberg found marker chromosomes in 
32 out of 50 papillary tumours.55 In 12 recurrent tumours, only one was 
marker chromosome negative. In invasive TCC, a correlation was seen 
between the numbers of marker chromosomes and progression. More recently, 
the additional value of marker chromosomes to histopathology could not be 
confirmed. In a study on 50 patients with a maximal follow-up of 17 years, 
Falor and Ward-Skinner found that absence of marker chromosomes did not 
rule out ultimate recurrence and in cases with recurrence, the marker 
chromosome was of no additional value to histopathology.57 
Chromosome abnormalities may be the cause of malignant transformation, or 
may be caused by disease progression or selection because of drug resistance. 
If a cell culture is used, its influence on chromosomal structures has to be 
taken into account. Deletions in chromosome 1 are common in tumours at 
most sites, also in bladder cancer, indicating that it may be an early event in 
malignant transformation.5* Deletions in chromosome Ц 5 8 6 1 and 1759 have 
been identified as poor prognostic factors in bladder cancer. Loss of genetic 
material from the short arm of chromosome 11 might be related to invasive 
behaviour of a tumour.61 Deletions in 1 lp might be of special interest in view 
of the identification of the c-Ha-rasl oncogene on this chromosome arm.58 In 
this case, homozygosity for recessive cancer genes might explain the relation 
between the loss of chromosomal material and cancer. With the recent 
identification of the transformation-associated p53 gene as a tumour suppressor 
gene, located on chromosome 17,62 a possible relation has been found between 
p53 function and invasive behaviour of TCC. Deletion in chromosome 9 is 
seen in all stages of bladder cancer, which suggests that the loss of a tumour 
suppressor gene on chromosome 9 might be an early event in malignant 
transformation.59·63 It is intriguing to note that the genes which determine the 
ABH surface membrane antigenes are also located on chromosome 9 and that 
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the loss of ABH antigen expression may aJso be associated with an increased 
risk of tumour progression. Other important primary chromosomal changes 
may be trisomy 13 and trisomy 7.M Several other chromosome abnormalities 
have been detected, but no definite correlation has yet been found with bladder 
cancer.
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 Furthermore, Perucca et al. emphasized that there is considerable 
variability among different publications regarding the prevalence of 
chromosome abnormalities.68 Nevertheless, several cytogenetic as well as 
molecular findings have provided evidence that genetic deletions (existence of 
tumour suppressor genes) are involved in tumour progression. 
BIOCHEMICAL FACTORS AND TUMOUR-ASSOCIATED ANTIGENS 
Cell motility and extracellular matrix (ECM) degradation are thought to be 
important factors in the process of tumour invasion and/or metastases. The 
autocrine motility factor (AMF) is a cytokine which stimulates the motility of 
human tumour cells and may play a major role when tumour cells become 
locally invasive.69 AMF can be measured in the urine. Motility values (mean 
motility) are higher in bladder cancer patients (197.3, 22 patients) than in 
healthy controls (47.3, 27 patients, ρ< 0.001) and a correlation has been 
found between mean motility and tumour stage (135.4 in noninvasive TCC 
versus 229.3 in invasive TCC, ρ<0.001) and recurrence rate (228.2 in 
patients with recurrences versus 71.7 in tumour-free patients, p<0.001).70 
Plasmin plays an important role in ECM degradation. Plasmin degrades some 
components of the ECM and activates two important enzymes which degrade 
fibrillar collagen and collagen in the basement membrane. The levels of 
plasminogen activator (which transforms plasminogen into plasmin) were 
found to be higher in bladder cancer than in normal mucosa.71 Moreover, the 
levels increased with histological grade. Further studies must identify the 
prognostic significance of AMF and ECM degradation. 
Immunohistochemical staining of subepithelial basement membrane 
components can clearly show any interruption or absence of this membrane, 
which is of value for the early detection of microinvasion. In patients with a 
patchy or absent basement membrane the incidence of progression was 
significantly higher, but there was no relation with the recurrence rate.25,72 
However, in a multivariate analysis, the value of basement membrane staining 
was largely eliminated by tumour stage.25 
The value of the epidermal growth factor receptor (EGF-R) has been 
investigated recently.73,74 Normally, EGF-R is found only on the basal layer of 
epithelial cells. In bladder tumours, the urinary concentration of EGF and the 
EGF-R expression in tumours may be elevated. Messing found that EGF-R 
was expressed on superficial and deeper layers of the urothelium in low and 
high grade TCC, as well as in normal-looking urothelium in patients with 
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TCC elsewhere in the bladder.74 This might favour the interaction of 
premalignant and malignant urothelium with urinary EGF. Neal et al. studied 
101 patients with newly diagnosed bladder cancer, with a follow-up of 30 
months.73 They found an association between strongly positive 
immunohistochemical staining of the EGF-R (48 tumours) and high stage 
bladder cancer (p<0.001). In cases with pTa and pTl bladder cancer (52 
patients), EGF-R positivity was associated with multiplicity, short time to 
recurrence and high recurrence rate. In a multivariate analysis, EGF-R 
positivity was predictive of bladder-cancer-related death in all 101 patients 
(relative risk 3.4, p<0.001). In 52 patients with superficial TCCs, EGF-R 
positivity was predictive for time to recurrence (relative risk 2.3, p=0.03) and 
time to progression (relative risk 22.12, ρ<0.001). 
Elevated plasma tissue polypeptide antigen (TPA) levels have been 
demonstrated in malignant and benign conditions. In all stages of bladder 
cancer, plasma TPA might be a sensitive diagnostic marker.7 5 7 6 Urinary TPA 
was found to have a significant relation to the Τ category in a study on 81 
bladder cancer patients: TPA levels were elevated in 74% of the patients with 
invasive bladder cancer, compared to 15% of the patients with superficial 
tumours (p<0.001). 7 7 In invasive bladder cancer, TPA can be used to monitor 
therapy.78 However, the role of TPA in superficial bladder cancer is probably 
limited to the detection of recurrent disease and has no prognostic value. 
Transferrin receptor (TFR) expression is considered to be a marker of 
proliferative activity. Smith et al. found that TFR positivity on the initial 
primary tumour had a significant relation with recurrence rate.79 
Urinary CEA is useful for the early detection of bladder cancer and for 
monitoring treatment, but like urinary cytology, it probably does not carry any 
prognostic value. An increase in urinary immunoglobulins was found to be of 
negative prognostic value.31 
Recently Fradet et al. showed that monoclonal antibody (Moab) T138, 
measured by flow cytometry, is a good single indicator of cancer progression, 
better even than tumour cell DNA ploidy.80 The combination of both 
examinations might give additional information on the prognostic behaviour of 
bladder cancer. Several other Moabs have been used to stain TCC. Conn et al. 
used the Moab HMFG-2 to stain bladder tumours and mucosal biopsies.81 In 
76 bladder tumours, the staining pattern correlated with the tumour stage 
(p<0.01) and grade (p=0.01). In 35 mucosal biopsies, the staining pattern 
correlated well with the histopathology. The staining pattern also proved to be 
a good predictor of subsequent disease progression in superficial tumours. 
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CONCLUSIONS 
Many prognostic factors have been reported for recurrence and progression of 
superficial bladder cancer. Unfortunately, however, in many reports the 
prognostic significance of a certain factor has been claimed with a (small) Ρ 
value only, which has no quantitative meaning for the relevance of a factor 
This makes it rather difficult to make an objective interpretation of the results. 
Furthermore, many reports have only presented the results from univariate 
analyses, which may have led to overrated prognostic values (although a new 
factor which has prognostic significance only because of its correlation with 
other factors, may still be of practical use if it is cheap and easy to assess). 
Which factors can be used in urological practice, or may be used in the near 
future to make a prognostic assessment and to define treatment policy? 
Recurrence rate before and after treatment gives important information about 
future tumour behaviour. Cystoscopic features, such as tumour multiplicity 
and size should also be taken into account. Although there is considerable 
variability in the interpretation of histopathological features, tumour grade and 
especially tumour stage are of major prognostic importance. Controversial 
reports about blood group antigens have made the ABH antigenicity tests 
unsuitable for daily practice. A correlation exists between DNA ploidy and the 
malignant potential of a tumour, but whether or not this information has any 
additional meaning to conventional histopathology remains to be proven The 
same applies to marker chromosomes and other chromosomal abnormalities 
Cell motility and ECM degradation are promising factors to study the 
malignant potential in an early phase, as is the EGF-R. Despite the 
identification of new prognostic factors, urologists have to be aware that their 
predictions of the clinical course in individual patients with superficial bladder 
cancer will not always be accurate 
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SUMMARY 
Random urothelium biopsies are frequently used as a prognostic test in 
the management of superficial bladder cancer. However, to our knowledge 
the prognostic significance of this test, in addition to the already available 
prognosticators, has never been studied. We prospectively assessed the 
clinical course of 1001 patients with primary superficial transitional cell 
carcinoma of the bladder from whom random urothelium biopsies had 
been taken at initial endoscopical surgery. 
Actuarial risks of recurrence and disease progression were determined for 
each prognostic characteristic and comparisons were made using log-rank 
tests. The independent prognostic significance of random biopsies was 
examined with Cox's regression analyses. 
The 3-year risk of recurrence in patients with dysplasia or carcinoma in 
situ (CIS) in macroscopically normal-looking urothelium was only slightly 
higher than the risk in patients without dysplastic changes (57% and 51%, 
respectively; Ρ = 0.09). Concomitant dysplasia or CIS significantly 
increased the 3-year risk of disease progression (21% versus 7%; Ρ < 
0.001). After adjustment for the effects of age, tumor stage, grade, size 
and multicentricity, the result of random biopsies had no prognostic 
significance regarding the risk of recurrence, but the detection of 
dysplasia or CIS increased the risk of progression by a factor of 1.8. 
This result suggests that random urothelium biopsies may be useful as an 
additional guide in defining therapy in primary superficial bladder cancer. 
However, before the implementation of routine random biopsies in clinical 
practice, their value should be evaluated by means of a medical decision 
analysis. 
INTRODUCTION 
The most common form of bladder cancer is papillary transitional cell 
carcinoma (TCC). These carcinomas are usually confined to the bladder 
mucosa or show superficial invasion into the lamina propria. It has been 
recognized for some time that at least part of these superficial tumors are 
manifestations of cystoscopically occult widespread urothelial disease. In these 
cases, urothelial dysplasia may be detected with random biopsies of normal-
looking mucosa. In 1960 Eisenberg and associates were the first to show the 
clinical relevance of these concomitant dysplastic changes. Patients with 
cellular atypia in normal-looking mucosa had a poor prognosis, whereas 
patients with no mucosal atypia had controllable disease.' Since then, many 
authors have confirmed the prognostic significance of intraurothelial dysplasia 
in patients with superficial bladder cancer.213 
It is well known that the presence or absence of dysplastic abnormalities 
strongly correlates with other prognostic factors, especially with tumor 
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grade.5"14"16 To assess the independent prognostic significance of concomitant 
urothelial dysplasia, therefore, adjustment has to be made for this correlation 
with other factors. If the prognostic ability of the result of random biopsies is 
determined by its association with the factors already available, then random 
biopsies will be quite useless for patient management. However, apart from 
one small study on 37 patients with a pTlG3 tumor,13 the existing prognostic 
factors have not been formally adjusted for in the studies on random biopsies 
published so far. We performed an analysis on the independent prognostic 
effect of concomitant dysplastic abnormalities in primary superficial bladder 
cancer regarding time to first recurrence (the term 'recurrence' in this text 
means a new tumor occurrence) and time to disease progression. 
PATIENTS AND METHODS 
The study cohort 
Between January 1983 and December 1989, the Dutch South-East Cooperative 
Urological Group prospectively documented the patient and tumor 
characteristics of 1745 cases with histologically verified primary superficial 
TCC of the bladder. Superficial was defined as tumor extension limited to the 
mucosa (TNM stage pTa) or the lamina propria (pTl) of the bladder wall.17 
Because of its relatively aggressive behavior, primary carcinoma in situ (pTis: 
N = 52) was considered to be different from pTa and pTl tumors and, 
therefore, was not included in this series. A proportion of the urologists who 
participated in the project took preselected cold-cup biopsies of normal-looking 
urothelium from all their patients during initial endoscopical surgery. The 
biopsy sites were the left and right lateral wall, the trigone and dome. The 
results of these biopsies were classified as being positive if dysplasia (either 
mild, moderate or severe) or carcinoma in situ (CIS) was found in one or 
more of the specimens. In 1044 patients, random biopsies were taken. 
All the patients were initially treated with transurethral resection (TUR) of 
the tumor(s). Forty-three patients received additional treatment with interstitial 
radiotherapy, external radiotherapy or cystectomy because of residual tumor 
after TUR. These 43 patients were excluded from the analyses. Of the 
remaining 1001 patients, 607 were treated with TUR alone, and 394 received 
prophylactic adjuvant intravesical therapy (doxorubicin, mitomycin or bacille 
Calmette-Guérin). The patients were followed with cystourethroscopy and 
urinary cytology every three months for a period of one year. If there were no 
recurrences during this period, the patients were subsequently followed at 6-
month intervals. Once yearly, follow-up data were registered concerning the 
disease status and vital status. In 1991, all the data from the project were 
reviewed using the medical files. The median follow-up period for the study 
cohort was 3.5 years. 
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Statistical methods 
Time to recurrence and time to progression, calculated from the date of initial 
TUR, were used as end points in this study. Progression was defined as a shift 
to a higher tumor stage category or the development of regional or distant 
metastases. The follow-up of patients without tumor recurrence and disease 
progression was censored to the date of the last hospital visit. In case of death 
not related to the bladder cancer, the follow-up was censored to the date of 
death. 
We used the actuarial method (with the log-rank test) to assess the 
prognostic effect of the following factors: age, gender, tumor stage (pTl 
versus pTa), tumor grade (grade 3 versus 2 versus 1, according to the WHO 
grading system),18 tumor multicentricity (multiple versus solitary), tumor 
extent and the result of random bladder biopsies (dysplasia or CIS versus 
normal). Tumor extent was defined as the number of bladder areas involved (3 
or more versus 2 versus 1) instead of the size of the tumor. We distinguished 
the following bladder areas: bladder neck, trigone, dome, anterior and 
posterior wall, and left and right lateral wall. 
The independent prognostic effect of dysplastic mucosa or CIS in random 
biopsy specimens on time to recurrence and time to progression was analyzed 
in multivariate analyses using the proportional hazards model.19 In these 
multivariate analyses we first evaluated all the factors for inclusion in the 
model (with a stepwise procedure on level Ρ = 0.10), except for the random 
biopsy result. In this first phase, we also took the therapy into account 
(intravesical chemotherapy or BCG versus TUR alone). Only after arriving at 
the final model we included the random biopsy result and tested the 
improvement of the model with the likelihood ratio test. The possibility of a 
different prognostic effect of random biopsies in subgroups of patients was 
tested by means of interaction factors (cross-product terms). 
RESULTS 
During the period of follow-up, 513 of the 1001 patients suffered at least one 
recurrence, 102 patients had a recurrence in a higher tumor stage category or 
developed regional or distant metastases. The results of the univariate analyses 
on prognostic factors for the risk of recurrence and the risk of progression are 
summarized in Tables 6.1 and 6.2, respectively. 
The 3-year actuarial risk of recurrence in patients with dysplasia or 
carcinoma in situ in normal-looking urothelium was 57% (Table 6.1). In 
patients without these dysplastic abnormalities, the 3-year risk of recurrence 
was only slightly lower: 51%. This difference was borderline statistically 
significant (P = 0.09). Tumor stage, tumor extent, multicentricity and tumor 
grade were significant prognostic indicators for the risk of recurrence. 
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TABLE 6.1 Univariate analysis of prognostic factors for tumor recurrence 
Factor 
Age 
0-49 
50-59 
60-69 
70-79 
80+ 
Gender 
Male 
Female 
Tumor stage 
pTa 
pTl 
Tumor grade 
1 
2 
3 
Tumor extent 
1 area 
2 areas 
3 or more 
Multicentricity 
Solitary 
Multiple 
Unknown 
Random biopsies 
Normal 
Dysplasia/CIS 
No. 
90 
178 
319 
306 
108 
817 
184 
687 
314 
371 
456 
174 
616 
222 
163 
725 
270 
6 
793 
208 
3-yr risk of 
recurrence (actuarial) 
0.49 
0.52 
0.52 
0.54 
051 
0.53 
0.48 
0.47 
0.64 
0 46 
0.56 
0.56 
0.46 
0.58 
0.71 
0.48 
0.63 
0.51 
0.57 
Ρ value 
(log-rank test) 
0.96 
0.45 
<0.001 
0.01 
<0.001 
<0.001 
0.09 
The 3-year risk of tumor progression in patients with concomitant dysplastic 
abnormalities was much higher than that in patients with microscopically 
normal mucosa: 21% versus 7% (P < 0.001) (Table 6.2). As opposed to its 
effect on the risk of recurrence, the result of random biopsies was one of the 
most discriminating factors regarding the risk of progression. The same is true 
for tumor grade, which was strongly correlated with the result of random 
biopsies (the frequency of dysplastic abnormalities was 11%, 20% and 47% in 
patients with tumor grades 1, 2 and 3, respectively): whereas the risk of 
recurrence in patients with a tumor of grade 2 or 3 was identical, the risk of 
progression was much higher in patients with less differentiated tumors. 
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TABLE 6.2 Univariate analysis of prognostic factors for disease progression 
Factor 
Age 
0-49 
50-59 
60-69 
70-79 
80+ 
Gender 
Male 
Female 
Tumor stage 
pTa 
pTl 
Tumor grade 
1 
2 
3 
Tumor extent 
1 area 
2 areas 
3 or more 
Multicentricity 
Solitary 
Multiple 
Unknown 
Random biopsies 
Normal 
Dysplasia/CIS 
No. 
90 
178 
319 
306 
108 
817 
184 
687 
314 
371 
456 
174 
616 
222 
163 
725 
270 
6 
793 
208 
3-yr risk of 
progression (actuarial) 
0 02 
0.08 
0.09 
0.13 
0.16 
009 
0.12 
0.07 
0.17 
0.04 
0.09 
0.26 
0.07 
0.11 
0.18 
0.07 
0.17 
0.07 
0.21 
Ρ value 
(log-rank test) 
0.002 
0.35 
<0001 
<0.001 
<0.001 
<0.001 
<0.001 
Another difference with regard to the risk of recurrence was that age appeared 
to be a prognostic indicator for tumor progression. Detection of superficial 
bladder cancer in older age groups was associated with a somewhat poorer 
prognosis. 
After the univariate analyses, we used multivariate regression analyses to 
examine the independent prognostic effects of the factors listed in Tables 6.1 
and 6.2. In these regression models we controlled for the effect of intravesical 
chemotherapy or BCG. Age was analyzed as a continuous variable (the 
number of years in relation to the mean age of 66). In the regression model of 
time to first recurrence, tumor stage, tumor extent and multicentricity had 
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statistically significant prognostic effects at the Ρ = 0.10 level (Table 6.3). In 
this study, age, gender and tumor grade had no (statistically significant) 
independent prognostic value. The same held true for concomitant dysplasia or 
CIS. Adding the result of random biopsies to the model did not improve the 
model (-2 log likelihood = 0.93: Ρ > 0.50). The hazard ratio of the random 
biopsy result was only 1.12 (90% CI: 0.93 - 1.34). Also, none of the 
interaction terms of the random biopsy result with other factors was 
statistically significant, indicating the absence of prognostic relevance of 
random biopsies in subgroups of patients. 
TABLE 6.3 Results of multivariate proportional hazards regression model of 
time to first recurrence 
Factor 
Tumor stage 
pTl vs. pTa 
Tumor extent 
2 areas vs. 1 
3 or more areas vs. 1 
Multicentricity 
Multiple vs. solitary 
Therapy 
Instillations vs. TUR alone 
Random biopsies 
Dysplasia/CIS vs. normal 
Hazard Ratio 
1.51 
1.19 
1.68 
1.20 
0.70 
1.12 
90% Confidence 
Interval 
1.30- 1.75 
0.97- 1.45 
1 36 - 2.08 
1.00- 1.43 
0.60 - 0.83 
0.93- 1.34 
The results of the model of time to progression are summarized in Table 6.4. 
Tumor grade appeared to be the strongest prognostic factor. The risk of tumor 
progression in the patients with a grade 3 tumor was more than 5 times higher 
than the risk in the patients with a grade 1 tumor. Other factors with 
predictive value for disease progression were age and multicentricity. In 
contrast to the effect on time to recurrence, random urothelium biopsies had 
additional prognostic relevance regarding time to progression (-2 log 
likelihood = 7.2: Ρ < 0.01). The risk of tumor progression was increased by 
a factor of 1.8 (90% CI: 1.26 - 2.51) in the case of dysplastic abnormalities in 
apparently normal mucosa compared to a normal biopsy result. Inclusion of 
interaction factors led to no improvement in the model, indicating that the 
prognostic effect of mucosal abnormalities was approximately the same for 
different patient subgroups. 
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TABLE 6.4 Results of multivariate proportional hazards regression model of 
time to progression 
Factor 
Age 
Each year in relation 
to 66 years 
Tumor grade 
grade 2 vs. 1 
grade 3 vs 1 
Multicentricity 
Multiple vs solitary 
Random biopsies 
Dysplasia/CIS vs normal 
Hazard Ratio 
1 02 
2 12 
5 47 
1.82 
1 80 
DISCUSSION 
90% Confidence 
Interval 
1 01 - 1 04 
1 28 - 3 49 
3 29 - 9 12 
1 31 -2 53 
1 26 -2 51 
The coexistence of dysplastic abnormalities in normal-looking epithelium 
adjacent to urinary bladder tumors was first reported by Melicow in 1952.20 In 
10 total cystectomy specimens, cellular abnormalities were seen ranging from 
hyperplasia and dysplasia to carcinoma in situ. Five control tumor-free 
bladders, obtained from autopsy cases, showed only occasional cellular 
hyperplasia. Other histological examinations of cystectomy specimens2126 and 
of random mucosal biopsies in vivo,14"162731 have confirmed the high 
prevalence of atypia and carcinoma in situ in areas not cystoscopically 
suspected of harboring malignancy. In all the studies which examined the 
correlation with tumor grade, the frequency of dysplastic abnormalities was 
found to be higher in patients with less differentiated exophytic tumors. A 
correlation was also found with multicentricity and tumor stage.11·16 
Eisenberg and associates were the first to evaluate the prognostic relevance 
of concomitant cytological changes in bladder biopsies.' Although random 
biopsies were taken from 53 patients with low stage tumors, the clinical 
course of only 24 of them was presented. Eight patients never showed any 
evidence of disease recurrence in an average of eight years of follow-up None 
of them had associated proliferative abnormalities. Seven patients, all with 
associated proliferative lesions, experienced therapy failure, with an average 
survival of 3 years. The remaining 9 patients (3 with associated proliferative 
lesions) survived for well over five years but suffered recurrent tumor 
formation. More recent studies confirmed the potential prognostic significance 
of random mucosal biopsies, both for tumor recurrence and tumor 
progression.2 13 However, the results of some of these studies are difficult to 
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interpret because biopsies were not only taken at initial diagnosis but also 
during follow-up,6 or because biopsies were also taken from macroscopically 
suspicious mucosa.312 The results of these biopsy procedures are hardly 
comparable with those from biopsies from normal urothelium taken at initial 
diagnosis.29 In addition, some of the studies were very small with patient 
numbers of less than 50.4·8·9·12·13 The small study size is probably one of the 
reasons why none of the studies analyzed the independent prognostic effect of 
random biopsies in an unselected series of patients with superficial bladder 
cancer. 
In newly diagnosed superficial bladder cancer, conventional histopathology 
(tumor stage and tumor grade) and some clinical factors (multicentricity and 
tumor size) are routinely used as prognostic factors.32,33 It is not very likely 
that random urothelium biopsies will ever replace one or more of these 
factors, but they may be useful as an additional prognostic test. To our 
knowledge, the present study is the first to focus on the independent effect of 
dysplastic abnormalities in normal-looking urothelium and suggests that 
random biopsies add very little prognostic information (if any) to the risk of 
recurrence, but they do add prognostic information to the risk of progression. 
The major hypothesis for the prognostic relevance of dysplastic changes in 
mucosal biopsies is that these changes reflect a premalignant state of the entire 
urinary bladder surface. New tumor occurrences originate from these 
intraurothelial lesions.34 If this hypothesis is true, why then (at least in our 
study) did the random biopsies have very little predictive value regarding the 
risk of recurrence? One possible reason is the very high frequency of 
recurrences in superficial bladder cancer which may obscure a relatively small 
extra risk because of intraurothelial abnormalities. Another possible 
explanation for the absence of a prognostic effect on the risk of recurrence 
relates to the interpretation of random urothelium biopsies. Considerable 
variability exists in the assessment of the presence and classification of flat, 
dysplastic lesions and the separation of these presumably premalignant changes 
from reactive changes.35 In a recent study by the British Medical Research 
Council, six expert pathologists examined 92 representative random biopsy 
slides. The reproducibility of interpretation appeared to be so poor that the 
authors questioned random biopsies as a useful guide for defining therapy.36 
For example, one pathologist found mild or moderate dysplasia in 60% and 
severe dysplasia or CIS in 27% of the slides compared to another pathologist 
who found dysplasia in 6% and CIS in a further 7%. Pathologists replicated 
their first assessment on only 62% of occasions, although most of the 
disagreement was by only one grade.36 
The reproducibility of interpretation improves with the severity of the 
lesions. Therefore, one could argue that only CIS rather than dysplasia and 
CIS should be regarded as an abnormality in order to increase the prognostic 
significance. We examined this in our study but found that the hazard ratio for 
the risk of first recurrence increased only slightly from 1.12 to 1.17 (not 
statistically significant). 
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Despite the current lack of reproducibility in the interpretation of random 
biopsies, the presence of dysplasia and/or CIS in apparently normal urothelium 
appears to have prognostic value regarding future tumor progression. Adjusted 
for the effect of other prognostic indicators, concomitant dysplasia or CIS 
increased the risk of progression with 80%. This increase in risk of 
progression, however, does not necessarily mean that it is worthwhile to use 
random biopsies as an additional guide in the choice of treatment for primary 
superficial bladder cancer. This also depends, for instance, on the efficacy of 
adjuvant intravesical chemotherapy or BCG for preventing tumor progression. 
This efficacy is believed to be rather poor,37'38 which is in accordance with the 
absence of any effect of adjuvant therapy in our study (although this finding is 
difficult to interpret in a non-randomized study). Furthermore, the usefulness 
of random biopsies depends on the number of patients who will be treated 
adjuvantly because of concomitant dysplastic abnormalities. Because of the 
correlation with other prognostic factors, such abnormalities are relatively rare 
findings in patients who are routinely treated with TUR alone. Therefore, a 
medical decision analysis is needed to study the clinical relevance of taking 
random urothelium biopsies on a routine basis. 
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SUMMARY 
The ultimate goal of prognostic assessment is optimization of individual 
counselling. Very often, however, studies on prognostic factors focus on 
discriminating between high risk and low risk subgroups without 
considering the relevance of one or more factors for predicting disease 
outcome in individual patients. This ability to predict disease outcome on 
a patient level may turn out to be poor despite the existence of highly 
statistically significant prognostic factors. As an example, we quantified 
the accuracy of prediction of future recurrences and disease progression in 
individual patients with superficial bladder cancer. 
The study cohort consisted of 1674 patients with primary superficial 
bladder cancer who were followed prospectively between 1983 and 1991 in 
the Netherlands. In each patient, tumor stage, grade, extent and 
multicentricity were assessed. Biopsies of cystoscopically normal-looking 
urothelium were taken from 1001 patients. By analyzing one-half of the 
patients with proportional hazards regression, we computed relative risks 
of recurrence and progression. A prognostic index score based on these 
relative risks was then applied to the other half of the patients to 
determine whether group outcome could be predicted accurately. To 
assess the accuracy of prediction in individuals we used a method similar 
to the construction of ROC curves in diagnostic test assessment. 
The 3-year risk of first recurrence was 55% (95% CI: 51%-59%). The 3-
year risk of first progressive disease was 10% (95% CI: 8%-12%). For the 
risk of first recurrence, tumor stage, tumor extent and multicentricity 
were found to have statistically significant prognostic ability. Prognostic 
factors for the risk of disease progression were tumor stage, grade, 
multicentricity and the result of urothelium biopsies. For patients with a 
prognostic index score which suggested a low risk for recurrent and 
progressive disease, the predicted 3-year risk of first recurrence was still 
44%, but the predicted 3-year risk of progression was only 3%. For 
patients with a prognostic index score which suggested a high risk, the 
predicted risks were 74% and 22%, respectively. These predicted risks 
appeared to be fairly accurate when applied to the other half of our case 
series. However, in any two patients chosen at random, the chance that 
the patient with the worst predicted prognosis would have a shorter 
recurrence-free and progression-free follow-up interval, was calculated to 
be only 58% and 67%, respectively. 
Although the available prognostic factors in superficial bladder cancer 
may be useful for identifying high risk and low risk subgroups, 
predictability in individuals is highly inaccurate. More relevant prognostic 
factors are needed to reduce current overtreatment and undertreatment 
and to improve the follow-up policy. Future prognostic research should 
place more emphasis on prediction in individuals. 
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INTRODUCTION 
The ultimate challenge of prognostication in clinical practice is accurate 
prediction of the clinical course in individual patients.' Very often, research 
into prognostic factors has dealt with the identification of high risk and low 
risk subgroups of patients by assessing the statistical significance of one or 
more host or disease characteristics. Occasionally, the accuracy of 
identification of these subgroups has been quantified. Prognostic assessment 
studies, however, have rarely emphasized the ability to predict disease 
outcome in individuals. This predictive ability in individuals may be very 
disappointing despite the existence of a number of statistically significant 
prognostic factors. We aimed to illustrate this with an example in superficial 
bladder cancer. 
In 1991, bladder cancer, excluding carcinoma in situ, was estimated to 
contribute 50,200 new cases of cancer in the United States.2 Among newly 
diagnosed cases, approximately 65% initially present with superficial 
transitional cell carcinomas, not invading the muscle layer of the bladder. In 
more than half of these patients, tumors recur after primary treatment with 
transurethral resection. 10%-20% of these patients develop muscle-invasion or 
metastatic disease.3 To prevent or delay tumor recurrence and (possibly) 
muscle-invasion, adjuvant intravesical instillations with chemotherapeutical or 
immunotherapeutical agents can be applied. 
In order to optimize treatment policy, much research has been conducted 
into the identification of prognostic factors for the risk of recurrence and 
progression. For these two types of disease outcome, the most important 
factors appear to be clinical and histo-pathological characteristics, such as 
tumor stage, grade, multicentricity, size and (possibly) the presence of 
dysplastic abnormalities in cystoscopically normal-looking urothelium.4"9 
Several other host and tumor characteristics have been explored for their 
prognostic ability, e.g., blood group antigen expression, DNA ploidy, certain 
biochemical factors and tumor associated antigens.10 Until now, these 
characteristics have not been used routinely in urological practice, mainly 
because there is still no agreement on their (independent) prognostic relevance. 
In the present study, we prospectively analyzed the clinical course of 
patients with superficial bladder cancer in an attempt to predict future tumor 
recurrences and disease progression. Prognostic index scores were constructed 
to determine the accuracy of disease outcome predictions not only for groups 
of patients, but also for individuals. 
METHODS 
The study cohort 
Between January 1983 and January 1990, the Dutch South-East Cooperative 
Urological Group prospectively documented the patient and tumor 
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characteristics of 2705 cases with primary bladder cancer. Of these, 1745 
(64.5%) had histologically verified superficial transitional cell carcinoma 
(TCC). Superficial was defined as tumor extension limited to the mucosa 
(TNM stage pTa) or the lamina propria (pTl) of the bladder wall with or 
without concomitant carcinoma in situ in random biopsies of normal-looking 
urothelium. Patients with primary carcinoma in situ (pTis: N=52) were not 
included in the study cohort because pTis was considered to be different from 
pTa and pTl tumors owing to its relatively aggressive behavior. Muscle tissue 
from the depth of the transurethral resection (TUR) of the bladder tumor was 
required to ascertain the tumor stage. The following items were registered 
from each patient: date of birth, gender, date of histological diagnosis, grade 
of differentiation (according to the WHO grading system," TNM classification 
(UICC, 1978), multicentricity, tumor extent and the result of random biopsies 
from normal-looking urothelium at the time of primary surgery. All the 
patients were treated with TUR. The necessity to apply adjuvant treatment was 
judged by the urologist. The patients were followed-up every three months. At 
every visit, cystoscopy and urine cytology were performed to detect 
recurrences. The median follow-up for the study cohort was 3.5 years. In 
1991, all the data from the project were reviewed using the medical files. 
Of the 1745 patients with superficial TCC, 1116 were treated with TUR 
alone and 558 were treated with adjuvant intravesical instillations 
(Adriamycin, Mitomycin-C, or Bacillus Calmette-Guérin vaccine). The 
remaining 71 patients were treated with interstitial radiotherapy (N = 17), 
external radiotherapy (N = 33) and cystectomy (N=21). These 71 patients 
were excluded from the analyses. Baseline characteristics of the study 
population (N = 1674) are listed in Table 7.1. 
Analysis of prognostic factors 
As disease outcomes, a first recurrence and first evidence of progressive 
disease were considered. We defined progressive disease as a shift to a higher 
disease stage category or the development of regional or distant metastases. 
The follow-up of patients without any recurrence and disease progression was 
censored to the date of the last hospital visit. In case of death not related to 
the bladder cancer, the follow-up was censored to the date of death. Cox's 
proportional hazards model for censored follow-up data was used to identify 
prognostic factors for recurrence and progression.12 In the model development, 
the following factors were evaluated multivariately for their statistical 
significance, using the likelihood ratio test with a significance level of 
P=0.10: age, gender, tumor stage (pTl versus pTa), tumor grade (grade 3 
versus 2 versus 1), multicentricity (multiple versus solitary), therapy (adjuvant 
intravesical instillations with chemotherapy or BCG versus TUR alone), tumor 
extent, the result of random bladder biopsies and interactions between therapy 
and any of the other factors. In the analyses, we did not specify the drug used 
for intravesical instillations. Although there is some evidence that the response 
rates to BCG are somewhat higher, differences in the efficacy of 
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TABLE 7.1 Characteristics at disease presentation of 1674 patients with 
primary superficial TCC of the bladder 
N % 
Gender 
Male 
Female 
Age 
< 39 
40-49 
50-59 
60-69 
70-79 
80+ 
Stage 
pTa 
pTl 
Grade' 
1 
2 
3 
Multicentricity 
Solitary 
Multiple 
Unknown 
Areas involved 
Neck only 
Trigone only 
Posterior wall only 
Right lateral wall only 
Left lateral wall only 
Dome only 
Anterior wall only 
2 Areas 
3 Areas 
> 4 Areas 
Quadrant biopsies (N = 1001)® 
No abnormalities 
Dysplasia 
Carcinoma in situ 
1351 
323 
46 
99 
278 
525 
526 
200 
1179 
495 
668 
772 
234 
1181 
483 
10 
26 
52 
120 
373 
386 
34 
24 
357 
156 
146 
793 
137 
71 
80.7 
19 3 
2.7 
5.9 
16.6 
31.4 
31.4 
11.9 
70.4 
29.6 
39.9 
46.1 
14.0 
71.0 
29.0 
1.6 
3.1 
7.2 
22.3 
23.1 
2.0 
1.4 
21.3 
9.3 
8.7 
79.3 
13.7 
7.1 
' In cases with different grades in one tumour, the highest grade was documented 
β
 Quadrant biopsies were not taken from 673 patients 
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chemotherapeutical agents are known to be small.13"13 Tumor extent was 
defined as the number of bladder areas involved (3 or more versus 2 versus 1) 
instead of the size of the tumor. We distinguished the following bladder areas: 
bladder neck, trigone, dome, anterior and posterior wall, and left and right 
lateral wall. Although the urologists who participated in the project were asked 
to take four random biopsies in macroscopically normal-looking urothelium 
(left and right lateral wall, trigone and dome), this was not done in 673 out of 
the 1674 patients. It appeared that some of the urologists took biopsies from 
all of their patients, irrespective of the patient or tumor characteristics, while 
others never did. As expected, therefore, the prognostic profile of the patients 
(as listed in Table 7.1) in the biopsied group and in the not biopsied group 
was the same. In order to make the series as large as possible, the group with 
no biopsy result was considered to be a separate biopsy category, in addition 
to the categories dysplasia or CIS, and normal. For assessment of dysplasia 
pathologists used the following grading system: absent, mild, moderate, 
severe, CIS. According to this system, CIS is a grade 3 lesion by definition. 
All non-dysplastic changes, such as hyperplasia, were categorized as 'normal'. 
Split-sample 
Preferably, the extent to which one is able to predict disease outcome with one 
or more prognostic factors should be evaluated in a patient series that was not 
used to identify these prognostic factors. To allow assessment of this 
predictive ability in "another" patient series, the data set was split at random 
into a "training" or model development sample, and a "test" or model 
validation sample. Only the training sample was used for prognostic factor 
analyses. The test sample was used to evaluate whether predictions from the 
model could be replicated on other patient samples or whether the model was 
"tailor-made" to fit all variability in the training sample.16 
Prognostic index and its reliability 
The results of the prognostic factor analyses on the training sample were used 
to construct a prognostic index score for recurrent disease (PIR) and for 
progressive disease (PI1*)· Both scores were calculated for each patient by 
summing the regression coefficients (beta values) of the final Cox models on 
recurrence and progression. Regression coefficients were considered for 
inclusion in the PI scores if at least one of the categories of the tumor 
characteristic was statistically significant. A high score indicated that a patient 
had a poor prognostic profile. 
The value of a prognostic index in clinical practice depends on its predictive 
accuracy, which has two major components: reliability and discrimination. 
Reliability refers to the amount of agreement between the predicted and 
observed clinical course of disease. For instance, if patients with a certain 
prognostic profile are predicted to have a 3-year risk of 50% of recurrent 
disease, then 50% of such patients should have a recurrence within 3 years. 
We compared the observed and predicted risks of recurrence and progression 
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in three subgroups of patients (a low, intermediate and high risk group) in the 
test sample. We first calculated the predicted risks for each patient separately 
using the proportional hazards assumption:12·17 
S,(y) = S
r
(y)E X W P , ) where 
S,(y) = the predicted probability of still being disease-free y years 
after initial treatment for individual i in the test sample 
S
r
(y) = the observed fraction of patients with the best prognostic 
profile in the training sample (the reference group) who 
were disease-free after y years 
5PI = the prognostic index score for individual i in the test 
sample minus the mean prognostic index score of the 
aforementioned reference group. 
Finally, these individual probabilities of being disease-free were averaged for 
the three subgroups. The definition of these three "risk" groups was based on 
the distribution of the prognostic index scores, so that the low and high risk 
group each represented at least 20% of all the patients. 
Prognostic index and its discrimination ability 
The second component of predictive accuracy, discrimination, refers to the 
ability to distinguish between individual patients who will have a positive 
disease outcome and those who will have a negative disease outcome. This 
predictive discrimination can be quantified through a method proposed by 
Harrell and associates, in which every possible pair of patients in the study is 
compared with respect to the observed and predicted outcome.18"19 The 
resulting index "c" (for "concordance") is the probability that in a pair of 
patients chosen at random, the predicted and observed outcomes are 
concordant, i.e., the patient with the worst predicted prognosis (the higher PI) 
will indeed have a shorter disease-free follow-up interval, and vice versa. С 
values in the region of 50% indicate that the clinical value of a prognostic 
index to determine which patient has a better prognosis, is as good as the flip 
of a coin. Values of с near 100% indicate perfect prediction of disease 
outcome. In fact, this method to ascertain the ability to discriminate patients 
on their course of disease is analogous with the construction of Receiver 
Operating Characteristic (ROC) curves used in diagnosis.20 The interpretation 
of с is analogous with the interpretation of the area under a ROC curve. 
We calculated с by comparing the prognostic index score and the observed 
clinical course in all possible pairs of patients in both the training sample and 
the test sample. 
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RESULTS 
The 3-year actuarial risk of first recurrence in the training sample (N = 854) 
was 55% (95% CI: 51%-59%). The 3-year risk of first progressive disease 
was 10% (95% CI: 8%-12%). From proportional hazards regression, tumor 
stage, extent and multicentricity appeared to have predictive ability for the risk 
of first recurrence. Age, gender, tumor grade and random biopsies had no 
(statistically significant) additional value for prediction. Adjuvant intravesical 
chemotherapy or immunotherapy instillations seemed to lower the risk of first 
recurrence, but had no statistically significant independent effect on the risk of 
progression. For this risk of progression, the most important prognostic 
factors were tumor stage, grade, multicentricity and dysplasia or CIS in 
random biopsy specimens. In both the recurrence and progression model, 
there were no significant interactions between therapy and the other factors. 
The final models with regression coefficients (beta), standard errors and Ρ 
values based on the training sample are shown in Table 7.2. The risk of first 
recurrence as well as the risk of progressive disease hardly increased after 
3 years of follow-up. Therefore, we evaluated whether the results of the 
prognostic factor analysis would change with restriction of the follow-up 
period to a maximum of 3 years. This restriction appeared to have no effect 
on the results presented in Table 7.2. 
By summing the beta coefficients, a prognostic index score for progression 
(PIP) was calculated for each patient in the test sample (N = 820). For instance: 
for a patient with multiple pTlG2 tumors and dysplasia or CIS in the biopsy 
specimens, PIP = 0.56 + 0.53 + 0.95 + 0.64 = 2.68. PIP for a patient with 
a solitary pTaGl tumor without any abnormalities in the biopsy specimens was 
0. Subsequently, all the patients were categorized in a low, intermediate, or 
high risk group according to their PIP (Table 7.3). 
Likewise, a PIR was calculated for each patient in the test sample, but now 
only for the patients who had not received adjuvant intravesical instillations 
(N=554). We used this restriction because we did not want to include therapy 
(an intervention factor instead of a host or tumor characteristic) in a 
prognostic score. 
In order to evaluate the reliability of PIR and PIP we compared the observed 
and predicted actuarial risks of tumor recurrence and progression in the test 
sample (Figures 7.1 and 7.2; Note that the scales of the Y axis in the figures 
differ). Both the risks of recurrence and the risks of progression were fairly 
close to the predicted risks, even though the risk of recurrence was somewhat 
underestimated in the high risk group and overestimated in the low risk group. 
The risk of progression was slightly underestimated in the intermediate risk 
group. Nevertheless, the reliability of the indices seemed to be quite good. 
For example, if we predict that the 4-year risk of progression for a group of 
patients with a solitary pTa grade 1 or 2 tumor without any abnormalities in 
the random biopsies is 3%, we can be quite sure that in approximately 3% of 
these patients progression will be diagnosed within 4 years (Table 7.3). 
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This high reliability of both PIR and PIP does not necessarily mean that we 
will be able to predict the disease outcome in individual patients. To examine 
this, we compared all possible pairs of patients in the test sample (the number 
of pairs was 335,790) and calculated the с score of predictive discrimination 
TABLE 7.2 Final model results of the Cox regression analysis in 854 patients 
with superficial TCC of the bladder (the "training" sample) 
Prognostic 
Factor 
Tumor stage 
pTa 
pTl 
Tumor grade 
1 
2 
3 
Multicentricity 
Solitary 
Multiple 
Number of areas 
involved 
1 
2 
3 or more 
Therapy 
TUR alone 
Instillations 
Result of random 
biopsies 
Normal 
Not performed 
Dysplasia/CIS 
Recurrence model 
Beta 
0 
0 4 0 
-
-
0 
0 27 
0 
0 17 
0 52 
0 
-0 43 
" 
SE 
0 10 
0 12 
0 13 
0 14 
0 11 
Ρ 
< 0 0 0 1 
0 03 
0 18 
< 0 001 
< 0 001 
Progression model 
Beta 
0 
0 56 
0 
0 53 
0 98 
0 
0 95 
-
-
-
-
0 
0 37 
0 6 4 
SE 
0 23 
0 30 
0 35 
0 22 
0 25 
0 29 
Ρ 
0 02 
0 07 
0 005 
< 0 0 0 1 
0 15 
0 03 
Note: Tumor grade and random biopsy result had no statistically significant effect in the 
recurrence model; likewise, number of areas involved and therapy were not 
significant in the progression model 
The с for recurrent disease was only 57.6%. The с for progressive disease 
was 67.3%. (In the training sample these percentages were 58.2% and 71.9%, 
respectively.) Thus, in two patients chosen at random, the chance that the 
patient with the worst predicted prognosis will have a shorter recurrence-free 
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follow-up interval was no more than 58%, even in the sample used for model 
development. This prediction, therefore, is not much better than a guess. The 
individual discrimination ability for progression was only slightly higher. If we 
compare all the possible pairs of patients with respect to the progression-free 
interval, then in approximately 67% of these comparisons the patient with the 
better prognosis will stay progression-free for a longer period of time. 
TABLE 7.3 Observed and predicted actuarial risks of first recurrence and 
progressive disease in the "test" sample (N=820/ according to 
Ρ f and Pf "risk groups" 
Observed (+ predicted) risk of first 
recurrence (expressed as percentages) 
Risk group (% of PIR range' 1 year 2 year 3 year 4 year 
all patients) 
Low (40%) 0 21 (24) 32 (37) 38 (44) 42 (48) 
Intermediate (40%) 0.17-0.57 40(32) 56(49) 60(57) 63(61) 
High (40%) 0.67-1.19 60(48) 71(66) 81(74) 84(78) 
Observed (+ predicted) risk of first 
progression (expressed as percentages) 
Risk group (% of Plp range* 1 year 2 year 3 year 4 year 
all patients) 
Low (36%) 0-0.53 2 (2) 3(2) 4 ( 3 ) 4 ( 3 ) 
Intermediate (42%) 0.56-1.73 4(4) 9(5) 10(6) 12(8) 
High (22%) 1.85-3.13 9(11) 13(16) 18(18) 21(22) 
s
 For Ρ f the "test" sample consisted of 554 patients treated with TUR only 
' Pi" and PV° are not continuous variables 
DISCUSSION 
In urological practice it is known that the clinical course of superficial bladder 
cancer is rather unpredictable, despite an ongoing search for new prognostic 
factors. In many cases, the significance of prognostic factors has been claimed 
on the grounds of a small Ρ value. This statistical significance, however, 
reflects the likelihood that a given difference in disease outcome could have 
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FIGURE 7 1 Observed and predicted risk of first recurrence in 554 patients 
with superficial TCC treated with TUR alone (the "test " sample) 
according to three prognostic index (Pf) "risk groups " 
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FIGURE 7 2 Observed and predicted nsk of first evidence of progressive 
disease in 820 patients with superficial TCC (the test sample) 
according to three prognostic index (Pf) "nsk groups " 
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arisen by chance; it does not measure the extent to which the factor can 
differentiate low risk from high risk subgroups of patients. Even if a 
prognostic factor does have such ability to differentiate subgroups, this is no 
guarantee that prediction of disease outcome for individual patients (the 
ultimate goal of prognostic factors) will be accurate. This predictive accuracy 
can be studied with the aid of a prognostic index. 
In this paper, prognostic indices are presented for the risk of first 
recurrence and for the risk of progressive disease in primary superficial 
bladder cancer. The former index was based on tumor stage, multicentricity 
and the number of bladder areas involved. The latter was based on tumor 
stage, grade, multicentricity and the result of random biopsies. Although 
adjuvant intravesical therapy also had a statistically significant (beneficial) 
effect on the risk of recurrence, we did not include therapy in the prognostic 
index and applied the index to patients treated with TUR alone. The 
prognostic index for progression applies to all the patients because intravesical 
therapy did not lower the risk of progression. This supports the hypothesis that 
intravesical therapy does not alter the ultimate outcome of the disease,21'22 but 
the finding has to be interpreted with some caution because our study was not 
initiated to study therapy effects. Furthermore, some evidence exists that 
especially BCG may prevent disease progression in high-risk patients.23 
It is shown that the prognostic indices can be used to differentiate subgroups 
of patients with different risks for disease outcome. By summing the 
prognostic-factor-specific model coefficients in Table 7.2 one can easily see 
which risk group a new patient belongs to. As is shown in Table 7.3 and 
Figures 7.1 and 7.2, where the observed risks of recurrence and progression 
in a test sample are compared to the corresponding predicted risks, the 
prognostic indices are fairly reliable. Although for the intermediate risk group, 
the observed and predicted risks of progression seem to differ considerably, 
the maximum absolute difference is only 4%. Despite this satisfactory 
reliability of the prognostic indices however, especially the index for recurrent 
disease does not have sufficient predictive accuracy for individuals. This is not 
very surprising considering the urological experience that many patients with a 
(relatively benign) solitary small tumor confined to the mucosa develop 
recurrences (in our study approximately 40% within 3 years!), whereas most 
patients with (presumed aggressive) multiple pTlG3 tumors do not develop 
progressive disease (approximately 75%). Even though, this poor individual 
predictability has not been quantified before. It was shown that prediction of 
recurrence-free survival ("c" = 58%) was only slightly better than a guess 
based on the flip of a coin. Prediction of progression-free survival ("c" = 
67%) was relatively good but still far from perfect. This means that in 
superficial bladder cancer individual counselling based on a patient's 
prognostic profile is hardly possible. 
If we cannot use a prognostic index for individual counselling, then what is 
the value of such an index? First, it can be used to select a subgroup of 
patients with a low risk of progression so that they can be scheduled for 
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longer intervals between successive endoscopies, thus reducing hospital visits 
and financial cost. According to our study, this subgroup consists of patients 
with a solitary pTa grade 1 or grade 2 tumor without any concomitant mucosal 
abnormalities. Even in this group (with a predicted 3-year risk of progression 
of only 3%) recurrences are very common, but these recurrences can be easily 
managed by repeated resections or fulguration and, therefore, do not require 
any additional measures.24 However, if we modify the follow-up schedule we 
are making an important assumption, i.e. that the delay of resection or 
fulguration of recurrences will not increase the risk of progression in this 
subgroup. 
Second, prognostic index scores can be used in future studies on new 
prognostic tests. In such studies it might be worthwhile to start with the 
construction of a prognostic index based on the factors already available. 
Subsequently, a prognostic index can be made wich includes the new test. 
This would enable the evaluation of the test to be based on any improvement 
in the predictive accuracy of the index, instead of basing the evaluation on 
statistical significance only." 
Our results so far show that a prognostic index is not very useful in the 
planning of treatment for superficial bladder cancer. The insufficient predictive 
accuracy of such an index inevitably leads to considerable overtreatment and 
undertreatment. This predictive accuracy may improve with more objective 
criteria for the assessment of the prognostic factors already available. 
Especially the reproducibility of tumor grade and concomitant dysplastic 
changes in normal-looking urothelium is known to be poor,8,2526 but it is also 
possible for pathologists to make different interpretations of the tumor stage 
category.9,2729 In our study, most resection specimens were not reviewed by a 
reference pathologist. This may have had some effect on our results. Even 
though, we aimed to evaluate the predictability of disease outcome in a case 
series which is representative for all patients with superficial bladder cancer. 
Because review pathology is no routine practice, it could have hampered 
generalizations of our results. Review pathology, of course, is no solution for 
poor predictability of recurrence and tumor progression in every day clinical 
practice. More objective criteria for prognostic factors may be a solution. 
However, in addition to obtaining more objective criteria for prognostic 
factors, an ongoing search for new (and stronger) prognostic factors is 
probably necessary. 
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SUMMARY 
The presence of concomitant dysplasia or carcinoma in situ in normal-
looking urothelium is considered to be of prognostic value in patients with 
superficial transitional cell carcinoma of the bladder. Therefore, random 
urothelium biopsies may be a useful additional guide for defining therapy 
in order to prevent or delay tumour recurrence. The purpose of this study 
was to evaluate whether it is worthwhile to implement routine random 
biopsies in the management of patients with primary superficial bladder 
cancer. For this purpose, we defined and compared two hypothetical 
management policies, one of which incorporates random biopsies as an 
additional prognostic test. In the 'no-biopsy policy', all patients are 
treated with transurethral resection alone, except for patients with a 
pTlG3 tumour who are treated adjuvantly with prophylactic intravesical 
therapy. In the 'biopsy policy', the choice of treatment is influenced by 
the presence or absence of dysplastic urothelium in random biopsy 
specimens, again except in patients with a pTlG3 tumour who are treated 
adjuvantly, irrespective of the result of random biopsies. 
Decision analysis was used to compare the outcome of these two 
hypothetical policies with respect to the expected 3-year risks of 
recurrence and progression. Baseline data used in the analysis originated 
from a large unselected case series, prospectively documented in the 
Netherlands. The 'biopsy policy' resulted in a 3-year risk of recurrence 
and a 3-year risk of progression of 52% and 11%, respectively. These 3-
year risks were almost identical to the 'no-biopsy policy': 54% and 11%, 
respectively. 
By means of a so-called sensitivity analysis we examined what the results 
would have been if dysplastic urothelium had been detected more often, if 
such dysplastic urothelium had higher prognostic value, and if intravesical 
therapy was more efficacious. Under very optimistic assumptions about 
these three characteristics, the expected 3-year risks of recurrence and 
progression in the 'no-biopsy policy' were 63% and 15%, respectively. 
With routine random biopsies, these risks were estimated to be 58% and 
11%, respectively. In that case, however, intravesical therapy would have 
to be applied to 43% of all the patients, vs. 12% in the 'no-biopsy policy'. 
In view of the expected small difference in disease outcome between the 
two management policies, even under fairly optimal conditions, it is our 
opinion that taking random biopsies of normal-looking urothelium at the 
time of the transurethral resection has no practical value. 
INTRODUCTION 
Predominant factors used to predict disease outcome in newly diagnosed 
patients with superficial transitional cell carcinoma (TCC) of the bladder are 
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tumour stage, degree of differentiation of the tumour, multicentricity and 
tumour
 s i z e s-7·1314·21·-6·30·"·42·49·33 Despite these well-known prognostic factors, 
however, the clinical course of patients with superficial TCC appears to be 
rather unpredictable. It has been recognised for some time that random 
urothelium biopsies may improve this predictive ability. After the first paper 
by Eisenberg and associates in I960,9 numerous investigators confirmed the 
hypothesised prognostic relevance of concomitant dysplastic abnormalities in 
normal-looking urothelium.1·6-81214·34·38·43·4*'30·35·57 Because of this prognostic 
ability it would seem reasonable to use random biopsies as an additional guide 
for defining therapy, i.e., adjuvant intravesical instillations can be 
administered in the case of pathological findings, while transurethral resection 
(TUR) alone can be applied otherwise. However, the ultimate benefit of 
random urothelium biopsies as an additional prognostic test is not determined 
solely by its prognostic ability. The rationale of taking random urothelium 
biopsies from patients with primary superficial bladder cancer depends on 
several factors: 
- the number of patients who have dysplastic abnormalities in normal-looking 
urothelium; 
- the accuracy and reproducibility of the assessment of dysplastic 
abnormalities in biopsy specimens; 
- the biological association between dysplastic changes and future new tumour 
occurrences ('recurrent tumours') and tumour progression; 
- the correlation between dysplastic abnormalities and other prognostic factors; 
- the number of patients who would have been treated with intravesical 
instillations anyway; 
- the efficacy of intravesical therapy for preventing tumour recurrences and 
progressive disease. 
In this study, we evaluated the benefit of using random biopsies as an 
additional prognostic test in primary superficial bladder cancer. By using 
decision-analytical methods, it was attempted to take all the aforementioned 
factors into account. Quantitative data needed for the analysis were derived 
from a large case series documented prospectively in the Netherlands. 
PATIENTS AND METHODS 
Decision model 
To evaluate the rationale of using random biopsies in the management of 
primary superficial bladder cancer we compared two hypothetical policies. See 
Figure 8.1. Both policies deal with an unselected population of patients with 
suspected primary superficial TCC, but only one incorporates random biopsies 
in its management. In all the patients at least one papillary tumour is seen at 
cystoscopy, without any concomitant macroscopically visible lesions suspicious 
of carcinoma in situ (CIS). Because the prevalence of CIS in mucosa with a 
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FIGURE 8.1 Decision tree for the management of primary superficial TCC of 
the bladder (applies only to patients with bladder mucosa not 
suspicious of CIS) 
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red and flat or mossy appearance is very high,52 these lesions have to be 
biopsied anyway.44 
In our first hypothetical management policy, no random urothelium biopsies 
will be taken. The choice of treatment is based on the histopathology of the 
resected tumour(s): all patients are treated with TUR only, except for the 
patients with a pTlG3 tumour. In the alternative policy, random urothelium 
biopsies will be taken from all the patients at the time of TUR. We assume 
that these random biopsies are primarily taken to optimise treatment 
management. If the histopathology reveals dysplasia or CIS in at least one 
biopsy specimen, then the patient will be treated adjuvantly, otherwise the 
treatment will be TUR alone. An exception is made for the patients with a 
pTlG3 tumour who will be treated with adjuvant intravesical therapy 
irrespective of whether or not dysplastic abnormalities are diagnosed in 
normal-looking mucosa. 
Patients 
All the quantitative data needed for the decision-tree evaluation were derived 
from a large unselected series of newly diagnosed bladder cancer patients 
prospectively documented by the Dutch South-East Cooperative Urological 
Group. This case series is described in detail elsewhere.54,60 In summary, the 
series consisted of 1,745 patients with histologically verified primary 
superficial TCC diagnosed between January 1983 and December 1989. 
Superficial was defined as tumour extension limited to the mucosa (TNM stage 
pTa) or the lamina propria (pTl) of the bladder wall with or without 
concomitant abnormalities in random biopsies of normal-looking urothelium. 
Patients with primary carcinoma in situ (pTis: N=52) were not included in the 
study cohort. Owing to its relatively aggressive behaviour, primary CIS was 
considered to be a separate entity. Of all 1,745 patients, 1,116 were treated 
with TUR alone, 558 had TUR plus intravesical instillations (Adriamycin, 
Mitomycin C, or Bacillus Calmette-Guérin) and 71 received additional 
treatment with interstitial or external radiotherapy or cystectomy. 
Twenty-seven per cent of all the patients presented with a solitary pTaGl 
tumour (see Figure 8.1). Twelve per cent had a solitary or multiple pTlG3 
tumour. The remaining 61 % had superficial tumours other than solitary 
pTaGl and pTlG3. 
Although the urologists who participated in the project were asked to take 
four cold-cup biopsies (left and right lateral wall, trigone and dome) of 
normal-looking urothelium from all of their patients during initial TUR, this 
was not done in 701 patients. It appeared that some of the urologists took 
biopsies from all of their patients, irrespective of the patient or tumour 
characteristics, while others never did. Therefore, the prognostic profile of the 
patients in the biopsied group and in the not-biopsied group was the same 
(Table 8.1). 
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TABLE 8.1 Clinical characteristics at disease presentation in 1,745 patients 
with primary superficial TCC 
Factor Cases biopsied 
(N=1,044) 
Cases not biopsied 
(N=701) 
N N 
Age 
0-49 
50-59 
60-69 
70-79 
80+ 
Sex 
Men 
Women 
Tumour stage 
pTa 
pTl 
Tumour grade M 
1 
2 
3 
No of areas involved $ 
1 area 
2 areas 
3 or more 
Multicentricity 
Solitary 
Multiple 
Unknown 
Biopsy result 
No abnormalities 
Dysplasia 
Carcinoma in situ 
92 
189 
333 
318 
112 
857 
187 
693 
351 
371 
465 
208 
633 
233 
178 
751 
286 
7 
816 
142 
86 
8 8 
18 1 
31 9 
30 5 
10 7 
82 1 
17 9 
66 4 
33 6 
35 5 
445 
19 9 
606 
22 3 
17 0 
72 4 
27 6 
78 2 
13 6 
82 
57 
106 
217 
228 
93 
558 
143 
494 
207 
298 
328 
75 
409 
140 
152 
472 
224 
5 
8 1 
15 1 
31 0 
32 5 
13 3 
79 6 
20 4 
70 5 
29 5 
42 5 
46 8 
10 7 
58 3 
20 0 
21 7 
67 8 
32 2 
tt In cases with various grades in one tumour, the highest grade was documented 
$ Instead of the size of the tumour, the number of bladder areas in which tumour 
tissue was found was documented 
The results of random biopsies were classified positive if dysplasia (either 
mild, moderate or severe) or CIS was found in one or more specimens. Of all 
the patients who were biopsied (N = 1,044), 22% had abnormalities in at least 
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one biopsy specimen (14% dysplasia and 8% CIS). The presence of these 
concomitant abnormalities was strongly correlated with the histopathology of 
the primary tumour. Dysplasia or CIS was detected in 11% of the solitary 
pTaGl patients, in 49% of pTlG3 patients and in 20% of all the remaining 
patients with other tumours. 
All the patients were followed-up every three months with cystoscopy and 
urine cytology. Follow-up data were documented until July 1991. In 1991, all 
the patient and disease characteristics at first presentation as well as the 
follow-up data were reviewed using the medical files. The follow-up of 
patients without any recurrence and disease progression was censored to the 
date of the last hospital visit. In case of death not related to the bladder 
cancer, the follow-up was censored to the date of death. The median follow-up 
period of the study cohort was 3.5 years. 
Analysis 
The two hypothetical policies (Figure 8.1) were compared with regard to the 
expected 3-year risk of recurrence and the expected 3-year risk of progression 
(progression was defined as a shift to a higher tumour stage category or the 
development of regional or distant metastases). For this, we calculated the 
3-year risks of recurrence and progression for each branch of the decision tree 
in Figure 8.1 using the Cox's proportional hazards model.5 
The proportional hazards model was used for the following reason. Because 
the prognostic ability of concomitant dysplastic changes in normal-looking 
urothelium and the beneficial effect of adjuvant intravesical therapy are very 
important for the conclusions from our study we intended to perform a 
so-called sensitivity analysis. In order to enable a sensitivity analysis {i.e. an 
evaluation of the stability of a conclusion from a decision analysis by varying 
the quantitative value of one or more characteristics in a decision tree) we 
modelled the time to recurrence and time to progression as a function of 
tumour characteristics, the result of random biopsies and the applied therapy. 
The resulting hazard ratios (or relative risks) from the model reflect the 
prognostic ability of these factors. 
The factors which were fixed in the Cox model were the type of tumour 
(solitary pTaGl vs. pTlG3 vs. other), random biopsy 'result' (not performed 
vs. normal mucosa vs. dysplastic mucosa) and therapy (TUR alone vs. 
adjuvant intravesical chemotherapy or BCG; patients who were treated more 
aggressively (N=71) were excluded from the analysis). Possible (additional) 
interactions between these factors were tested for their statistical significance 
with a step-wised model using the likelihood ratio test with significance level 
P=0.10. None of the interaction factors appeared to be statistically significant. 
The underlying proportionality assumptions of the Cox model with the fixed 
factors appeared to hold and the preditive reliability of the model was found to 
be fairly good.61 The results of the multivariate proportional hazards analysis 
are summarised in Table 8.2. 
Chapter 8 - Random biopsies 110 
According to the definitions we used for the factors in the model, the 
reference group comprised the patients with a solitary pTaGl tumour who 
were not biopsied and were treated with TUR alone. The 3-year actuarial risk 
of recurrence in this reference group was 42%; the 3-year actuarial risk of 
progression was 3%. With these observed risks and the relative risks in 
Table 8.2, the expected risks of recurrence and progression for each branch of 
the decision tree were calculated using the proportional hazards assumption: 
RY = l-(l-R 0)n r T where: 
RY = the expected 3-year risk of recurrence (or progression) in patients 
in a particular branch of the tree (Y), 
RQ = the 3-year risk of recurrence (0.42) or the 3-year risk of 
progression (0.03) in the reference group, 
Пгг = product of the branch-specific relative risks. 
For example, the expected 3-year risk of recurrence in patients with a solitary 
pTaGl tumour (RR = 1) who have concomitant dysplastic abnormalities in 
normal-looking urothelium (RR = 1.11) and who received intravesical 
instillations (RR=0.73) is: 
RY = l-(l-0.42) , m π ·° 7 3 ' 
= l-(0.58) ( 0 8 , ) 
= 0.36 or 36% 
Subsequently, the two hypothetical management policies in the decision tree 
were evaluated using the computer programme DECISION MAKER.47 
RESULTS 
The 3-year risks of recurrence and progression for all the patient subgroups in 
the two management policies are summarised in Figure 8.1. Of all the patients 
with a solitary pTaGl tumour who had been treated with TUR alone, 42% had 
at least one recurrence within 3 years. Only 3% manifested progressive 
disease. These risks were only slightly lower when random biopsies showed 
no mucosal abnormalities. In the patients who had such concomitant mucosal 
abnormalities, the risks of recurrence and progression were higher. Unlike the 
risk of progression, however, the higher risk of recurrence was totally 
compensated for by the prophylactic effect of intravesical therapy. In our 
study, intravesical chemotherapy or BCG was apparently less effective for 
preventing progression. The same phenomenon was seen in the patients with a 
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tumour other than solitary pTaGl or pTlG3. When treated with TUR alone, 
this group of patients had risks of recurrence and progression of 59% and 
11%, respectively. In the case of a normal random biopsy result, these risks 
were 58% and 9%, respectively Due to intravesical therapy, the risk of 
recurrence decreased to 52%, despite the finding of concomitant dysplastic 
urothelium. In this case, however, the nsk of progression increased to 19%. 
In both management policies, the patients with a pTlG3 tumour were treated 
with intravesical therapy. The 3-year risks of recurrence and progression in 
these patients were 56% and 26%, respectively. 
TABLE 8.2 Results of Cox's multivariate regression analyses on 1674 patients 
with superficial TCC of the bladder (of whom 864 suffered 
recurrent disease and 172 progressive disease) 
Prognostic Recurrence Progression 
Factor 
RR' (95% CI)® RR (95% CI) 
Tumour type 
Solitary pTaGl 
'Other' 
pTlG3 
Result of random biopsies 
Not performed 
No dysplastic changes 
Dysplasia/CIS 
Therapy 
TUR alone 
Adjuvant intravesical 
chemotherapy/BCG 
' RR = Relanve Risk 
® 95% CI = 95% Confidence Interval 
The expected overall 3-year risk of recurrence with the 'no biopsy policy', 
was 54%. This risk was only slightly lower if random urothelium biopsies had 
been taken from all the patients: 52%. This means a difference of only 2% in 
the risk of recurrence as the ultimate gain of taking random biopsies, whereas 
27% instead of 12% of all patients would have to be treated with adjuvant 
intravesical therapy owing to the presence of mucosal abnormalities. 
Expressed in terms of a decrease in the 3-year risk of progression, no benefit 
1 
1 65 (1 39 - 1 95) 
2 08 (1 60 - 2 69) 
1 
0 97 (0 84 - 1 12) 
111 (0 89 - 1 38) 
1 
0 73 (0 63 - 0 86) 
1 
4 52 (2 43 - 8 25) 
9 98 (5 05 - 19 69) 
1 
0 71 (0 50 - 1 02) 
1.57 (1.03 -2.39) 
1 
0 98 (0 70 - 1 38) 
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at all could be observed from taking random biopsies. In both policies, the 
expected 3-year risk of progression was 11%. 
STABILITY OF THE CONCLUSION 
The conclusion from our study should be that there is little reason to take 
random urothelium biopsies from patients with primary superficial TCC of the 
bladder. The disappointing ultimate benefit of random biopsies may be 
explained (at least partly) by three factors. First, the low prevalence of 
dysplastic changes in patients with low grade tumours (the high prevalence in 
patients with grade 3 tumours is clinically irrelevant because these patients are 
treated adjuvantly anyway); second, the poor independent prognostic ability of 
random biopsies; and third, the poor efficacy of intravesical chemotherapy. 
The latter two factors can be quantified by hazard ratios (or relative risks) 
which result from a multivariate proportional hazards model.5 In our study we 
found that the relative risks (RRs) of the absence and presence of dysplastic 
changes in normal-looking urothelium were only slightly different from 1 
regarding the risk of recurrence (RR=0.97 and RR = 1.11, respectively) (see 
Table 8.2). The RRs of a negative or a positive biopsy result on the risk of 
progression were a little higher (RR=0.71 and 1.57, respectively). While 
adjuvant intravesical therapy had a protective effect on the risk of recurrence 
(RR=0.73), such a protective effect (adjusted for other factors) was almost 
absent for the risk of progression (RR=0.98). 
It is possible that for some reason the prevalence of dysplasia or CIS in 
normal-looking mucosa was underestimated in our study. The same may also 
apply to the effects of random biopsies and intravesical therapy. In that case, 
the benefit of taking random biopsies would have been underestimated. In 
order to examine the stability of our conclusion, we first reviewed the 
literature with respect to these three factors and used the results of this review 
in a so-called 'sensitivity analysis'. 
Literature review of key-information 
With respect to the prevalence and the prognostic ability of concomitant 
dysplastic urothelium we reviewed 38 papers.1-4'6*-9·1113·20·22'23·27-29·31·33'34'36'^43· 
45^ *6,48,50-52,55-59 p r o m these papers we made a selection based on the following 
criteria: 1) prospective (unselected) study population; 2) biopsies taken from 
normal-looking urothelium; 3) biopsies taken once at initial diagnosis of the 
primary tumour; 4) the definition of a positive biopsy result was reported; and 
5) the results from the study were reported (separately) for patients with 
superficial disease. In the studies which fulfilled these criteria, the prevalence 
of dysplastic abnormalities ranged from 24% to 43% (see Table 8.3). 
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TABLE 8.3 Literature review: Prevalence (%) of dysplasia or CIS in 
normal-looking mucosa® 
Reference 
NBCCG-A, 1977" 
Soloway, 197845 
Heney, 1978'5 
Wallace, 1979" 
Heney, 198213 
Heney, 1983'4 
Smith, 198343 
Wolf, 19875' 
Flamm, 198912 
This study 
Study 
size 
N = 61 
N=42 
N=75 
N=27 
N=47 
N = 183 
N = 112 
N=259 
N=216 
N=1044 
Prevalence in 
all patients 
41% 
33% 
43% 
33% 
38% 
33% 
34% 
25% 
24% 
22% 
Prevalence in patients 
Grade 1 
20% 
15% 
23% 
0% 
12% 
11% 
with tumour of 
Grade 2 
30% 
59% 
41% 
17% 
24% 
20% 
Grade 3 
50% 
77% 
55% 
54% 
57% 
47% 
® In studies where non-dysplastic abnormalities (hyperplasia, metaplasia, inflammation, 
reactivity, cystitis and atypia) were used as distinct entities in addition to dysplastic 
changes, we considered only dysplastic changes to be positive findings 
This prevalence was strongly correlated with tumour grade. The highest 
reported prevalences in grade 1 and grade 2 tumours (in studies with more 
than 100 patients) were 23% and 41%, respectively.14 To assess the 
independent prognostic ability of random biopsies regarding the risk of 
recurrence and the risk of progression, we tried to select studies in which 
adjustment was made for the effects of other prognostic factors. Such 
adjustment was considered to be necessary because of the strong correlation 
between the presence of concomitant urothelial lesions and tumour grade (but 
also tumour stage and multicentricity1259 However, all the studies which dealt 
with the prognostic ability of random biopsies, based their conclusions on the 
results of univariate analyses only Therefore, we were not able to quantify the 
independent prognostic effect of random biopsies from the literature. 
To quantify the effect of intravesical chemotherapy and BCG on the risk of 
recurrence and the risk of progression we used two review papers.16"17 In 11 
randomised trials on primary or recurrent superficial TCC which compared 
TUR alone to Thiotepa, Doxorubicin, Mitomycin С or BCG, fairly wide 
discrepancies were reported between the benefits of adjuvant therapy.16 The 
maximum reported decrease in the risk of recurrence was 46 %, while once an 
increase of 5% was reported in the risk of recurrence with Thiotepa. 
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Combining all the study results, the 1-year risk of recurrence in patients 
treated with TUR alone was 44%, and the 1-year risk of recurrence in patients 
treated adjuvantly was 31%. Using the proportional hazards assumption (see 
Patients and Methods section), this protective effect of intravesical therapy can 
be converted into a relative risk of 0.65. 
Even though there is still little evidence that adjuvant intravesical 
chemotherapy or immunotherapy can prevent progression to invasive bladder 
cancer,
23,32
 a few recent studies have given some indication of a beneficial 
effect of BCG on progression.1 0 1 8 1 9 In a review on (primary and recurrent) 
pTl bladder cancer, Herr and Jakse reported progression (in tumour stage or 
grade) within 3-5 years in 29% of the patients treated with TUR alone. In the 
patients treated with intravesical chemotherapy or BCG this percentage was 
estimated to be 17%.17 With these percentages, the relative risk of adjuvant 
intravesical therapy would be 0.55. 
Sensitivity analysis 
Based on the literature review, in the sensitivity analysis we assumed a 
prevalence of concomitant dysplasia in patients with a solitary pTaGl tumour 
of 23 % instead of the observed 11%. We further assumed this prevalence in 
patients with a tumour other than solitary pTaGl and рТЮЗ to be 4 1 % 
instead of 20% as we found in our study. With these quite extreme 
percentages (Table 8.3), the 3-year risk of recurrence would be 55% with the 
no-biopsy policy and 51% with the biopsy policy. To achieve this 4% 
reduction in the risk of recurrence, however, an extra 31 % of all the patients 
(43% compared to 12%) would have to be treated with intravesical therapy. 
Even though, the 3-year risk of progression was now expected to be 12% with 
both policies. This similarity of the risk of progression in both policies was 
caused by the poor efficacy of intravesical therapy. Therefore, in accordance 
with the findings from the literature we assumed the effect of intravesical 
therapy to be RR=0.55 instead of the RRs we estimated from our case series 
(0.73 for the risk of recurrence and 0.98 for the risk of progression). 
Furthermore, in the sensitivity analysis we assumed a fairly extreme 
prognostic ability of dysplastic changes in normal-looking urothelium with a 
RR of 3.0 (instead of 1.11 and 1.57 for the risks of recurrence and 
progression, respectively). With these optimistic assumptions, favouring the 
policy of routine random biopsies, the 3-year risk of recurrence would become 
63% in the no-biopsy policy and 58% in the biopsy policy. The 3-year risk of 
progression, still at the expense of 43% vs. 12% of the patients treated 
intravesically, would be 15% and 11% in the two policies, respectively. 
DISCUSSION 
In our opinion the principal aim of taking random urothelium biopsies is to 
improve the urologist's ability to distinguish between patients who should be 
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treated with adjuvant intravesical therapy and those who should not. Until 
now, a number of authors have concluded that random biopsies may be used 
as a guide in defining therapy for superficial bladder cancer because they 
found that random biopsies have a statistically significant prognostic effect. 
However, several arguments exist against such a conclusion. 
1. In most of the studies on the prognostic significance of biopsy results of 
normal-looking mucosa, the effect on the development of recurrences (or new 
occurrences) was studied. Because of small study sizes or short follow-up 
periods the effect on tumour progression was not studied, even though tumour 
progression is considered to be a more important characteristic of disease 
outcome. 
2. The correlation between dysplastic changes in normal-looking urothelium 
and other established prognostic factors is well-known, especially the 
correlation with tumour grade. This means that random biopsies may not add 
to the prognostic information already provided by these factors. The 
experimental evidence of the prognostic ability of random biopsies, however, 
is based on studies in which no adjustment was made for the prognostic effect 
of other factors, e.g., through multivariate analyses. 
3. The prognostic ability of random biopsies is not quantified by its degree of 
statistical significance. This prognostic ability (as expressed by a relative risk 
for instance) may be fairly poor despite a statistically significant Ρ value. For 
example, for progression we found a small, but still statistically significant, 
relative risk of 1.57. 
The hypothesis for the prognostic relevance of random biopsies is that 
concomitant dysplastic changes reflect a premalignant state of the entire 
urothelial surface which is prone to developing new tumour occurrences and 
muscle invasion. Poor prognostic ability does not necessarily mean that this 
hypothesis is false. In theory, a high predictive ability of mucosal 
abnormalities may be obscured by low accuracy and poor reproducibility in 
the interpretation of biopsy specimens. In a study by the Medical Research 
Council it was shown that the reproducibility in the interpretation of random 
biopsies was very poor.37 Unfortunately, it is not possible to separate the 
biological behaviour of dysplastic urothelium areas (the real prognostic 
potential) from the inaccuracy in the interpretation of random biopsies. The 
prognostic ability of random biopsies may improve, therefore, with more 
objective criteria for morphological abnormalities,37 or with alternative 
methods of interpretation, such as DNA flow cytometry.33 
4. In primary superficial bladder cancer, no definite consensus has been 
reached yet on treatment policy. Even though, because of the strong 
correlation between dysplastic changes in normal-looking urothelium and other 
prognostic factors, it is likely that most of the patients with dysplastic 
urothelium would have been treated adjuvantly anyway (e.g., patients with a 
grade 3 tumour). Thus, for most patients with concomitant mucosal 
abnormalities, this finding is irrelevant for the choice of treatment. 
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5. If the primary interest in a prognostic factor is optimization of treatment 
management then this prognostic factor will be fairly insignificant with low 
treatment efficacy. The efficacy of intravesical therapy in primary superficial 
bladder cancer is no longer doubted regarding the prevention of new 
occurrences. However, it remains to be proven regarding the risk of 
progression. 
The purpose of our study was to examine the rationale of routine quadrant 
biopsies of normal-looking urothelium in primary superficial bladder cancer. 
We used decision-analytical methods in order to be able to take all the 
aforementioned factors into account. Based on the data from a large unselected 
prospective series of newly diagnosed superficial bladder cancer patients, we 
found that there is little reason to take random urothelium biopsies at initial 
endoscopical surgery. If random biopsies are taken from all the patients, then 
the 3-year risk of recurrence decreases by only 2%. The 3-year risk of 
progression does not change at all. In sensitivity analyses we tested the 
stability of this conclusion by using findings from the literature on the 
prevalence of dysplastic abnormalities in patients with low grade tumours, and 
on the prophylactic effect of intravesical instillations with chemotherapy or 
BCG. Furthermore, we assumed a fairly extreme independent prognostic effect 
of the presence of dysplasia or CIS in normal-looking urothelium when the RR 
was considered to be 3.0 for both the risk of recurrence and the risk of 
progression. This RR would mean that in a hypothetical population with a 
certain prognostic profile, a 3-year risk of recurrence of 50% would increase 
to 87% in the case of concomitant urothelial abnormalities. An assumed 3-year 
risk of progression of 15% would change to 39%. Despite all these 
assumptions we found that the ultimate benefit of random biopsies remained 
limited. Compared to the no-biopsy policy, the 3-year risks of recurrence and 
progression were reduced by no more than 5% and 4%, respectively, whereas 
an extra 31 % of patients with primary disease would have to be treated with 
intravesical instillations. 
In our opinion, this extra proportion of patients who would have to be treated 
with intravesical therapy, and as such would experience discomfort to varying 
degrees, is the major disadvantageous effect of the use of random biopsies as 
an additional prognostic test. Although rarely fatal, side-effects of 
intravesically instilled agents are quite common.24 The second (less important) 
disadvantage of taking random biopsies as an additional prognostic test is the 
direct and indirect financial cost. The direct cost relates to the 
histopathological interpretation of extra biopsy specimens. The indirect cost 
results from the application of intravesical instillations to more patients. To 
some extent, however, the financial cost will be compensated for by saving 
some patients from having to undergo one or more endoscopic resections (or 
more aggressive treatment). 
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As aforementioned, no definite consensus has yet been reached on the clinical 
management of patients with superficial bladder cancer. In our 'no-biopsy 
policy' we defined a conservative treatment policy (except for the patients with 
a pTlG3 tumour, all the patients were treated with TUR alone) in order to 
evaluate the maximum possible benefit of the alternative 'biopsy policy'. 
Urologists may not agree with these (simplified) policies. Alternative policies 
are those in which random biopsies are applied more selectively The urologist 
does not know the histopathology result of the resected tumour (stage and 
grade) before he has to decide whether or not to take random biopsies From 
the prior endoscopy, however, he will know the size and multicentricity of the 
tumour. Thus, an alternative policy may be to treat all the patients with 
multiple tumours with intravesical chemotherapy and to take random biopsies 
only from the patients with solitary tumours. We evaluated this 'alternative 
biopsy' strategy with the same decision-tree we used before (see Figure 8 1), 
by applying it to patients with a solitary tumour only (70% of all the 1745 
patients with superficial TCC in our case series). Using the same assumptions 
as we did before, the 3-year risks of recurrence and progression in the no-
biopsy policy were 59% and 11%, respectively. In the biopsy policy these 
risks were 53% and 9%, respectively Thus, the beneficial effect of routine 
random biopsies remained disappointing. 
We conclude that there is no good reason to take routine random biopsies of 
normal-looking urothelium in patients with newly diagnosed superficial 
bladder cancer. The ultimate benefit of taking random biopsies is only a slight 
decrease in the risks of recurrence and progression (even if optimal conditions 
are assumed) at the expense of a substantial increase in the number of patients 
who would have to be treated with adjuvant intravesical instillations 
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SUMMARY 
In clinical practice, prognostic factors are primarily used to identify and 
select patients with a relatively poor prognosis who may need more 
aggressive treatment in order to improve their prognosis. Preferably, 
assessment of the ability of prognostic factors to distinguish these high risk 
patients from low risk patients should take place in the absence of such 
prognosis-modifying adjuvant therapy. Adjuvant therapy may dilute the 
effect of prognosticators (covariate-treatment interactions) and such a 
situation may go unnoticed in tests for interaction because of their low 
statistical power. Therefore, for the evaluation of prognostic factors, it is 
argued that the study population should be restricted to patients who do 
not receive adjuvant therapy. This restriction might result in a less 
powerful analysis, but it carries the advantage that undetectable biases are 
avoided. Non-random treatment assignment will not invalidate this 
restricted analysis provided that all the prognostic factors on which 
treatment choice was based, are known and incorporated into the analysis. 
INTRODUCTION 
The aim of prognostic assessment is to identify a set of covariates (or 
'prognostic factors'), which in combination will enable the optimal 
discrimination of patients with a poor prognosis from those with a favourable 
prognosis. Prognostic factors do not necessarily have any direct causal 
relationship with the outcome of a disease. For example, in low-stage cancer 
where it is believed that the tumour has been completely removed by 
'curative' surgery, the tumour itself can no longer influence the prognosis, but 
the tumour's characteristics may still form useful prognostic factors. However, 
in addition to prediction, a second goal of prognostic assessment is elucidation 
or explanation (like in aetiological research). Knowledge of prognostic factors 
which have a direct causal relationship with disease outcome, facilitates the 
understanding of the pathophysiology of the disease and may direct specific 
interventions. For example, even though 'yellow stained fingers' may have 
predictive ability for myocardial infarction in patients with coronary artery 
disease, knowing that smoking is the real causal factor means a step forward 
in the understanding and management of the disease. In this paper, we 
consider both aspects of prognostic assessment to be important and assume 
that every (prognostic) factor has a certain, yet to be identified, quantitative 
effect on prognosis. 
In clinical practice, prognostic factors are primarily used to optimize 
treatment policies. A fairly conservative treatment (or none at all) may suffice 
for a group of patients with a relatively good prognosis, whereas a more 
aggressive treatment may be required for patients with a relatively poor 
prognosis (Figure 9.1). With this in mind, it seems trivial to say that 
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prognostic assessment should take place in the absence of the more aggressive 
treatment modality. If a group of patients receive (adjuvant) therapy, 
prognostic factors will not necessarily explain the 'natural history' of the 
disease in the absence of this (adjuvant) therapy, but they may predict the 
disease course under the influence of interactions between the treatment and 
the disease itself.1'2 This means that in a treated population, the potential 
importance of a new prognostic test may have been masked (or amplified) by 
treatment. For example, in low-stage bladder cancer, adjuvant intravesical 
chemotherapy may be administered after endoscopical resection of the 
tumour(s), in order to prevent recurrences. The presence of concomitant 
dysplastic lesions in biopsy specimens from the cystoscopically normal-looking 
urothelium might aid in the selection of patients who need such intravesical 
chemotherapy. Evaluation of the prognostic value of concomitant dysplasia in 
patients who were treated adjuvantly may be impossible, however, because the 
chemotherapy will have 'modified' the urothelium. 
FIGURE 9.1 Prognostically high and low risk patients with intended 
modification of the prognosis by (adjuvant) treatment for high 
risk patients 
100 
Cum. risk of morbidity/mortality (%) 
High risk 
Effect of therapy 
Low risk 
From sheer necessity, prognostic tests are frequently evaluated in cohorts of 
patients which contain various proportions of different treatment modalities. 
One fairly standard approach for prognostic assessment on the basis of the 
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data from these studies with randomized or non-randomized treatment 
assignment, is to fit a model using the full data set and then to assume that the 
effects of the prognosticators are the same in different treatment arms and to 
augment this assumption with tests for interaction. However, tests for 
interaction often have little statistical power, so that a non-significant result 
may not rule out clinically important differences in effects. In this paper, it is 
argued that a restricted data set (containing a particular treatment group) 
should be used for prognostic factor analyses instead of the full data set, even 
if treatment has been applied in a non-randomized fashion. 
DESIGN OF PROGNOSTIC FACTOR STUDIES 
Notation (Holland and Rubin, 1988)-
Consider a population of patients with some disease for which two treatment 
modalities к exist; k = c is some kind of standard therapy (or no therapy at all 
in some diseases) routinely administered to all patients (c ='control'); k = e is 
an optional adjuvant therapy from which patients may benefit at the expense of 
potential side-effects (e ='extra'). A response Y is recorded for each patient 
after exposure to one of the two modalities k: Y = 0 is still alive after time t; 
Y = l is death before t. Formally, instead of a single dependent variable Y we 
have a dependent variable Yk for each of the treatments to which a patient 
could have been exposed. If the patient had been exposed to treatment c, the 
value Y
c
 would have been recorded for that patient. If that same patient had 
been exposed to treatment e, then the value Y
e
 would have been recorded. 
Thus, the following vector is associated with each patient: 
(1) (Y„ Yc), 
where Yt is the patient's response after exposure to treatment k. 
Although formally each patient has a value for both Y
e
 and Y
c
, a patient is 
exposed to only one of the two treatments к and therefore, we observe only Y
e 
or Y
c
. In order to relate the vector in (1) to the data which are actually 
observed, the variable S is introduced, where S = k if the patient is treated 
with k; S is the variable which indicates the к assigned to each patient. The 
observed data from a patient is the vector 
(2) (Y., S). 
The notation Y
s
 is used because it indicates that we can observe only the 
response of a patient to the treatment to which he/she was exposed, that is 
(3) Y
s
=Y k if S = k, for k = c and k = e 
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The response Y not only depends on k, but it also depends on the patient 
himself. Subgroups of patients can be defined by the value of a covariate X or 
a vector of covariates X. The interest in treatment efficacy studies lie in k, 
whereas the interest in prognostic assessment lies in X. 
Prognostic assessment 
As aforementioned, in addition to prediction itself (what to tell the patient 
about his or her future), for clinical practice the interest in the covariates X 
will lie in the treatment policy (what to do for the patient).4 Especially in 
diseases such as cancer where intended effects of treatment may go hand in 
hand with considerable side-effects, the underlying motive for a prognostic 
factor study is usually improvement of the clinician's ability to discern patients 
who should receive adjuvant treatment k=e from those who should not 
(although a high failure rate may not be synonymous with a high 
responsiveness to k=e). With such a motive, the optimal design of the study 
is simple: select a population of patients with the disease of interest, do not 
intervene with k=e and observe the realisation of Y
c
 in subgroups with 
different host and/or disease characteristics X. 
Studies are seldom initiated, however, strictly because one is interested in 
prognostic factors. Frequently, prognostic factor analyses are carried out using 
data from a randomized controlled trial. If data are only used from the control 
arm (k=c), the prognostic factor study will still have an optimal design 
(although specific eligibility criteria for a trial may affect the generalizability 
of the results). In Table 9.1 the results of a hypothetical large trial are 
summarized. Fifty per cent of all the patients were treated with the standard 
treatment k=c after randomized assignment. Using the data from this trial, a 
particular covariate Х
я
 an ordinal factor with 3 levels (low, intermediate and 
high), was evaluated for its prognostic significance. Logistic regression 
modelling of the data in Table 9.1 as observed among patients treated with 
k=c, yielded an odds ratio (OR) of 4.1 (95% CI: 1.8-9.3) for X, = 
intermediate vs. X, = low. For X, = high vs. X, = low, OR=7.9 (95% CI: 
3.6-17.5). (For reasons of notational simplicity, the time at which death 
occurred was not considered.) Below, we assume that these ORs are the 'real' 
quantitative effects of X
r 
NO RESTRICTION OF THE POPULATION 
With regard to the identification of prognosticators to be used in treatment 
management, we are not really interested in the prognostic effect of Xj in 
patients who have already received adjuvant treatment k=e. Nevertheless, 
using all the patients in the analysis would yield a narrower confidence 
interval around the estimated effect of X
r 
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TABLE 9.1 Results of a 
Covariate 
Low 
Intermediate 
High 
Total 
Dead 
(Y.= D 
9 
29 
44 
82 
hypothetical randomized clinical mal 
Alive 
(Y.=0) 
91 
71 
56 
218 
k=c (standard therapy) 
Total 
100 
100 
100 
300 
Pr(Y
c
=l|S = c) 
0.09 
0.29 
0.44 
0.27 
Covariate 
x, 
Low 
Intermediate 
High 
Total 
Dead 
(Y. = D 
5 
17 
29 
51 
Alive 
(Y.=0) 
95 
83 
71 
249 
k = e (adjuvant therapy) 
Total 
100 
100 
100 
300 
Pr(Y
e
=l|S=e) 
0.05 
0 17 
0.29 
0.17 
Logistic regression analysis on both the left hand side and the right hand side 
data in Table 9.1 (all k), resulted in ORIntiraied,ate vs U w = 4 . 0 (95% CI: 2.1-7.6) 
and ORHlgbvs ^ = 7 . 9 (95% CI: 4.2-14.7). (For k=e vs. k=c, OR=0.5; 95% 
CI: 0.3-0.8). The width of the confidence intervals shows that the statistical 
power of the study did increase when all the patients were included. However, 
this analysis is only valid in situations where there is no interaction between к 
and Xj, as was the case in our hypothetical trial. The ORs for Xj = Xj in the 
group of patients treated with k=e and the group treated with k=c were the 
same. A test for interaction produced a likelihood ratio statistic (Chi2LR) with 2 
degrees of freedom (df) of 0.01 (p=0.99). 
Let us now assume a hypothetical trial with trealment-covariate interaction 
(see Table 9.2). It can be seen that k=e did not have any effect on the low 
risk group, whereas k=e almost halved the chance of dying in the high risk 
group. Nevertheless, the test for interaction was not significant in this 
reasonably large trial with 600 patients: Chi2LR=2.60 with df=2: p=0.27. If 
we were to specify a model without interaction terms in addition to Xj and K, 
however, this would result in 'biased' ORs. Naturally, we wanted to find 
ORinirrmodi«ie ν· L o w = 4 . 1 a n d O R H l g h V 5 Uw = 7.9 (because the data in the left hand 
side of the table did not change), but the analysis resulted in OR = 3.3 and 
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OR=5.3, respectively. Unbiased ORs were obtained while maintaining the 
interaction terms in the model, even though these terms were not statistically 
significant. In that case, the ORs were 4.1 (95% CI: 1.8-9.3) and 7.9 (95% 
CI: 3.6-17.5). Note that the confidence intervals are exactly the same as those 
in the situation where we restricted the analysis to the standard therapy group 
k=c. This is not very surprising because the model was saturated by the 
incorporation of all the possible interaction factors in the model. Thus, in the 
case of treatment-covariate interactions, including all the patients in the 
analysis does not increase the power of the study. 
TABLE 9.2 Results of a hypothetical randomized clinical trial with treatment-
covariate interaction 
Covariate 
Low 
Intermediate 
High 
Total 
Dead 
(Yc=D 
9 
29 
44 
82 
Alive 
(Yc=0) 
91 
71 
56 
218 
k = c (standard therapy) 
Total 
100 
100 
100 
300 
Pr(Yc=l|S=c) 
0.09 
0.29 
0.44 
0.27 
Covariate 
Low 
Intermediate 
High 
Total 
Dead 
(Ye=D 
9 
20 
24 
53 
Alive 
(Y,=0) 
91 
80 
76 
247 
k=e (adjuvant therapy) 
Total 
100 
100 
100 
300 
Pr(Ye = l|S=e) 
0.09 
0.20 
0.24 
0.18 
In real life, the situation will not be as simple as in our trial. There may be a 
large number of covariates X with covariate-covariate interactions, which may 
also interact with k. In this case, the analysis as well as the interpretation of 
the results will become fairly complicated. In our opinion, therefore, it is 
preferable to restrict the analysis to k=c, except in the (utopical) situation in 
which one is absolutely certain that there are no treatment-covariate 
interactions. 
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THE USUAL DESIGN OF A PROGNOSTIC FACTOR STUDY 
Data from a randomized trial may not always be available or suitable to be 
used for prognostic factor analyses, for instance, because some covariate Xj of 
interest was not part of the study protocol. It is sometimes possible to perform 
a prognostic factor study on data from a patient series which has already been 
documented for other purposes. Very often, part of such a series will have 
been assigned to some kind of adjuvant therapy k=e in a non-randomized 
fashion. How does this non-randomized treatment assignment affect the 
results of the analysis? 
Let us assume that in a hypothetical patient series, X, is the only host or 
disease characteristic which influenced treatment assignment. Most of the 
patients with a low score on Xj were treated conservatively with k = c, whereas 
most of the patients with a high score on Xj were treated with k=e . The fact 
that not all the patients with Xj = low were treated with k = c and not all the 
patients with Xj = high were treated with k=e, is the result of some patients' 
and some physicians' preferences (not related to prognosis) for one of the two 
modalities. If we further assume the same treatment-covariate interaction as 
was illustrated in Table 9.2, this would lead to the data presented in 
Table 9.3. Because treatment assignment is based on Xj only, for each Xj = Xj, 
Pr(Yc = l ¡ S = c) and Pr(Ye=l ¡ S = e) are the same as in the randomized trial 
of Table 9.2. However, owing to the non-randomized assignment, 121 patients 
would die in this series compared to 135 in the trial of Table 9.2. 
Analysis of the left hand side data in Table 9.3 (k=c) yielded the following 
results: ORInlermcdiate vs. ^ = 4 . 2 (95% CI: 2.1-8.4) and ORHlgh V5 L<,W=7.9 (95% 
CI: 3.2-19.4). The similarity with the results from the aforementioned trial is 
not surprising, because for every Xj; Pr(Yc = l ¡ S=c) remained constant. An 
analysis without any restriction on k=c showed that the power of tests for 
treatment-covariate interactions was even lower than it was in the randomized 
trial situation: Chi2LR=1.60 (df=2: p = 0.45). When treatment-covariate 
interactions were not included in the model using the full data set, the 
estimated prognostic effects were even more biased than in the randomized 
trial situation. For example: where the real ORH,6h vs InlerTned„le = 1.9, this OR 
was estimated to be 1.6 (95% CI: 1.0-2.5) in the randomized trial situation 
(Table 9.2) and 1.4 (95% CI: 0.9-2.3) in the non-randomized situation 
(Table 9.3). 
Thus, in the case of a single prognostic covariate, valid results can be obtained 
from a prognostic factor analysis on studies with non-randomized treatment 
assignment, as long as the analysis is restricted to k = c (or alternatively, as 
long as all possible treatment-covariate interactions are included in the 
regression model, whether statistically significant or not). 
Chapter 9 - Treatment assignment 129 
TABLE 9.3 Results of a hypothetical non-randomized 
treatment-covariate interaction 
Covariate 
Low 
Intermediate 
High 
Total 
Dead 
(Yc = D 
15 
29 
13 
57 
k=c (standard therapy) 
Alive Total 
(Y.=0) 
155 170 
71 100 
17 30 
243 300 
patient series with 
Pr(Yc = l |S = c) 
0.09 
0.29 
0.44 
0.19 
Covariate 
x, 
Low 
Intermediate 
High 
Total 
Dead 
(Y.=D 
3 
20 
41 
64 
k=e (adjuvant therapy) 
Alive Total 
(Ye=0) 
27 30 
80 100 
129 170 
236 300 
Pr(Ye=l]S=e) 
0.09 
0.20 
0.24 
0.21 
NECESSARY CONDITION 
The single covariate situation presented above can be generalized to the 
situation where treatment assignment is based on a vector of covariates. As 
long as this vector X is known, valid estimates of the prognostic effects of X 
(and other covariates) can still be obtained if the study population is restricted 
to the standard treatment group k=c when X is taken into account. In the non-
randomized situation, Pr(Ys=l ¡ S=c, X) is equal to Pr(Yc = l ¡ X) 
regardless of the dependence between treatment assignment S and X. This can 
be expressed as follows. 
The probability that some endpoint Ys will be observed, given the assigned 
treatment S=k and covariates X, is 
(4) Pr(Ys = y ! S=k, X = x) 
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Pr(Yk = y , S = k, X=x) 
Pr(S=k, X=x) 
Pr(Yk = y, S=k, X = x) / Pr(X=x) 
Pr(S=k, X=x) /Pr(X=x) 
( 5 ) Pr(Yt=y. S = k | X=x) 
Pr(S = k ¡ X=x) 
If all X which influenced the treatment assignment S (and may have influenced 
YJ are known and included in the model, then Pr(Yk = y ¡ X = x) and Pr(S = k 
¡ X = x) are independent and (5) is equivalent to: 
Pr(Yk=y | X = x) * Pr(S=k | X=x) = 
Pr(S = k ¡ X = x) 
(6) Pr(Yk=y ! X=x) for k=c and k=e 
Note from (6) that treatment assignment S disappeared from (4). This does not 
mean that treatment itself is not important for a patient's prognosis. It only 
means that the estimated prognostic effects of X after restriction of the 
analysis to k = c will not be biased by treatment assignment. The necessary 
condition, therefore, is the incorporation of all covariates X which influenced 
both the treatment assignment and had an independent prognostic effect on Yk. 
This condition has been defined by Rosenbaum and Rubin as strongly 
ignorable treatment assignment in their work on causal inference from non-
randomized studies.5,6 Treatment assignment (i.e., the distribution of S, given 
X and YJ is strongly ignorable if: 
(a) given X, S is independent of Yk for all k, and 
(b) Pr(S=k ¡ X=x) > 0 for all k. 
In Table 9.3, we assumed that for every Xj the conditional probabilities 
Pr(Yc = l ¡ S=c) were similar to those in the randomized trial situation. If the 
condition of strongly ignorable treatment assignment is not met, then Pr(Yc = 1 
¡ S = c) for each Xj in Table 9.3 is dependent on some unknown factor and 
biased estimates of ORIntermediale vs. ^ and ORHlgllvs ^ will be obtained. 
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DISCUSSION 
In studies on treatment efficacy, one of the basic validity issues is the 
physician's reasoning in deciding how to treat a patient. Although this decision 
is primarily based on the patient's prognostic profile, it can be fairly complex 
and difficult to quantify. Therefore, differences in outcomes between treated 
and control groups may not reflect the effects of the treatment, but rather 
pretreatment differences which may not have been measured. To overcome 
this, Rosenbaum7"9 and Rosenbaum and Rubin5610'12 have repeatedly advocated 
the use of a scalar function of covariates (the so-called 'propensity score') to 
balance covariates, in order to obtain strongly-ignorable treatment assignment 
in observational studies. This condition of strong ignorability is less restrictive 
than that of randomization and the plausibility of assuming that the condition 
holds true needs to be considered carefully in any real application.3 (For a 
more detailed discussion of the evaluation of strongly ignorable treatment 
assignment, see Rosenbaum and Rubin5 and Rosenbaum7). Although the use of 
the propensity score may suffice in most instances, there will always be the 
possibility that the estimated efficacy of some therapy has been biased by 
some unmeasured covariate. From a theoretical point of view, this makes it 
impossible to study intended therapy effects using non-randomized studies.13 
In our opinion, the role of randomization in prognostic assessment is not 
entirely comparable to its role in treatment efficacy assessment. If we wished 
to compare the efficacy of k=e to that of k=c in a particular population, 
some difficult-to-measure covariates in this population may be important for 
treatment assignment and may also influence the prognosis Yk. An example of 
these covariates is comorbidity. To achieve comparability ('internal validity') 
of the treatment group and control group, к must be assigned at random. In 
theory, the possible confounding effect of comorbidity will be prevented by 
this randomization. If the primary interest is not treatment efficacy but the 
prognostic effects of covariates X, these effects would have to be adjusted for 
the prognostic effect of comorbidity, at least if the emphasis lies in causal 
relationships between covariates and the prognosis (i.e. elucidation). However, 
whether or not the study was randomized, we do not have access to data on 
comorbidity. The only thing we do know is that unmeasured factors will be 
equally distributed over the treatment arms in the case of a randomized trial. 
Although this may facilitate the generalizability of the results of prognostic 
assessment using data from the control arm of a trial, it will still be impossible 
to assess the 'real' quantitative effects of X (adjusted for comorbidity). 
A problem which may result from restricting the analysis to one treatment 
group in an observational study, is that of statistical power. In a randomized 
study population, prognostic characteristics will be balanced over the treatment 
groups. In a non-randomized study, there will be different distributions of 
prognostic characteristics over the various treatment groups. The patient group 
that has been treated with the least intensive regimen probably contain 
relatively more patients with a favorable prognosis. In our hypothetical 
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example presented in Table 9.3, most of the patients with Xj = high had been 
given k=e . There may be situations in which all of these patients were treated 
with k=e , so it will be impossible to study the prognostic value of Xj = high 
in k=c . This extreme situation is reflected in one of the conditions of strongly 
ignorable treatment assignment: Pr(S=k ¡ X=x) > 0 for all k. If this 
condition is met, then the ability to assess the prognostic value of a new test 
(whether or not in specific prognostic subgroups) is a matter of power rather 
than of validity. In other words, the problem does not lie in the fact that the 
patient group treated with k = c was selected, but in the size of this selected 
group. 
The application of treatment as a prognostic factor to solve this potential 
power problem is a very appealing approach, because it is not necessary to 
restrict the study population, so all the prognostic subgroups will be 
represented in the analysis. However, treatment itself may affect the estimated 
quantitative value of prognostic factors. As was shown above, significance 
tests can be used to check for the existence of interaction, but the lack of 
power of these tests may lead to biased estimates and possibly to wrong 
conclusions. Moreover, if one insists on doing tests, the logical choice is an 
equivalence test rather than a significance test.14 Restricting the group of 
patients to those who really are of interest (patients who were treated with 
k = c only), however, is much easier. Furthermore, in situations where most 
patients with a certain prognostic profile were treated adjuvantly, such a 
restriction carries the advantage that therapy does not obscure any lack of 
power to assess the prognostic effect of some factor. 
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CHAPTER 10 
GENERAL DISCUSSION 
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The core of this thesis was based on data from the "Documentation project 
bladder cancer" which was initiated by urologists, pathologists and 
radiotherapists from the areas of the Comprehensive Cancer Centres IKO, IKZ 
and IKA-ST. In this chapter, the background of the project is described, as 
well as its shortcomings with regard to conducting scientific research using the 
available data. The major results of the studies presented in this thesis are 
summarized and leads are proposed for future research in superficial bladder 
cancer. 
BACKGROUND 
Superficial bladder cancer is a disease with a relatively short 'history'. Not so 
long ago, a large proportion of superficial bladder tumours were designated 
benign papilloma and were therefore not considered to be cancer.1 During the 
1970s, papillary-shaped non-invasive tumours became increasingly defined as 
carcinoma. Nowadays, these non-invasive tumours comprise approximately 
70% of superficial bladder carcinomas and approximately 45% of all bladder 
carcinomas. In urological practice, a clear distinction is made between patients 
with superficial disease and patients with invasive disease because of 
differences in prognosis and management. Most cancer registries and 
epidemiological studies on bladder cancer have not (yet) made such a 
distinction.2"3 Precise data on the occurrence and etiology of superficial 
bladder cancer is therefore relatively scarce. 
In contrast, much clinical research has already been conducted into the 
prognosis of patients with superficial transitional cell carcinoma (TCC) of the 
bladder. Overall figures for the risk of recurrence, risk of progression and 
mortality are available, although these figures are frequently based on more or 
less selective and small patient series. As a consequence, this research has not 
yet resulted in clinicians being able to make fairly accurate predictions of 
disease outcome in superficial TCC. The disease encompasses a spectrum that 
ranges from innocuous to life-threatening lesions, which are difficult to 
distinguish.4 
The same holds true for the treatment management of patients with superficial 
TCC. Quite a number of clinical trials have shown that the intravesical 
administration of chemotherapeutical agents inhibits recurrent tumour 
formation, but the effect of these agents on disease progression is still 
uncertain.3 Increasing evidence has suggested that BCG immunotherapy, 
unlike chemotherapy, can alter the natural history of superficial bladder cancer 
by providing long-term protection against tumour recurrence, by reducing the 
incidence of stage progression and by reducing disease mortality, but the 
available data are still limited.6 Inaccurate prognostication as well as 
ineffective prevention of disease progression are the primary reasons for the 
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relative absence of consensus regarding the management of patients with 
primary superficial TCC. 
BLADDER CANCER DOCUMENTATION PROJECT 
In order to gain an insight into the clinical management of patients with 
bladder cancer and to facilitate the comparison of treatment results with data 
from the literature, a "Documentation project bladder cancer" was initiated by 
urologists, radiotherapists, pathologists and oncologists in the south-eastern 
part of the Netherlands, who were also collaborating in the Comprehensive 
Cancer Centre IKO "Working Group Urological Oncology". The aim of this 
project was defined as "... to collect data on the character and extent of 
disease in patients with primary bladder cancer; to gain an insight into the 
epidemiology of the disease; and to evaluate the results of treatment".7 As an 
integral part of the documentation project a booklet "Guidelines for the 
treatment of bladder cancer" was prepared and distributed among the project's 
participants.8 
In 1982, a population-based cancer registry which could serve as a primary 
source and framework for the documentation project, was not yet in operation. 
For that reason, all the data in the project were documented by the 
participating urologists and radiotherapists. A data manager was appointed to 
collect the data. The decision as to whether or not a patient should be 
documented, was made by the treating urologist. 
From the start of the project, several research questions were of interest to the 
participants in the project, although they had not been formally 
operationalized. With respect to the group of patients with superficial bladder 
cancer, these research objectives were related to the ability of predicting 
disease outcome in individual patients and the rationale of taking cold-cup 
mucosal biopsies for prognostication and (subsequent) treatment management.9 
Most of the contents of this thesis concern the evaluation of the latter research 
questions. 
THE PROJECT'S DRAWBACKS 
Initially, the project was not set up with the aim of carrying out scientific 
research, but of carrying out applied research. Furthermore, as mentioned 
above, the research questions were not clearly defined at the very beginning of 
the project. Both of these factors led to a number of difficulties. 
The treatment guidelines 
The major difficulty with the analysis of the documented data was related to 
the treatment guidelines themselves. It was advised to treat patients with a 
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primary solitary superficial (pTa and pTl, Nx MO) tumour with transurethral 
resection (TUR) only. In the case of multiple primary tumours, the advised 
policy was TUR, if necessary in combination with intracavitary chemotherapy. 
In the case of a primary pTlG3 tumour with a diameter of less than 5 cm, it 
was advised to consider interstitial radiotherapy (radium, caesium) after 
preoperative external 3 χ 3.5 Gy radiotherapy. Thus, except for a solitary 
grade 1 or 2 tumour, more than one treatment option was listed for all the 
tumours. Moreover, if it was decided to administer intracavitary 
chemotherapy, the urologist could choose from four agents: thiotepa, 
doxorubicin (Adriamycin), cisplatin or ethoglucid (Epodyl). 
After the start of the project, many papers appeared in the scientific 
literature on the efficacy (and side-effects) of these and other agents 
(mitomycin-C, Bacillus Calmette-Guérin) which once more influenced the 
treatment policy of the participating urologists. All this resulted in a lack of 
uniformity of treatment policy. Quite a number of patients with a primary 
solitary grade 1 tumour were treated with adjuvant intravesical instillations 
(27%), whereas a surprisingly high percentage of patients with pTlG3 
tumours were treated with TUR only (26%). 
Treatment assignment 
This non-randomized treatment assignment as well as the diversity of agents, 
made it impossible to evaluate treatment effectiveness. We wondered, 
however, in what way the application of therapy in a non-randomized fashion 
may have affected the results of the prognostic factor analyses. In superficial 
bladder cancer, there are no uniformly accepted indications for the 
administration of intravesical therapy.10 In our project, the most important 
factor for treatment assignment appeared to be a factor which was not related 
to the patient's prognosis, i.e. the urologist's (and the patient's) preference: 
some urologists administered intravesical instillations to almost all their 
patients, whereas others hardly ever did. Other factors which were important 
for treatment assignment were age, tumour stage, grade, multiplicity, size and 
concomitant intraurothelial dysplastic changes. Owing to the availability of 
information about all these factors, it was possible to make adjustments for 
treatment assignment in order to obtain valid results in the prognostic factor 
analysis." A factor which may have influenced treatment policy in some 
patients but was not measured in the project, is comorbidity (unrelated to 
superficial bladder cancer). However, we assumed that comorbidity could not 
have influenced the two endpoints in our study: recurrence and progression. 
Low statistical power 
The primary topic of interest was to evaluate the ability of prognosticators to 
identify and select patients with a relatively poor prognosis who might benefit 
from adjuvant intravesical instillations. For this purpose, we wanted to aim the 
study at patients who had not received these instillations, but due to the non-
randomized treatment assignment, some prognostic subgroups of patients were 
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underrepresented in the TUR only group. For example, only 10 of 86 patients 
with carcinoma in situ (CIS) in the cystoscopically normal-looking urothelium 
of 1044 patients, were treated with TUR only. The statistical power to 
evaluate the prognostic effect of CIS in this group of patients was therefore 
extremely low. 
Data collection 
Another difficulty was related to the compilation of data by the participating 
urologists and radiotherapists. Despite their enthousiastic participation 
throughout the years, they appeared not to be professional 'data managers'. 
Data collection was stopped in July 1991 and the documented data of almost 
2000 patients with pTa, pTl or pTis were checked for validity using the 
medical files. It was found that 85 patients (4%) had recurrent disease or 
cancer of the upper urinary tract at first registration instead of a primary 
bladder cancer. Errors were made with the registration of tumour stage, 
tumour grade, the result of random biopsies and the treatment applied in 146 
(7%), 91 (5%), 259 (13%) and 38 (2%) records, respectively. We were able 
to solve this problem by checking all the records. Where necessary, correction 
of the data was carried out and the records of 100 patients were deleted. 
Item list 
Owing to the fact that some research questions were not formulated until after 
the project had started, a number of relevant items were missing from the 
documentation protocol. Several of these items, such as tumour multiplicity at 
first diagnosis and disease progression during follow-up, could be collected 
retrospectively. Unfortunately, it was not feasible to collect all the potentially 
relevant information, which meant that only incomplete data could be analysed 
for the following items: the specific chemotherapeutical or immuno-
therapeutical agent administered after initial TUR and subsequent TURs (for 
recurrences), the multiplicity of recurrences, the exact localisations of 
recurrences and the cause of death. 
Review pathology 
Tumour stage, tumour grade and the result of random urothelial biopsies were 
based on local pathology reports. Only the histological material of patients 
who were entered in a randomized trial and the histological slides of patients 
with a pTlG3 tumour were reviewed by one pathologist. The absence of 
review pathology in the majority of patients in the project rendered the project 
(in the terminology of Schwartz and Lellouch)12 'pragmatic' instead of 
'explanatory'. It reflects everyday practice rather than a purely scientific 
situation under optimal conditions. Prognostic factors, such as tumour stage 
and grade, may have gained prognostic significance if a reference pathologist 
had been able to improve the distinction between Ta and Tl rumours and 
between low and high grade tumours, thereby reducing possible 
misclassification by the local pathologist. On the other hand, the benefit of 
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involving a reference pathologist in a study on prognostic factors is not as self-
evident as it is in a study on treatment efficacy. Not only the generalizability 
of the results of a study may be decreased, but also a reference pathologist 
may not be the gold standard that we might think he is. For example, two 
reproducibility studies showed poor consistency in the grading of bladder 
tumours and the interpretation of random bladder biopsies by a number of 
experienced reference pathologists.1314 Thus, a reference pathologist may 
introduce systematic misclassification of the histopathology and bias the results 
of a prognostic factor analysis in an unpredictable direction. 
Patient accrual 
Patients were entered into the documentation project prospectively. Therefore, 
at the time of entry, there were no follow-up data. However, the project was 
not population-based, because the urologists decided whether or not to 
document a patient, which could have resulted in a selected patient series. 
Therefore, we compared the distribution of age, sex, tumour stage, grade and 
morphology in the documentation project to that in the population-based IKO 
cancer registry. Fortunately, no differences were observed in the distribution 
of these characteristics. The documentation project appeared to reflect 
everyday clinical practice, as it was meant to do. 
RESULTS 
As listed in Chapter 1, the aims of this thesis "Prognostic assessment in 
superficial bladder cancer" were: 
- to study trends in bladder cancer occurrence and mortality in the 
Netherlands; 
- to study the prognostic significance of concomitant intraurothelial dysplastic 
lesions (detected by means of random urothelium biopsies) for recurrent 
tumour formation and disease progression in primary superficial bladder 
cancer; 
- to quantify the predictive power of the available set of prognostic factors in 
primary superficial bladder cancer; and 
- to evaluate the rationale of the implementation of random urothelium 
biopsies in the management of patients with primary superficial bladder 
cancer. 
The most important findings were as follows. 
- Bladder cancer mortality in males was still seen to be increasing in 1988. 
Because the risk of dying from bladder cancer appeared to decrease in 
successive birth cohorts born after 1910, mortality in males will probably 
decline in the near future. Bladder cancer mortality rates in females were 
fairly stable between 1955 and 1988 (Chapter 2). 
- Over the past two decades, a dramatic increase has been observed in the 
occurrence of bladder cancer. This increase was caused almost entirely by 
Chapter 10 - General discussion 141 
changes in the classification of low-grade non-invasive bladder tumours. 
From 1975 onwards, the occurrence of invasive bladder cancer has 
increased only slightly. In more recent years, no clear trend has been 
observed towards lower disease stages and better survival (Chapter 3). 
- The 5-year risk of recurrent disease in patients with primary superficial 
bladder cancer was approximately 60%. The 5-year risk of progression was 
estimated to be 13%. Considering this risk of progression, quite surprisingly 
the 5-year relative survival was calculated to be approximately 86% 
(Chapter 4). 
- The risk of recurrence in patients with dysplasia or CIS in macroscopically 
normal-looking urothelium was only slightly higher than the risk in patients 
without any dysplastic changes. In addition to other prognostic factors, 
concomitant dysplastic changes significantly increased the risk of 
progression (Chapter 6). 
- Prediction of recurrent tumour formation and disease progression in patients 
with primary superficial bladder cancer on the basis of tumour stage, grade 
size, multicentricity and the result of random urothelium biopsies, was only 
accurate on average in whole patient groups. Predictions of these disease 
outcomes in individuals were found to be highly inaccurate (Chapter 7). 
- The implementation of random urothelium biopsies in the management of 
patients with primary superficial bladder cancer does not lead to any 
noteworthy decrease in the risks of recurrence and progression, whereas a 
considerable number of extra patients will be treated with adjuvant 
intravesical instillations on the basis of positive biopsy results (Chapter 8). 
LEADS FOR FUTURE RESEARCH 
Histopathology 
Histopathological characteristics are very important in the management of 
patients with superficial bladder cancer. However, the reproducibility of 
histopathology, especially the tumour's degree of differentiation, is still poor.13 
A great deal of research is ongoing into quantitative methods in urological 
oncology. These quantitative methods may result in more reproducible (and 
valid) histology reports and improve their prognostic value. But until more 
standardized automated fixation, embedding, staining, selection and measuring 
techniques become available, quantitative light microscopy cannot be applied 
as a routine tool for prognostic assessment, although it may play an important 
role in the comparison of subsequent samples in patient follow-up.15 
Molecular biology 
Superficial bladder cancer encompasses a heterogeneous group of tumors 
whose neoplastic features differ markedly. The true biological potential of 
these tumours is determined by their genetic blueprint. Tumour stage and 
grade are manifestations of these genotypes. Until now, cytogenetic studies 
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and Restriction-Fragment-Length Polymorphism (RFLP) analyses have shown 
that chromosomal changes (e.g. allelic losses, variation in chromosome 
number and aneuploidy) are associated with a loss of cell differentiation. 
Marker chromosomes are associated with an increased risk of recurrence and 
progression. Non-random abnormalities have been found on chromosomes 1, 
3, 5, 7, 9, 11 and 17. Especially deletions of chromosomes lip and 17p are 
believed to be relevant in tumour progression.16 Mutations in the p53 gene on 
17p are associated with tumour progression (not only in bladder cancer, but in 
many other cancers).17"18 Many tumour markers are correlated with tumour 
stage and grade, but the biological significance (regarding the patients' clinical 
course) of a number of these markers remains unclear.19 Recently, the 
decreased expression of E-cadherin, an intercellular adhesion molecule, has 
been found to be associated with poor survival in patients with bladder 
cancer.20 Further progress in the field of molecular biology and studies on the 
clinical relevance of tumour markers may facilitate the more accurate 
identification of patients with a high risk of tumour progression and death 
from bladder cancer. 
The 'malignant' bladder 
It has been recognized for some time that in (at least) a proportion of all the 
patients with superficial bladder cancer, the tumours are manifestations of 
cystoscopically occult widespread disease. Such 'field change defects' can be 
detected by taking random biopsy specimens from normal-looking urothelium 
and examining them for morphological dysplastic lesions. However, the 
prognostic significance of dysplastic changes, if present, appears to be limited. 
For this reason, prognostic research into superficial bladder cancer still 
focusses on the characteristics of the resected tumour(s). But this research 
identifies the malignant tumour rather than the extent to which the remaining 
bladder mucosa is potentially 'malignant'. Despite the fact that the resected 
tumour may form an indirect indicator of a patient's prognosis, it is the 
remaining bladder mucosa which will give rise to new, possibly invasive, 
tumour occurrences. Sharper focus on the remaining bladder mucosa to 
identify yet unknown cellular changes may help to detect the patients who 
truly run a significant risk for progression. If better cytological evaluation 
methods become available, random biopsies may ultimately prove to be a 
useful procedure for prognostic assessment. 
Recurrence 
More adequate definitions of disease outcome are required. In our project for 
example, the time to first recurrence (or 'risk of recurrence') was analysed. A 
considerable number of patients, however, suffered one (or a few) occasional 
recurrence(s) without any real malignant potential. In clinical practice, such a 
patient will be managed quite differently from a patient who suffers multiple 
recurrences within a short period of time. For this reason, some studies used 
the 'recurrence rate' as an endpoint instead of 'risk of recurrence'. The 
Chapter 10 - General discussion 143 
recurrence rate is defined as the number of follow-up cystoscopies at which a 
recurrence is detected, divided by the total number of months of follow-up.21 
A clear disadvantage of this measure is that patients are not considered as 
independent observations: one patient with five positive follow-up cystoscopies 
is equivalent to five patients with one positive cystoscopy. It may be possible 
to define a new endpoint which incorporates both the time to recurrence and 
multiplicity (e.g. time to multiple recurrences either diagnosed in one 
cystoscopy session or in two successive cystoscopies). Such an alternative 
endpoint may create more sensitive circumstances for the identification of 
prognostic factors. 
Progression 
Progression, a shift to a higher tumour stage category or the development of 
regional or distant metastases, the other endpoint in superficial bladder cancer, 
also deserves some further attention. In our study, we found that the 5-year 
relative survival in superficial bladder cancer was approximately 86%. This 
finding is consistent with other reports.22'24 The 5-year risk of progression was 
found to be only 13%. This finding is consistent with the overall risk of 
progression found by the U.S.A. National Bladder Cancer Collaborative 
Group.4 Per definition, in superficial bladder cancer, bladder-cancer-related 
death is only possible after disease progression. Furthermore, not all the 
patients who suffer disease progression will die from bladder cancer. It may 
be wondered, therefore, why we found an excess risk of dying from bladder 
cancer, which was very similar to the risk of progression. One fairly 
theoretical explanation is that bladder-cancer-related death was overestimated 
by calculating the relative survival because of bias from comorbidity-related 
death. Another possible explanation is that bladder cancer death (because of 
disease progression) was misclassified as non-bladder-cancer-related death in 
some of the patients. 
Treatment management 
More research is necessary in order to specify the optimal treatment 
management of patients with superficial bladder cancer. Firstly, recent studies 
have revealed that incomplete transurethral resection (TUR) occurs more 
frequently than was previously believed in patients with T1G3 tumours. 
Approximately 60% of all the patients suffered tumour recurrence at the same 
site in a study by Jakse and associates.25 Klan and colleagues found residual 
tumour with an early second resection of the same site in 40%.26 Possibly, the 
techniques of TUR need to be improved. Secondly, controversy exists 
regarding not only the ideal agent to administer for intravesical instillations, 
but also the ideal regimen.27 The primary focus of such research must be 
disease progression.2' Currently, the available chemotherapeutical agents have 
not proven to be effective in preventing progression. Recently, some 
promising results have been reported with BCG.6,2'M Hopefully, ongoing 
research to evaluate the sequential combination of intravesical chemotherapy 
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using mitomycin-C and intravesical immunotherapy with BCG (University 
Hospital Nijmegen protocol no. 911201) will add to these promising results. 
Methodology of prognostic assessment 
Although patient management is strongly individualized in clinical practice, the 
results from research into prognostic assessment are seldom translated in terms 
of individual patients. More specifically, the ability to distinguish between 
patients who will have a positive disease outcome and those who will have a 
negative disease outcome has rarely been quantified. However, quantification 
of this discrimination ability is no easy task and suitable methods are still 
lacking. In our study, we used a method which is comparable to the 
construction and interpretation of Receiver Operating Characteristic (ROC) 
curves in diagnostic assessment.31 With this method, an index of concordance 
'c ' is calculated by comparing the observed and predicted disease outcomes 
within all possible pairs of patients. For any given pair, we say that the 
predictions are concordant with the outcomes if the patient with the higher 
probability estimate of (let us say) survival, lived longer. If both patients are 
still alive, or if only one has died and the follow-up of the other is shorter 
than the survival time of the first, we do not count that pair. The 'c ' index is 
the proportion of all the pairs of patients for which we could determine the 
order of survival such that the predictions were concordant. This index is a 
linear transformation of a Kendall-Goodman-Kruskal type correlation between 
a set of predicted probabilities and the true outcomes.32 The major advantage 
of 'c ' is that it is easy to interpret because it estimates the probability that for 
a pair of patients chosen at random, the one with the longer predicted survival 
is the one who will survive longer. However, there are some clear 
disadvantages. Firstly, in clinical practice, a physician is confronted with just 
one patient rather than a pair chosen at random. Secondly, as explained above, 
a number of pairs cannot be counted in the calculation of 'c ' because of 
censoring. Therefore, research is ongoing in the field of medical statistics to 
design more suitable measures. Korn and Simon have recently advocated the 
use of measures of explained variation for survival data based on loss 
functions (analogous to R2 in the analysis of variance).33 These measures do 
not have the disadvantages of the measures based on rank correlations, such as 
' c ' . However, the interpretation of the measures is more difficult and different 
loss functions lead to different results. Thus, hopefully sooner or later, more 
research in this field will result in an optimal measure for discrimination 
ability (or synonymously: predictive power). 
Cancer registry 
Finally, the role of Dutch regional cancer registries (held by the 
Comprehensive Cancer Centres) in projects such as the bladder cancer 
documentation project, deserves some emphasis. As aforementioned, the 
bladder cancer documentation project could not make use yet of the 
infrastructure of the cancer registry. Nowadays, the cancer registry can 
Chapter IO - General discussion 145 
provide the following facilities: a population-based documentation of patients 
with some kind of cancer; professional registrars who know their way around 
every hospital in the Netherlands and are trained to collect data according to 
strictly defined rules; high quality facilities for data storage and analysis which 
comply with the existing confidentiality legislations, and professional 
methodological expertise to assist with the design and execution of studies. 
Furthermore, the initiation of documentation projects is an area of special 
attention in the Comprehensive Cancer Centres' policies. Therefore, the 
Comprehensive Cancer Centres may serve as a fruitful platform for interaction 
between oncology, clinical epidemiology and medical technology assessment 
outside the boundaries of university hospitals. 
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Almost 6 per cent of all primary cancers are located in the urinary bladder. 
Among the 15 million inhabitants of the Netherlands, approximately 3400 new 
cases of bladder cancer are diagnosed each year, with a strong male 
predominance. Bladder cancer is the third most frequently occurring tumour in 
men, after lung cancer and prostate cancer. In the Netherlands, approximately 
1100 Dutch men and women die from the disease each year. (Chapter 1) 
According to data from the Dutch Central Bureau of Statistics, there has been 
an increasing trend in bladder cancer mortality in Dutch men since the 1950s. 
In 1955, only 350 bladder cancer deaths were registered. After adjusting for 
the ageing of the Dutch population in the past decades, male mortality rates 
were found to have increased from 7.5 per 103 person-years in the period 
1955-1959 to 12.4 per 105 person-years in the period 1985-1988. In contrast, 
female mortality rates per 10' person-years were found to have hardly 
increased from 2.9 in the first to 3.0 in the latter calendar period, indicating 
the absence of any temporal trend in females. Statistical modelling of male 
mortality rates from 1955 to 1988 by age, calendar period and birth cohort, 
showed that the observed rates can be described adequately by a so-called age-
cohort model. This means that the increasing temporal trend can be explained 
by a changing risk of dying from bladder cancer in successive birth cohorts, 
instead of a changing risk in successive calendar periods. It was found that the 
risk of dying from bladder cancer increased from the 1875 birth cohort to the 
1910 birth cohort, but decreased thereafter. For example, compared to men 
born in 1910, the calculated risk of bladder cancer death for men (of the same 
age) born in 1940 was 67%. There may have been a calendar period effect as 
well, but this was found to be quantitatively negligable. The lower risk for 
generations born after 1910 has not yet resulted in a decreasing trend in 
bladder cancer mortality rates in the Netherlands. Possibly, such a decline will 
be observed within the next decade when more cohorts with a relatively low 
risk reach high risk ages. This would correspond with the sharp fall in the 
proportion of smokers among Dutch males from 90% in the late 1950s to 40% 
in the 1980s, as smoking is believed to be the most important aetiological 
factor in bladder cancer. {Chapter 2) 
In most Western communities, increasing trends in bladder cancer incidence 
can be observed which are comparable with the increasing trend in mortality. 
However, these increasing trends do not necessarily reflect increasing risks of 
developing bladder cancer. Changes in the classification and reporting of low-
stage and low-grade papillocarcinomas may have resulted in biased trends in 
time of bladder cancer incidence as well as bladder cancer survival. Using 
data from the population-based Eindhoven cancer registry, it was found that 
age-adjusted male bladder cancer incidence per 103 person-years rose from 
25.9 in 1975 to 40.7 in 1989. Female incidence rose from 3.1 to 8.5. These 
increases in incidence were probably almost entirely caused by the 
introduction of a new grading system in 1973 and a new staging system in 
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1978. These new classification systems resulted in the registration of non-
invasive pTa papillary carcinomas, formerly classified as 'benign' or 
'borderline' papillomas. Taking this alteration in classification into account, 
there has been only a small increase in the occurrence of bladder cancer in 
females. No clear shift towards lower disease stages and lower fatality rates 
have been observed during the past two decades. (Chapter 3) 
In urology, non-invasive pTa papillary carcinomas, relatively rare flat 
carcinomas in situ (pTis) and tumours which invade the lamina propria of the 
bladder wall (pTl), are defined as superficial bladder cancers. Although the 
majority of patients with primary bladder cancer initially present with a 
solitary or multiple superficial tumour(s), quantitative knowledge of disease 
characteristics of superficial bladder cancer is fairly scarce. Using data from a 
documentation project in the south-eastern part of the Netherlands, it was 
found that 65% (N = 1745) of all primary bladder cancers were diagnosed with 
stage pTa or pTl transitional cell carcinoma (52 patients or 2% had primary 
pTis). Of all the patients with pTa/pTl cancer, 81% were men. The median 
age at diagnosis was 67 years both in males and females. Haematuria was the 
main first symptom in more than 80% of all the patients. In 32% of all the 
patients a pTl tumour was diagnosed, 16% had a grade 3 tumour and 29% 
had multiple tumours at first presentation. All these percentages were higher 
in patients who were older at diagnosis. Within 3 years after the diagnosis, 
more than 50% of all the patients suffered at least one recurrence. Patients 
with a recurrence were prone to having more recurrences. In 10% of all the 
patients, tumour progression was observed within 3 years. Both the risk of 
recurrence and the risk of progression strongly depended on the 
aforementioned tumour characteristics. The calculated 5-year relative survival 
of patients with superficial bladder cancer was 86%. (Chapter 4) 
Despite the prognostic ability of, e.g., tumour stage, grade and multiplicity, it 
is the urologist's experience that the outcome of disease in patients with 
superficial bladder cancer is difficult to predict. Therefore, a great deal of 
research is ongoing into the identification of additional prognostic factors for 
tumour recurrence, tumour progression and bladder cancer death. The 
literature was reviewed to make an inventory of the available evidence of the 
prognostic ability of clinical factors, histopathological factors, blood group 
antigens, cytogenetic factors, biochemical factors and tumour-associated 
antigens. Recurrence rate before and after treatment, cystoscopic features, 
such as tumour multiplicity and size, and the histopathological characteristics 
(tumour stage and grade) appeared to be the most important prognosticators. 
The value of blood group antigens is controversial. DNA ploidy and 
chromosomal aberrations are promising factors but further studies are 
necessary to establish the exact biological role of most of the observed 
aberrations. Cell motility, extracellular matrix degradation and the epidermal 
growth factor receptor are also promising factors. Although some monoclonal 
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antibodies (e.g., Mab T138) were shown to have prognostic ability for tumour 
progression, it is not yet known which antigen changes in neoplastic cells are 
causally related to tumour progression. The significance of any new prognostic 
factor additional to the clinical and histopathological characteristics used in 
clinical practice until now, remains to be proven. (Chapter 5) 
A factor which is believed to have such additional meaning is the presence of 
concomitant dysplastic lesions diagnosed with random biopsies from the 
cystoscopically normal-looking urothelium. In the bladder cancer 
documentation project (described in Chapter 4) random biopsies were taken 
from the 'normal' bladder mucosa in 1044 patients. In 22% of these patients, 
dysplasia (13.6%) or carcinoma in situ (8.2%) was found. The calculated 3-
year actuarial risk of recurrence in patients with such dysplastic lesions was 
57%, whereas this risk was 51% in patients without dysplastic lesions 
(P=0.09). In patients with and without dysplastic lesions, the calculated 3-
year risk of tumour progression was 21% and 7%, respectively (P<0.001). 
After adjusting for the effects of the routinely used prognostic factors by 
means of a proportional hazards model, the result of random biopsies was not 
found to have any prognostic significance regarding the risk of recurrence, but 
the presence of concomitant intraurothelial dysplastic lesions increased the risk 
of progression by a factor of 1.8 (90% CI: 1.3-2.5). Although the interacting 
effect of adjuvant intravesical chemotherapy instillations was accounted for in 
the analyses, the therapy applied may have obscured the real prognostic ability 
of concomitant dysplasia to some extent. (Chapter 6) 
In clinical practice, prognostic factors are primarily used to optimize the 
management of individual patients. In superficial bladder cancer, the ability to 
predict the disease outcome on the basis of the available prognostic factors has 
never been quantified. Using a random 50% sample of the patients registered 
in the documentation project, prognostic index scores were constructed for the 
risks of recurrence and progression. The prognostic indices were based on 
tumour stage, extent, grade, multiplicity and the result of random biopsies. 
Patients with a low prognostic index score were predicted to have a 44% 
chance of having a recurrence within 3 years and a 3% chance of tumour 
progression within 3 years. These predicted risks for patients with a high 
score were 74% and 22%, respectively. The predicted risks were found to be 
fairly reliable when compared to the observed risks of recurrence and 
progression among the remaining 50% of the patients. However, the 
predictive accuracy of the prognostic indices for disease outcome in individual 
patients was disappointing. In any two patients chosen at random, the chance 
that the patient with the worst predicted prognosis would have a shorter 
recurrence-free and progression-free follow-up interval, was calculated to be 
only 58% and 67%, respectively. Thus, the use of prognostic factors for the 
prediction of disease outcome in individuals, is not much better than the flip of 
a coin. (Chapter 7) 
Summary 151 
Although the presence of concomitant urothelial dysplastic lesions was shown 
to have prognostic value for the risk of tumour progression in patients with 
primary superficial bladder cancer {Chapter 6), this does not necessarily mean 
that it is worthwhile to implement taking random biopsies in everyday 
urological practice. Apart from financial cost considerations, the rationale of 
taking biopsies also depends on, e.g. the number of patients with dysplastic 
abnormalities, the extent to which these biopsies can differentiate high risk 
from low risk patients, the number of patients who would have been treated 
adjuvantly anyway and the efficacy of adjuvant therapy. By means of decision 
analysis, it was attempted to take all these relevant factors into account. 
Comparing a hypothetical patient management policy in which random 
biopsies were taken from all the patients, to a policy in which random biopsies 
were not taken, showed that the 3-year risks of recurrence and progression 
were almost identical with both policies. Under very optimistic assumptions 
regarding the aforementioned factors which favour the policy of taking random 
biopsies, sensitivity analyses revealed that the risks of recurrence and 
progression could be reduced by 5% and 4%, respectively. In that case, 
however, 43% instead of 12% of all the patients would have been treated with 
intravesical instillations. It was concluded that there is no good reason to take 
routine random biopsies. (Chapter 8) 
Prognostic factors are primarily used to discern high risk patients who need a 
more aggressive treatment regimen from low risk patients for whom more 
conservative management may suffice. Therefore, prognostic assessment 
studies should preferably take place in the absence of such prognosis-
modifying adjuvant therapy. Adjuvant therapy may obscure the potential effect 
of prognostic factors because of treatment-covariate interactions which may be 
difficult to identify in the analysis. If prognostic factor analyses are carried out 
using patient series in which adjuvant therapy was administered to a 
proportion of the patients, it is argued that the analysis should be restricted to 
the patients who did not receive adjuvant therapy. The statistical power of this 
restricted analysis may be lower, but undetectable biases are avoided. It was 
shown that non-random treatment assignment does not invalidate the results of 
the restricted analysis as long as all the prognostic factors on which treatment 
choice was based, are known and are incorporated into the analysis. With this 
condition, a situation is achieved which is defined as 'strongly ignorable 
treatment assignment' in the statistical literature. (Chapter 9) 
A large part of the research presented in this thesis was based on data from 
the "Documentation project bladder cancer". As this project was not initiated 
to carry out scientific research, some methodological problems were 
encountered in the analysis of the data. These problems are discussed in the 
final chapter of this thesis. Furthermore, some leads for future research into 
superficial bladder cancer are proposed. (Chapter 10) 

SAMENVATTING 
Samenvatting 154 
Bijna 6% van alle primaire maligniteiten is gelokaliseerd in de urineblaas. 
Onder de 15 miljoen inwoners van Nederland worden elk jaar ongeveer 3400 
nieuwe patiënten gediagnostiseerd. De meeste patiënten zijn van het mannelijk 
geslacht. 
Bij mannen is blaaskanker na longkanker en prostaatkanker de meest voor-
komende vorm van kanker. In Nederland sterven elk jaar ongeveer 1100 
mannen en vrouwen aan blaaskanker. (Hoofdstuk 1) 
Volgens gegevens van het Centraal Bureau voor de Statistiek bestaat er sinds 
de vijftiger jaren een stijgende trend in blaaskankersterfte. In 1955 werden 
slechts 350 overlijdens aan blaaskanker geregistreerd tegenover het huidige 
jaarlijkse cijfer van 1100. Na correctie voor het effect van vergrijzing in de 
laatste decennia blijken de sterftecijfers onder mannen te zijn gestegen van 7,5 
per 105 persoonjaren in 1955-1959 tot 12,4 per 103 persoonjaren in de periode 
1985-1988. De sterftecijfers onder vrouwen bleven daarentegen vrij constant: 
2,9 per 105 persoonjaren in de eerste ten opzichte van 3,0 per 105 
persoonjaren in de laatste kalenderperiode. Bij statistische modellering van de 
sterftecijfers bij mannen van 1955 tot 1988 met parameters voor leeftijd, 
kalenderperiode en geboortecohort, bleek dat de geobserveerde cijfers 
adequaat kunnen worden beschreven door een leeftijd-cohort model. Een 
kalenderperiode-effect bleek verwaarloosbaar klein te zijn. Dit betekent dat de 
stijgende trend in sterfte beter verklaard zou kunnen worden door een 
veranderend risico om aan blaaskanker te overlijden in opeenvolgende 
geboortecohorten dan een veranderend risico in opeenvolgende kalender-
perioden. Het risico nam toe vanaf het geboortecohort 1875 tot aan het cohort 
1910, maar nam weer af voor jongere cohorten. Bijvoorbeeld: het risico op 
blaaskankersterfte voor mannen geboren rond 1940 was 67% van het risico 
voor mannen (van dezelfde leeftijd) geboren rond 1910. Dit lagere risico voor 
jongere generaties heeft nog niet geresulteerd in een dalende trend in 
blaaskankersterfte. Het is waarschijnlijk dat een dalende trend zich de 
komende jaren zal inzetten wanneer meer geboortecohorten met een relatief 
laag risico hogere (risico) leeftijden bereiken. Dit zou overeenkomen met de 
sterke daling in het percentage rokers onder de Nederlandse mannelijke 
bevolking van 90% in de vijftiger jaren naar 40% in de tachtiger jaren. 
Immers, roken wordt geacht de belangrijkste risicofactor van blaaskanker te 
zijn. (Hoofdstuk 2) 
In de meeste Westerse landen worden ook stijgende trends gezien in de 
incidentie van blaaskanker. Deze stijgende trends worden echter niet 
noodzakelijkerwijs veroorzaakt door een stijgend risico op het krijgen van 
blaaskanker. Met name veranderingen in de (classificatie en rapportage van het 
laag-stadium en laag-gradig papillocarcinoom hebben mogelijk geresulteerd in 
vertekende trends in zowel incidentie als overleving van het blaascarcinoom. 
Met behulp van gegevens van de IKZ-SOOZ kankerregistratie werd berekend 
dat de voor leeftijdsopbouw gecorrigeerde incidentiecijfers per 103 
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persoonjaren bij mannen zijn gestegen van 25,9 in 1975 tot 40,7 in 1989. De 
incidentiecijfers bij vrouwen stegen van 3,1 tot 8,5. Waarschijnlijk werd de 
stijging in incidentie vrijwel geheel veroorzaakt door de introdukties van een 
nieuw graderingssysteem in 1973 en een nieuwe Massificatie van ziektestadium 
in 1978. Deze nieuwe klassificaties resulteerden in de registratie van het niet 
invasieve papillaire pTa blaascarcinoom, voordien geklassificeerd als 
"onrustig" papilloom. Wanneer rekening wordt gehouden met de verandering-
en in Massificatie blijkt er slechts sprake te zijn van een zeer geringe stijging 
van de incidentie bij vrouwen. Bovendien blijkt er in dat geval in de laatste 
decennia geen duidelijke verschuiving te zijn opgetreden naar een lager 
ziektestadium en betere overleving. (Hoofdstuk 3) 
Het niet invasieve papillaire pTa blaascarcinoom, het relatief zeldzame 
primaire carcinoom in situ (pTis) en de tumoren die slechts invasie vertonen in 
de lamina propria (pTl) worden in de urologie gedefinieerd als oppervlakkig 
blaascarcinoom. Ofschoon de meeste blaaskankerpatiënten zich primair 
presenteren met een solitair of multipel oppervlakkig carcinoom zijn er weinig 
kwantitatieve gegevens beschikbaar over de ziektekarakteristieken. Uit 
gegevens van het Documentatieproject Blaascarcinoom, een gezamenlijk 
project van IKO, IKZ en IKA-Stedendriehoek/Twente, bleek dat 65% 
(N = 1745) van alle patiënten met een primair blaascarcinoom gediagnostiseerd 
werd met een stadium pTa of pTl overgangscelcarcinoom (52 patiënten, ofwel 
2%, werd gediagnostiseerd met primair pTis). 81% van alle pTa/pTl 
patiënten was van het mannelijk geslacht. De mediane leeftijd bij diagnose bij 
zowel mannen als vrouwen was 67 jaar. Haematurie was het belangrijkste 
eerste symptoom bij meer dan 80% van alle patiënten. Bij 32% van de 
patiënten was er sprake van een pTl carcinoom, 16% had een graad 3 tumor 
en 29% van alle patiënten werd gediagnostiseerd met multipele tumoren. Al 
deze percentages waren hoger bij patiënten met een hogere leeftijd bij 
diagnose. Binnen 3 jaar na de diagnose werd bij meer dan 50% van alle 
patiënten minstens één recidief gediagnostiseerd. Patiënten met een recidief 
hadden een relatief hogere kans om nog meer recidieven te krijgen. Tumor-
progressie binnen 3 jaar werd gezien bij 10% van alle patiënten. Zowel het 
risico op een recidief als het risico op tumorprogressie was afhankelijk van de 
bovengenoemde tumorkarakteristieken. De 5-jaars relatieve overleving van 
patiënten met een oppervlakkig blaascarcinoom was 86 %. (Hoofdstuk 4) 
Ondanks de prognostische betekenis van bijvoorbeeld tumorstadium, graad en 
multipliciteit heeft de uroloog de ervaring dat het ziekteverloop bij patiënten 
met een oppervlakkig blaascarcinoom moeilijk te voorspellen is. Daarom vindt 
er veel onderzoek plaats naar additionele prognostische factoren voor 
recidivering, progressie en blaaskankersterfte. In de literatuur werd gezocht 
naar beschikbare gegevens over de prognostische waarde van klinische 
factoren, histopathologische factoren, bloedgroepantigenen, cytogenetische 
factoren, biochemische factoren en tumor-geassocieerde antigenen. 
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Cystoscopische karakteristieken zoals tumormultipliciteit en grootte en de 
histopathologische factoren stadium en graad blijken de meest belangrijke 
prognostische factoren te zijn. Het optreden van recidieven is prognostisch 
voor frequente recidivering en progressie. De waarde van bloedgroepantigenen 
is controversieel. DNA ploïdie en een aantal specifieke chromosoom-
afwijkingen zijn veelbelovende factoren maar de precieze biologische betekenis 
van de meeste van deze afwijkingen moet nog worden onderzocht. 
Celmotiliteit, extracellulaire matrix degradatie en de EGF-receptor zijn 
eveneens mogelijke prognostische factoren. Hoewel de prognostische waarde 
voor tumorprogressie werd aangetoond van sommige monoclonale 
antilichamen (bijvoorbeeld Mab Tl 38) is het nog niet bekend welke 
veranderingen in antigenen in neoplastische cellen causaal gerelateerd zijn aan 
tumorprogressie. De additionele betekenis van welke factor dan ook naast de 
al bekende klinische en histopathologische factoren moet nog worden 
aangetoond. {Hoofdstuk 5) 
Een factor waarvoor een dergelijke additionele prognostische betekenis wordt 
vermoed is de aanwezigheid van dysplastische laesies in het macroscopisch 
normaal ogend blaasslijmvlies. In het Documentatieproject Blaascarcinoom 
{Hoofdstuk 4) werden random biopsieën van het 'normale' urotheel genomen 
bij 1044 patiënten. Bij 22% van deze patiënten werd dysplasie (13,6%) of 
carcinoma in situ (8,2%) gevonden. Het 3-jaars actuariële risico op recidief bij 
patiënten met dergelijke dysplastische laesies was 57%. Het risico bij patiënten 
zonder dysplastische laesies was 51% (P=0,09). Het 3-jaars risico op 
tumorprogressie bij patiënten met en zonder dysplastische laesies was 
respectievelijk 21% en 7% (P<0,001). Na correctie voor het effect van de 
standaard prognostische factoren met behulp van het proportional hazards 
model, had het resultaat van random biopsieën geen additionele prognostische 
betekenis meer voor recidivering. Echter, het risico op progressie werd 
verhoogd met een factor 1,8 (95% BI: 1,3-2,5) bij aanwezigheid van dysplasie 
of CIS. Hoewel werd getracht om het mogelijk verstorende effect van 
adjuvante chemotherapie instillaties te corrigeren in de analyse is het mogelijk 
dat chemotherapie het werkelijke prognostische effect van dysplastische laesies 
in 'normaal' urotheel heeft vertroebeld. {Hoofdstuk 6) 
In de klinische praktijk zijn prognostische factoren met name van belang om 
het behandelingsbeleid te optimaliseren voor elke individuele patiënt. Bij het 
oppervlakkig blaascarcinoom is de mogelijkheid om het verloop van de ziekte 
te voorspellen op basis van de beschikbare prognostische factoren echter nog 
nooit gekwantificeerd. Met behulp van de gegevens van een 50% random 
steekproef van de patiënten in het documentatieproject werden prognostische 
indices geconstrueerd voor het risico op recidief en progressie. De indices 
werden gebaseerd op tumorstadium, uitbreiding, graad, multipliciteit en het 
resultaat van random biopsieën. Voor patiënten met een lage prognostische 
index score werd een 3-jaars risico op recidief voorspeld van 44% terwijl een 
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3-jaars risico op progressie werd voorspeld van 3%. De voorspelde risico's 
voor patiënten met een hoge score waren respectievelijk 74% en 22%. Bij 
vergelijking met de geobserveerde risico's op recidief en progressie bij de 
overige 50% van de patiënten in het project, bleken de voorspelde risico's vrij 
betrouwbaar te zijn. Echter, de nauwkeurigheid van voorspelling van het 
ziekteverloop bij individuele patiënten met behulp van de indices was 
teleurstellend. Er werd berekend dat voor elk random paar van patiënten, de 
kans dat de patiënt met de voorspelde slechtste prognose inderdaad een kortere 
recidiefvrije overleving heeft, maar 58% is. Deze kans is 67% voor 
progressievrije overleving. Voorspelling van het ziekteverloop bij de 
individuele patiënt met een primair oppervlakkig blaascarcinoom op basis van 
prognostische factoren is dus niet veel beter dan een pure gok. (Hoofdstuk 7) 
Hoewel de aanwezigheid van dysplastische laesies in het normaal ogend 
urotheel prognostische waarde bleek te hebben voor het risico op progressie 
{Hoofdstuk 6), is de zin van het nemen van random biopsieën bij elke nieuwe 
patiënt niet vanzelfsprekend. Afgezien van een kostenaspect, is de potentiële 
waarde van random biopsieën afhankelijk van bijvoorbeeld het aantal patiënten 
met dysplastische laesies, de mate waarin de aanwezigheid van deze laesies 
een goede en slechte prognose kan onderscheiden, het aantal patiënten dat ook 
al adjuvant behandeld zou zijn wanneer geen dysplasie of CIS zou zijn 
ontdekt, en het effect van die adjuvante behandeling. Door middel van een 
besliskundige analyse werden deze factoren in beschouwing genomen. 
Wanneer een hypothetisch behandelingsbeleid dat (mede) gebaseerd is op het 
resultaat van random biopsieën vergeleken wordt met een beleid waarbij geen 
random biopten worden genomen blijken de 3-jaars risico's op recidief en 
progressie nagenoeg identiek te zijn bij beide vormen van beleid. Onder vrij 
extreme aannames met betrekking tot de hiervoor genoemde factoren, allen het 
beleid van het nemen van random biopten bevoordelend, werd met behulp van 
een sensitiviteitsanalyse aangetoond dat het risico op recidief en progressie 
respectievelijk 5% en 4% lager wordt met het nemen van random biopsieën. 
In dat geval wordt echter 43% van de patiënten behandeld met adjuvante 
chemotherapie tegen 12% wanneer geen random biopsieën worden genomen. 
Geconcludeerd werd dat het weinig zin heeft om random biopsieën te nemen 
bij alle nieuwe patiënten met een oppervlakkig blaascarcinoom. (Hoofdstuk 8) 
Prognostische factoren worden voornamelijk gebruikt om patiënten met een 
relatief slechte prognose te onderscheiden van patiënten met een relatief goede 
prognose. Voor de eerste groep is mogelijk een (meer agressieve) adjuvante 
behandeling noodzakelijk terwijl voor de tweede groep een min of meer 
conservatieve behandeling zou kunnen volstaan. Studies naar prognostische 
factoren vinden daarom bij voorkeur plaats in afwezigheid van een dergelijke 
prognose-modificerende adjuvante behandeling. Immers, adjuvante 
behandeling kan het potentiële effect van prognostische factoren maskeren 
door interacties tussen die factoren en behandeling, terwijl het aantonen van 
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dergelijke interacties in de analyse zeer moeilijk is. In het geval dat een studie 
naar prognostische factoren plaatsvindt met gegevens van patiënten waarvan 
een gedeelte adjuvant werd behandeld, is het aan te raden de analyse te 
beperken tot de conservatief behandelde patiënten. De power van zo'η 
'restrictie-analyse' is mogelijk lager, maar niet-detecteerbare vertekening door 
toegepaste therapie wordt voorkomen. Er werd aangetoond dat ook bij non-
random behandelingstoekenning een restrictie-analyse leidt tot valide 
resultaten. Voorwaarde is wel dat alle factoren waarop de behandelingskeuze 
werd gebaseerd bekend zijn en worden opgenomen in de analyse. In dat geval 
is er sprake van een situatie die in de statistische literatuur wordt gedefinieerd 
als "strongly ignorable treatment assignment". (Hoofdstuk 9) 
Een groot gedeelte van dit proefschrift werd gebaseerd op de gegevens van het 
"Documentatieproject Blaascarcinoom". Omdat dit project niet primair werd 
opgezet met de bedoeling wetenschappelijk onderzoek te verrichten, bestonden 
er enige problemen bij de analyse van de gegevens. In het laatste hoofdstuk 
van dit proefschrift worden deze problemen besproken. In dat hoofdstuk 
worden ook aanbevelingen gedaan voor toekomstig onderzoek bij het 
oppervlakkig blaascarcinoom. (Hoofdstuk 10) 
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STELLINGEN 
behorende bij het proefschrift: 
"Prognostic assessment in superficial bladder cancer" 
Bart Kiemeney 
Nijmegen, 29 juni 1993 
1. De in Nederland nog steeds stijgende sterfte aan blaascarcinoom zal voor 
de eeuwwisseling gaan dalen. (Dit proefschrift) 
2. De ogenschijnlijke toename in het optreden van (oppervlakkig) 
blaascarcinoom sinds 1975 is het gevolg van klassifikatieveranderingen. 
(Dit proefschrift) 
3. Dysplastische laesies in normaal-ogend blaasslijmvlies bij patiënten met 
een oppervlakkig blaascarcinoom hebben enige additionele prognostische 
waarde voor tumorprogressie. (Dit proefschrift) 
4. Een betrouwbare voorspelling van het ziekteverloop bij een patiënt met 
een primair oppervlakkig blaascarcinoom is op dit moment niet 
mogelijk. (Dit proefschrift) 
5. Het nemen van random biopsieën van normaal-ogend blaasslijmvlies bij 
patiënten met een oppervlakkig blaascarcinoom heeft weinig zin. (Dit 
proefschrift) 
6. De wijze van correctie voor de invloed van toegepaste therapie in studies 
naar prognostische factoren verdient methodologische aandacht. (Dit 
proefschrift) 
7. De wereld wordt niet gekenmerkt door wat we zien, maar door wat we 
over het hoofd zien. (Jopie Huisman, 1992) 
8. Als eis voor registratie tot epidemioloog ligt een gedegen mathematisch 
statistische kennis minstens zo voor de hand als een gedegen medische 
kennis. 
9. Het aanhangen van de gedachte 'schoenmaker blijf bij je leest' is 
dodelijk voor de wetenschap. 
10. Positieve discriminatie gaat per definitie gepaard met 'negatieve 
discriminatie' en is dus verwerpelijk. 
11. Het gebruik van de term ziektebeloop in plaats van de juiste term 
ziekteverloop, is opmerkelijk daar in de kliniek weinig op zijn beloop 
wordt gelaten. 
12. Beter tien vogels in de lucht dan één op het strand. 


